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Summary 
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia of the 
Western world, and unfortunately despite advances in chemotherapeutic agents 
CLL remains incurable to date. CLL is a highly heterogeneous disease. CLL 
patients exhibiting progressive disease often become refractory to standard first 
line therapies, underpinning the need for novel drugs. An emerging field is 
targeted monoclonal antibody (MAb) development. Rituximab (RTX) a chimeric 
anti-CD20 MAb is registered as a first line therapy in combination with 
fludarabine and cyclophosphamide. A next generation type I, human IgG1 anti-
CD20 MAb, ofatumumab (OFA), binds to a novel epitope of CD20 resulting in 
higher potency of complement dependent cytotoxicity (CDC) induction. OFA has 
recently been given FDA approval for treatment in combination with 
chlorambucil for previously untreated CLL patients when fludarabine based 
regimes are not appropriate. OFA is also licensed as a single agent for the 
treatment of CLL patients refractory to both fludarbine and anti-CD52 MAb 
alemtuzumab.  
This research was conducted to establish what factors within CLL biology may 
influence RTX or OFA efficacy, in order to highlight the improved activity of OFA 
in comparison to RTX for the treatment of CLL. The ability of OFA to elicit a CDC 
response is an important part of its efficacy. Within this study we have 
demonstrated that OFA activity is limited in the treatment of CLL by several 
different factors including; complement levels, CD20 expression, 
microenvironmental stimulation and CLL genetic mutations. 
Our study identified that a large proportion, 37.5%, of CLL patients harbour 
complement deficiencies within their sera, this then led to a significant amount 
of complement exhaustion with successive OFA treatments, abrogating CDC 
induction. The detection of excessive complement exhaustion potentially has a 
clinical impact on the administration of anti-CD20 MAbs.  
CD20 expression levels also impact upon CDC induction by OFA, CD20 expression 
levels display a positive linear correlation with the percentage of CDC induction. 
Importantly OFA is superior in the induction of CDC in CLL patients with low 
CD20 expression levels in comparison to RTX. It is well established that CLL 
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patients have lower CD20 expression compared to other B cell malignancies, 
which is an important factor for anti-CD20 MAb efficacy as CDC induction is 
critically dependent on the expression levels of the target antigen on the surface 
of the cell.  
Recurrent mutations within NOTCH1 (NOTCH1MUT) have recently been identified 
as a poor prognostic marker within CLL. Emerging data suggests this mutation 
confers resistance against anti-CD20 MAbs, possibly through a down-regulation of 
CD20. We demonstrate that NOTCH1MUT CLL cells do display reduced expression 
levels of CD20, however this alone did not appear to contribute to all the 
reduced susceptibility towards anti-CD20 MAb activity. Preliminary gene 
expression data in combination with Ca2+ flux analysis suggest that NOTCH1MUT 
CLL cells have deregulated Ca2+ signalling which highlights the role of CD20 as a 
store-operated Ca2+ channel, and provides another mechanism for their 
resistance.  
Microenvironmental stimulation also impacts upon CLL cell response to RTX and 
OFA. Mimicking CLL cell interaction with their microenvironmental niche, caused 
an increase in CDC induction within different CLL cytogenetic subsets, 
independently to changes in CD20 expression. This is important as the 
interaction of CLL cells with other components of the microenvironment cause 
an up-regulation of anti-apoptotic proteins aiding CLL survival and promoting 
drug resistance. 
In conclusion this study highlights the increased efficacy of OFA as a 
chemotherapeutic agent in the treatment of CLL in comparison to RTX. 
Collectively these results also demonstrate that a change within the dosing 
schedule of OFA and complement supplementation using an exogenous source 
such as fresh frozen plasma could diminish some of the limitations in CDC 
induction, and potentially lead to enhanced clinical efficacy.  
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1 Introduction 
The body’s ability to mount an effective immune response is fundamental for our 
health and wellbeing. The first line of defence when fighting invading pathogens 
is innate immunity, the second is the adaptive immune system. Innate immunity 
is fast acting and relatively nonspecific compared to adaptive immunity. Innate 
immunity clears target pathogens through several different pathways including 
phagocytosis, inducing apoptosis and complement activation. In contrast the 
adaptive immune system consists of two responses; cell-mediated immunity in 
which the effector cells are T lymphocytes (T cells) and humoral immunity 
mediated by B lymphocytes (B cells). Adaptive immunity displays extensive 
specificity, adaptability and memory against foreign molecules. Despite the 
body’s rigorous control mechanisms, numerous immune disorders and 
malignancies have been identified. My research focused on chronic lymphocytic 
leukaemia (CLL) a malignancy of B cells and monoclonal antibody (MAb) 
immunotherapy. MAbs harness the body’s innate immune system to efficiently 
clear cancerous cells, described in more detail in section 1.4. 
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1.1 B cell development 
All blood cells are derived from multipotent haemopoietic stem cells (HSCs); B 
cells develop from HSCs located within the bone marrow (BM). Stromal cells 
located within the BM guide the developing HSC to differentiate into a B cell 
through cell to cell contact and the release of cytokines and chemokines. A 
schematic of the maturation of HSCs into B cells is shown in Figure 1.11.  
 
Figure 1.1 B cell development.  
Modified from Murphy. K., 2012. 
 
HSCs committed to the lymphoid lineage become multipotent progenitor cells 
(MPPs) which express FLT3, a tyrosine kinase receptor, this then interacts with 
FLT3 ligand present on BM stromal cells. Activation of the FLT3 pathway is 
fundamental for MPPs to transform into the common lymphoid progenitor (CLP) 
along with the initiation of the transcription factor PU.11,2. In mice this is also 
characterised by the expression of IL-7 receptor on CLP cells, with IL-7 being 
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secreted by stromal cells, although how fundamental IL-7 receptors are for 
human B cell development and growth is still to be established3. Other 
components that stimulate the HSC to B cell commitment include the expression 
of stem-cell factor (SCF). SCF is a cytokine secreted by BM stromal cells which 
associates with the receptor tyrosine kinase c-Kit on precursor cells. The 
chemokine stromal cell-derived factor 1 (CXCL12) is constitutively secreted from 
BM stromal cells in order to retain the B-cell precursors within the BM 
microenvironment1,2. The transition to the pro-B cell stage from CLP is specified 
by the activation of the transcription factors E2A and early B-cell factor (EBF). 
Transcription factors PU.1 and Ikaros are essential for the initiation of E2A 
expression. Sequentially, E2A then induces EBF expression, which then act in 
tandem to initiate the expression of proteins associated with differentiation into 
the pro-B cell4.  
Further development of the B cell is characterised by rearrangements of the B 
cell receptor (BCR), which occurs in a step wise fashion as the B cell 
differentiates from the early pro-B cell into the mature B cell. The BCR 
comprises of two identical heavy chains and two identical light chains which 
form the surface immunoglobulin (Ig), shown in Figure 1.2. Gene rearrangement 
of the BCR is a highly controlled operation with several check points to prevent 
self-activation and deregulation of the immune system. The first rearrangement 
occurs in the diversity (DH) locus of the immunoglobulin heavy chain (IGH) gene, 
whereby the D segment joins to the joining (JH) segment. The germline 
arrangements of the IGH and light chain (IGL) loci are shown in Figure 1.2, and 
are derived from an extensive repertoire of the different gene segments1. E2A 
and EBF activity is critical for D to JH joining to occur, as these transcription 
factors mediate the expression of proteins required for gene rearrangement; 
recombination activating genes 1 and 2 (RAG-1 and RAG-2)1. PAX5 is also a 
fundamental transcription factor in B cell development, without PAX5 expression 
developing B cells fail to fully commit to the B cell lineage and to develop past 
the pro-B cell stage. PAX5 expression targets both CD19, the B cell co-receptor 
component, and also B-cell linker protein (BLNK) which is required for signalling 
from the mature B cell BCR1,4. D-JH rearrangements mark the transition into the 
pro-B cell stage. At the late pro-B cell stage only one allele of the variable heavy 
chain (VH) gene segment will rearrange to join the DJH sequence. RAG-1 and 
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RAG-2 form a complex with several different enzymes, mostly ubiquitous DNA 
modifying proteins, which form the V(D)J recombinase. RAG-1 and RAG-2 
mediate the endonucleolytic cleavage of the target DNA introducing double 
strand breaks and DNA repair mechanisms bring the desired segments together. 
The diversity of BCR-antigen recognition is further enhanced at the pro-B cell 
stage by the enzyme terminal deoxynucleotidyl transferase (TdT), which inserts 
non-template nucleotides in between the rearranged gene segments1.  
When V-DJH rearrangement is successful, a full length μ heavy chain is produced 
and the cell is now termed a pre-B cell. A large proportion of developing B cells 
are lost at this stage due to unsuccessful rearrangements of the μ heavy chain. 
The immune system requires strict control mechanisms to prevent the 
production of ineffective inert and self-reactive B cells. Before the pro-B cell 
develops further, the functionality of the recently produced heavy chain needs 
to be checked. E2A and EBF in the pro-B cell signal the production of two 
surrogate light chains, λ5 and VpreB, which pair with the heavy chain to become 
the pre-B cell receptor1. Invariant proteins Igα (CD79a) and Igβ (CD79b) are also 
important in the formation of the pre-B cell receptor as well as the fully 
functioning BCR until the death of the B cell or it becomes a fully differentiated 
plasma cell. Igα and Igβ span the cell membrane and through interaction with 
the pre-BCR or BCR are able to transduce intracellular signals through the kinase 
activity of the immunoreceptor tyrosine activation motifs (ITAMs) in their 
cytoplasmic tails1. Upon successful rearrangement of the heavy chain and 
correct pairing with the two surrogate light chain molecules the pre-BCR will 
cluster on the surface of the cell. Subsequent intracellular signalling then 
inhibits RAG-1 and RAG-2 expression, thus preventing further rearrangement of 
the heavy chain genes. The cells are now susceptible to the activity of IL-7, 
leading to cell proliferation and development into the large pre-B cell1. Large 
pre-B cells go through several rounds of cell divisions to produce resting small 
pre-B cells. Once again the expression of RAG proteins is initiated, but this time 
it is to induce the rearrangement of light chain genes. There are two forms of 
the light chains (κ and λ) but only one will be expressed in conjunction with the 
heavy chain. Light chains lack the D segment and therefore rearrangement 
between V and J occurs. Successful rearrangement of the light chain produces an 
intact IgM molecule on the surface of the now immature B cell. Surface IgM then 
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associates with Igα and Igβ to form the BCR1. At this stage it is important for the 
B cell to be tested to prevent auto reactivity.  
Self-reactive B cells are prevented from entering the circulating compartment by 
either; undergoing apoptosis, developing a new receptor by receptor editing, 
undergoing a permanent state of anergy against antigens or become 
immunologically ignorant1. This ensures that surviving B cells are tolerant to 
self-antigens. B cells that pass this check point become mature B cells that 
express surface IgD as well as IgM, mature B cells then egress from the BM and 
migrate towards peripheral lymphoid tissues.
 
Figure 1.2 Germline arrangements of the immunoglobulin heavy and light chain loci and 
BCR structure.  
Modified from Murphy. K., 2012 
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1.1.1 B cell immune response 
The humoral immune response is characterised by the secretion of antibodies 
from plasma cells, which are terminally differentiated B cells. The humoral 
immune response is activated when the BCR comes into contact with an antigen. 
The antigen is then internalised and degraded. Antigen peptides are processed 
and transverse to the B cell surface and bind to the major histocompatibility 
complex class II (MHC II); this is then recognised by activated CD4+ T cells 
(helper T cells). The helper T cell provides activating signals to the B cells to 
proliferate and differentiate into antibody producing plasma cells. Helper T cells 
express CD40 ligand (CD154) which interacts with CD40 expressed on the B cell, 
this binding helps stimulate the B cell to proliferate, undergo Ig class switching 
and somatic hypermutation (SHM)1,5-7. Helper T cells also produce cytokines to 
aid B cell proliferation and differentiation. In some instances it is possible for 
some antigens, such as bacterial polysaccharides to induce antibody production 
from B cells in a T cell independent manner; these antigens are termed B cell 
mitogens and can induce proliferation of B cells1. However in the majority of 
cases B cell/helper T cell interaction is required. B cells and T cells inhabit 
different areas of the peripheral lymphoid tissues; B cells are located within the 
primary lymphoid follicles and T cells in the T-cell areas. B cells that have 
encountered antigen move along a CCR7 chemokine gradient within the primary 
lymphoid follicles towards the T-cell area. T cells also migrate towards CCR7 
ligand being highly expressed by dendritic and stromal cells at the T cell/B cell 
boundary. Expression of CXCR5 is then induced in T cells and they start to 
proliferate1,7. At this point T cells can differentiate into either effector cells or 
follicular helper T cells (TFH cell); TFH cells recognise peptides displayed on the 
MHC II of B cells, and in doing so activate the B cell. Once associated, the B and 
T cells then migrate back to the primary lymphoid follicle where they proliferate 
and form a germinal centres (GC), termed secondary lymphoid follicles.  
1.1.1 Germinal centre reaction 
B cells comprise the majority of GC, with antigen-specific TFH cells making up 
10% of the population1. The surrounding area of a GC is comprised of resting B 
cells, called the mantle zone. The production of the GC is important for long 
term defence against invading pathogens, such as if the infection becomes 
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chronic or if the host becomes re-infected. B cells enter the GC as it enables 
them to undergo crucial modifications such as SHM and class switching of surface 
Ig to provide a more tailored immune response. The GC can be distinguished by 
two different zones, the light zone and the dark zone (Figure 1.3)8.  
 
Figure 1.3 Germinal centre reaction.  
Modified from Heesters. B., et.al. 2014. 
The dark zone of the GC contains densely packed rapidly proliferating B cells 
termed centroblasts, which express the chemokine receptors CXCR4 and CXCR5, 
but low levels of IgD. Within the dark zone, stromal cells express CXCL12, a 
ligand for CXCR49,10. As with the BM, CXCL12 expression retains the centroblast 
within the dark zone. To produce B cells with a higher affinity to invading 
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pathogen, surface Ig undergoes SHM of the V gene region. SHM results in the 
inclusion of individual point mutations within the Ig, subsequently several B cell 
clones which have very subtly different affinities towards the target antigen are 
produced11. Approximately 1 per 103 base pairs (bp) are changed each time the 
cell divides, this mutation rate is much higher than the rest of the genome. The 
B cell is able to target just the V region for increase mutation rate by the 
enzyme activation-induced cytidine deaminase (AID). AID catalyses the 
deaminating of cytidine residues directly on DNA. It is thought that the inclusion 
of somatic mutations into the DNA is through the error prone repair mechanisms 
after AID has damaged the DNA, although the full extent of AID activity is not 
fully elucidated1,8,10,12. Most of the mutations generated will produce a different 
amino acid within the antigen binding site of the Ig which will result in altered 
binding affinity towards the target antigen. The majority of the mutations 
generated will lower the binding affinity to the antigen. Only B cells that have 
increased affinity receive pro-survival signals and the rest are removed by 
apoptosis. Eventually the rates of division of the centroblast subside and they 
enter the growth phase, halting the expression of CXCR4 and increasing Ig levels. 
After this transformation the centroblasts are termed centrocytes, which 
transverse into the light zone and are held there by follicular dendritic cells 
(FDC) producing CXCL13; a ligand for CXCR5. The affinity of the BCR is tested on 
the FDC bearing the target antigen, if binding is successful then CXCR4 is re-
expressed and the B cell travels back into the dark zone to undergo successive 
rounds of SHM, termed affinity maturation8,10-13. Activated B cells within the GC 
can also undergo class switching recombination (CSR) of the Ig, the heavy chain 
V region associates with a different C exon of any isotype through non-
homologous end joining caused by AID11. There are five different classes of Ig; 
IgA, IgD, IgE, IgG and IgM, each type has a very specific and immunologically 
unique function. Therefore it is important for B cells to express the most 
appropriate Ig for the particular immune response. CD40/CD154 interaction of 
TFH cells associated with a B cell provides important B cell survival signals and 
also signals TFH cells to release cytokines to help guide B cells to undergo CSR 
from IgM into the desired Ig12. Centrocytes within the GC display a genetic 
profile of having high expression levels of pro-apoptotic genes such as B cell 
CLL/lymphoma 2 (Bcl-2) interacting mediator of cell death (BIM) and low levels 
of the anti-apoptotic genes Bcl-2 and Bcl-XL. It is thought that interaction with 
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BCR and antigen along with CD40-CD154 interaction on T cells is required to 
induce elevated expression levels of Bcl-2 and Bcl-XL to aid survival
10. Eventually 
some B cells will leave the GC and develop into either an antibody producing 
plasma cells or a memory B cells. Differentiation into a plasma B cell is 
associated with the down-regulation of PAX5 and Bcl6. Bcl6 is considered to be a 
master regulator of centroblasts and is critical for the generation and 
maintenance of the GC reaction10.  
1.1.2 BCR signalling 
The BCR can become activated via two different pathways; antigen dependent 
signalling or the lesser understood ligand-independent (termed tonic signalling). 
Signalling through the BCR can result in B cell survival, migration, proliferation 
and the induction of apoptosis (Figure 1.4)14-16.  
 
Figure 1.4 BCR signalling pathway.  
Modified from Choi. M. Y., et.al. 2012. 
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As previously described the BCR is associated with two heterodimers that are 
able to transduce an intracellular signal; CD79a and CD79b (Figure 1.2). BCR 
signalling is activated when a bound antigen causes BCR aggregation, tyrosine 
residues within CD79a and CD79b then become phosphorylated by the Src family 
of tyrosine kinases Lyn, Fyn and Blk17. Phosphorylation of ITAM generates 
docking sites for proteins with Src homology (SH2) domains, such as spleen 
tyrosine kinase (Syk). The signal transduction of the BCR can be amplified if a B-
cell co-receptor such as CD19, also clusters with the aggregated BCRs18. CD19 
also contains tyrosine residues that can be phosphorylated by Lyn and 
subsequently activated. This activation leads to the phosphorylation of 
phosphatidylinositol 3 kinase (PI3K) at the SH2 containing p85 subunit. PI3K in 
turn phosphorylates phosphatidylinositol-4,5-biphosphate (PIP2) to become 
phosphatidylinositol-3,4,5-triphosphate (PIP3)
17,19. PIP3 production results in the 
recruitment of Bruton’s tyrosine kinase (Btk). The adapter protein BLNK can be 
phosphorylated by Syk and Btk. BLNK has the ability to act as a scaffold for the 
activation of several different pathways. PLCγ2 docks on BLNK via its SH2 
domain, PLCγ2 also contains a pleckstrin-homology (PH) domain which interacts 
with PI3K generated PIP3
17. The interaction of PLCγ2 with PIP3 results in the 
cleavage of PIP2 into diacylglycerol (DAG) and inositol-1,4,5-triphosphate (IP3) 
which both individually lead to the activation of different cellular responses. 
DAG mediates the activation of protein kinase C (PKC)20. PKC then stimulates the 
mitogen-activated protein kinases (MAPK). MAPKs are serine-threonine protein 
kinases which include c-Jun NH2 terminal kinase (JNK), extracellular signal-
regulated kinase (ERK) and p3816,21. Each of these kinases then phosphorylate 
and activate particular transcription factors; c-Jun and ATF-2 are activated by 
JNK, Elk-1 and Myc are activated by ERK and ATF-2 and MAX by p38. IP3 on the 
other hand associates with IP3 receptors on the surface of the endoplasmic 
reticulum (ER) resulting in a cytoplasmic flux of calcium (Ca2+) from intracellular 
Ca2+ stores within the ER lumen. An increase in cytosolic Ca2+ levels results in a 
further cascade of Ca2+ release from store-operated calcium channels. Ca2+-
calmodulin complexes activate the transcription factor nuclear factor of 
activated T cells (NFAT)17,20,22. Classical PKCs (α, βI/II and γ) become activated 
in the presence of Ca2+ and DAG. PKCβ causes the activation of the pro-survival 
nuclear factor (NF)-κB pathway. Active PKCβ in turn activates CARD11. CARD11 
then recruits B cell lymphoma/leukaemia 10 (BCL10) and mucosa associated 
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lymphoid tissue lymphoma translocation protein 1 (MALT1), to form a complex 
termed CBM. CBM initiates inhibitor of κB kinase (IKK) which results in the 
activation of NF-κB14,15. The ERK and MAPK signalling pathway can be further 
propagated through the activation of the Rho family of GTPases signalling 
pathway, RAS/RAF1 signalling. RAS/RAF1 signalling becomes activated by Vav, a 
guanine exchange factor, which binds to BLNK resulting in tyrosine 
phosphorylation and activation23. Signalling through the BCR results in the 
propagation of a complex network of signalling pathways which finely tunes the 
B cell to survive, migrate, divide or undergo apoptosis (Figure 1.4). 
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1.2 Chronic lymphocytic leukaemia 
CLL is characterised by an unregulated clonal expansion of a B cell population 
with a distinct immunophenotype. This immunophenotype distinguishes CLL from 
other B cell malignancies. CLL cells express the T cell antigen CD5, B cell surface 
antigens CD19 and CD23, and have surface IgMlow and FMC7- 24. CLL is the most 
common leukaemia of the Western world, with a median age at diagnosis of 72 
years, however approximately 10% of CLL patients are diagnosed before 55 
years. More males are affected by CLL than females (1.7:1 ratio). CLL is typically 
diagnosed when 5,000 circulating B cells/μl are present in the peripheral blood 
for 3 months or longer25. 
There is a vast amount of heterogeneity in CLL; at the onset of disease it is very 
difficult to predict the clinical course. Some CLL patients may succumb to 
disease within a very short time course and require extensive treatment whilst 
others may never require medical treatment26,27. Historically CLL was thought to 
be a disease of accumulating B cells resistant to apoptosis. The investigation by 
Messmer et al. using deuterated water labelling, was pivotal for understanding 
CLL biology as they observed that in vivo, CLL cells are more dynamic than 
originally thought. They identified that there was significant death and 
proliferation of CLL cells, with 0.1 to over 1 % cell ‘birth rates’ of the entire 
clonal population per day, with higher proliferation rates corresponding to a 
more progressive disease28.  
1.2.1 Clinical staging 
There are two different staging methods used for CLL, proposed by Rai and 
Binet. Both staging systems have different classifications categories, which CLL 
patients fall into, based upon results of both physical examination and standard 
laboratory tests29,30. The Rai system; 
 Stage 0: Lymphocytosis and no enlargement of the LN, spleen or liver, and 
blood cell and platelet counts within a normal range. 
 Stage I: Lymphocytosis with enlarged LN and blood cell and platelet 
counts within a normal range. 
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 Stage II: Lymphocytosis with enlarged spleen +/- enlarged LN. Blood cell 
and platelet counts within a normal range. 
 Stage III: Lymphocytosis with anaemia +/- enlarged LN, spleen or liver. 
Platelet counts within a normal range. 
 Stage IV: Lymphocytosis with thrombocytopenia +/- anaemia. LN, spleen 
or liver enlarged. 
The Rai staging system is split into low, intermediate and high risk to determine 
appropriate treatment strategies. Low risk are those CLL patients with stage 0, 
intermediate risk are those at stage I&II and high risk patients are those with 
stage III&IV disease.  
The Binet system however includes the number of areas affected by CLL, such as 
the LNs (1 cm in diameter or larger) or an enlarged organ. Areas of the body 
investigated are the head and neck, axillae, groin, palpable spleen and palpable 
liver31. The Binet system;  
 Stage A includes up to two of the areas described above being affected 
and haemaglobin (Hb) levels ≥ 10 g/dL and platelets ≥ 100 x 109/L.  
 Stage B is defined by at least three or more areas being affected and Hb ≥ 
10 g/dL and platelets ≥ 100 x 109/L.  
 Stage C is defined as patients with Hb levels less than 10 g/dL and/or 
platelet counts less than 100 x 109/L. 
The different staging systems can be used to predict survival times for CLL 
patients; low risk or stage A confers 10 year survival, intermediate/stage B 
confers 5-7 year survival and high risk/stage C confers reduced survival to 2-3.5 
years for CLL patients within this group25,32. Although clinical staging provides a 
good indicator for when treatment will be required, it does not always provide 
an accurate system for predicting disease progression or explaining the large 
degree of heterogeneity observed within CLL.  
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1.2.2 Prognostic markers 
Prognostic markers are very valuable tools to help predict the clinical course the 
disease will follow and the time to first treatment. Extensive research into the 
heterogeneity in CLL has led to a comprehensive list of different prognostic 
markers, described below. 
1.2.2.1 Lymphocyte doubling time 
Lymphocyte doubling time (LDT) is an important indicator during early diagnosis; 
it can help predict the activity of the disease and time until first treatment is 
required. LDT is typically best used when lymphocyte counts are above 30,000 
cells/μl. LDT of 6 months, or more than a 50% increase in lymphocyte counts 
within 2 months, is an indicator of active disease requiring treatment as outlined 
by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 32-34.  
1.2.2.2 Serum markers 
There are three main serum markers that correspond with CLL prognosis; β2 
microglobulin, serum thymidine kinase and soluble CD23. β2 microglobulin is an 
extracellular protein which is non-covalently bound to the α chain of MHC class I 
proteins. Elevated β2 microglobulin levels are associated with poor prognosis, 
high tumour burden, bulky disease and displays a correlation with CD38 and 
zeta-chain-associated protein kinase 70 kDa (ZAP-70) expression levels35. Serum 
thymidine kinase expression is present in dividing cells and therefore provides a 
valuable marker for proliferating and rapidly progressing disease36. Soluble CD23 
is a low affinity receptor of IgE and expression correlates with diffuse BM 
infiltration, reduced survival and short LDT34,36. 
1.2.2.3 IGHV mutational status  
CLL patients typically fall into two distinct prognostic groups depending on the 
mutational status of their IGHV gene. As described earlier, during B cell 
development in the GC IGV genes undergo SHM to expand the Ig repertoire. It 
has been identified that approximately 40% of CLL cases have unmutated and 
60% have mutated IGHV gene segments
24. Patients with less than 2% variance 
between IGHV and germline sequence are classified as being unmutated. CLL 
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cells with mutated IGHV tend to be relatively anergic with weak B cell signalling 
and are associated with cytogenetic abnormalities trisomy 12 and 13q14 del37,38. 
Unmutated IGHV on the other hand correlates with a more aggressive clinical 
course, with shorter remission times and progression free survival (PFS), a higher 
association with the acquisition of high risk cytogenetic abnormalities and 
shorter survival times irrespective of the disease stage38-40. An investigation of 
Binet stage A CLL patients found that median survival times for unmutated 
patients was 95 months compared to 293 months for patients with mutated 
IGHV39. Interestingly the use of the specific variable region encoded by VH3-21 
gene segment is associated with a more aggressive disease irrespective of 
mutational status41,42. The costly and laborious nature involved in identifying 
IGHV mutational status of CLL patient cells led to the search for more easily 
identifiable surrogate markers, of which CD38 and ZAP-70 were identified43-45. 
1.2.2.4 ZAP-70 
ZAP-70 is a receptor associated protein tyrosine kinase, typically found in T cells 
and natural killer (NK) cells, and not in normal healthy mature B cells46. 
However ZAP-70 expression has been identified in CLL patients, with a strong 
correlation between expression and unmutated IGHV. Irrespective of mutational 
status, ZAP-70 expression is an independent poor prognostic marker resulting in 
reduced PFS and overall survival (OS), and a valuable indicator of time to first 
treatment34. ZAP-70 expression like mutational status remains constant over 
time, and is a good tool for predicting mutational status47. ZAP-70 expression 
can be established through flow cytometry and immunohistochemistry, and the 
correspondence with correct determination of mutational status has been shown 
to be between 77-95%34. In one study ZAP-70 expression of 5.54 fold or higher 
expression in unmutated CLL displayed 93% accuracy at correctly establishing 
the mutation status48. ZAP-70 augments the activity of BCR signalling. Upon BCR 
ligation, BCR signalling is enhanced in the presence of ZAP-70 resulting in an 
activating and proliferative response46. 
1.2.2.5 CD38 
CD38 is a transmembrane glycoprotein that has also been shown to be an 
independent poor prognostic marker44. Elevated CD38 expression has been 
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associated with advanced disease stage, high risk cytogenetic aberrations and 
reduced PFS and OS49. CD38 has cyclic adenosine diphosphate-ribose activity and 
can act as both a receptor and an enzyme. Like ZAP-70, CD38 is also thought to 
augment BCR signalling. The use of CD38 as a surrogate marker for mutational 
status is controversial as the association is not an absolute; it is also thought 
that CD38 expression levels vary during the course of the disease in contrast to 
mutational status50,51. Experiments with deuterium labelling have shown that 
high expression level of CD38 is associated with high proliferation rates, 
suggesting a more active disease52. 
1.2.3 Genetic influence and CLL 
Unlike other haematological malignancies there is no defining chromosomal 
abnormality that results in increased susceptibility to CLL. Indeed, familial CLL 
cases are rare and defined as having one affected relative53. Approximately 5% 
of CLL cases report family history of CLL54,55. Although there have been several 
conflicting reports it appears that familial CLL displays no adverse prognosis with 
little molecular differences between familial and sporadic CLL56. Monoclonal B 
cell lymphocytosis (MBL) has been suggested to precede the development of 
disease in the majority of CLL cases. MBL is characterised by an indolent 
expansion of monoclonal B cells within the peripheral blood at a concentration 
lower than 5,000 cells57. In some cases MBL cells display typical CLL surface 
protein phenotype, and can demonstrate similar chromosomal abnormalities58. 
13% of relatives of CLL patients present with MBL compared to approximately 3-
5% with no family history of CLL. The increased frequency indicates that there is 
some heritability towards the susceptibility of developing B cell clones59,60. 
 
1.2.3.1 Epigenetic alterations 
Epigenetic alterations can result in the activation or silencing of gene 
transcription without changing the DNA sequence. Epigenetic changes can be 
transmitted to daughter cells and when occurring in germline cells alterations in 
gene expression can be passed onto the following generation56. The epigenetic 
silencing of death associated protein kinase 1 (DAPK1) through the methylation 
of the promoter sequence has been frequently identified in both familial and 
sporadic CLL cases61. In a case study of a large family affected by CLL they 
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identified DAPK1 as predisposing factor to the development of CLL, with family 
members having a single nucleotide polymorphism (SNP) within the promoter 
sequence aiding the binding of the transcriptional regulator HOXB7 effectively 
silencing the gene61. DAPK1 is thought to mediate the induction of either 
apoptosis or autophagy following cellular stress. 
1.2.3.2 Cytogenetic abnormalities 
Several cytogenetic abnormalities have been frequently identified in CLL 
patients, which subsequently have an impact on PFS, OS and response to 
treatment. Fluorescent in situ hybridisation (FISH) is a valuable tool for 
identifying cytogenetic aberrations, which have been identified in approximately 
80% of CLL patients. The functional impact the different cytogenetic 
abnormalities have upon CLL patient survival and treatment free survival from 
the date of diagnosis is shown in Figure 1.562,63. CLL patients with a normal 
karyotype with no mutations detected by FISH typically have a median survival 
of 111 months (Figure 1.5)63,64.  
 
 
Figure 1.5 Impact of the different cytogenetic abnormalities within CLL upon the probability 
of survival and disease progression. 
Reproduced with permission from (Döhner. M.D., et.al. 2000), Copyright Massachusetts Medical 
Society.
63
 
 
6q21 del 
 
Deletions of chromosome 6q21 are observed at low frequencies within CLL (3-
6%), although they have not currently been determined to present a functional 
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impact on CLL patient survival, 6q del are associated with intermediate risk 65,66. 
Patients with 6q del present with atypical CLL morphology, high white cell 
counts, progressive disease and high CD38 expression65. 
 
Del 13q14 
The most commonly identified cytogenetic abnormality is the deletion of the 
band 13q14, observed in approximately 55-60% of CLL cases62. 13q14 del is the 
most favourable cytogenetic karyotype due to its association with slowly 
progressing disease with median survival of 133 months67. 13q14 del 
encompasses two microRNAs; miR15a and miR16-1, which negatively regulate 
the expression of the anti-apoptotic protein Bcl-268,69. Deletion of these two 
microRNAs in mice leads to the development of a clonal B-lymphoproliferative 
disorder similar to CLL70. 
 
Trisomy 12 
Trisomy of chromosome 12 is observed in approximately 7-20% of CLL cases, with 
median survival time of 114 months, similar to that of CLL patients with normal 
karyotype34. The full pathogenesis of trisomy 12 has not been fully elucidated, 
there appears to be little increase in reported incidences with advanced disease 
stage or the transition to refractory disease71. This suggests that trisomy 12 
provides little clonal advantage72. One suggested association is between the 
expression of trisomy 12 and CD49d a subunit of the late activation 4 receptor 
(VLA-4), which is important for the migration of CLL cells towards secondary 
organs73.  
11q22-q23 del 
Detection of 11q23 deletion is a poor prognostic indicator observed in 18% of CLL 
cases. 11q del is associated with a shortened median survival of 79 months, 
younger age at diagnosis and more advanced disease stage34. 11q del patients 
are also more likely to suffer from extensive peripheral, abdominal and 
mediastinal lymphadenopathy74. The pathogenic nature of 11q23 del acts 
through the deletion of the gene ataxia telangiectasia mutated (ATM) encoded 
within this region. ATM protein is a crucial component of the DNA damage 
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response pathway75,76. ATM becomes activated in the presence of undesirable 
double strand breaks caused by either an endogenous event or DNA damaging 
agent. ATM can then halt the cell at either G1/S or G2/M phase by preventing 
cyclin dependent kinase (Cdk) activity. Depending on the damage caused by the 
DNA break, ATM can either induce apoptosis or directly help repair the break. 
Monoallelic deletion of 11q23 results in poor prognostic and biallelic inactivity of 
the remaining ATM results in a more severe clinical outcome77,78. Mutations of 
ATM are observed in approximately 12% of CLL patients and 33% of 11q23 del 
patients. 77,79,80 
 
17p13 del 
The cytogenetic aberration associated with the poorest clinical outcome is 
deletion of 17p13, and 17p del is observed in 16% of CLL patients34. CLL patients 
with 17p13 del have a median survival of 32 months, with rapid disease 
progression. Early treatment strategies are required and 17p del typically display 
poor response to treatment62,81. The aggressive nature of 17p13 del is associated 
with this region harbouring the tumour suppressor TP53 gene locus. Monoallelic 
deletion of 17p13 is commonly associated with an inactivating mutation of the 
remaining allele, observed in over 80% of cases82. TP53 gene encodes for p53. 
p53 is commonly referred to as the guardian of the genome and is crucial for 
preventing the replication of cells that contain DNA damage. p53 regulates the 
transition of dividing cells from G1 to S phase and can activate apoptosis if DNA 
damage is detected83. CLL patients with 17p del have limited treatment 
strategies compared to other cytogenetic karyotypes. Many chemotherapeutic 
agents, such as alkylating and purine analogues, mediate CLL cell death through 
the induction of DNA damage and subsequently p53 driven apoptosis84. In 17p del 
patients that are fit enough, allogenic stem-cell transplantation is a 
recommended treatment strategy85. Alemtuzumab an anti-CD52 MAb is also used 
when allogenic stem cell transplantation is not appropriate86. The incidence of 
17p del increases dramatically in cases of relapsed and refractory CLL, observed 
in approximately 45% of cases, demonstrating clonal evolution of poor prognostic 
cytogenetic aberrations87. CLL treatment strategies are discussed in more detail 
in section 1.4. 
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1.2.3.3 Newly identified recurrent mutations 
Recent advances in sequencing technology have led to more readily available 
whole genome and whole exome sequencing of CLL cell DNA88,89, and the ability 
to conduct targeted deep sequencing. NFκB pathway is constitutively active in 
CLL and recent deep sequencing data of this pathway revealed frequent 
mutations encompassing IκBε90. IκBε mutations were identified in 7% of CLL 
patients, of these mutations approximately 60% were caused by an identical 4bp 
frameshift deletion resulting in truncated protein90. IκBε mutations were also 
predominantly associated with poor prognostic CLL patients with inferior 
outcome90. From whole genome analysis other novel mutations were also 
identified, with some demonstrating an impact on CLL prognosis. The numerous 
recurrent gene mutations found included; NOTCH1, XPO1, MYD88, KLHL6, SF3B1, 
ZMYM3, MAPK1, FBXW7, DDX3X and BIRC3. ZMYM3 is located on the X 
chromosome, the encoded protein forms part of a histone deacetylase (HDAC) 
multi-protein complex that epigenetically silences gene transcription91. DDX3X is 
also located on the X chromosome, and mutations in CLL demonstrate a 
predominance towards males being afflicted92. DDX3X mutations in CLL result in 
a truncated protein92. DDX3X is a dead-box RNA helicase associated with RNA 
splicing, RNA transport and translation initiation. DDX3X also interacts directly 
with XPO191. XPO1 is a nuclear exporter which transports over 200 proteins, 
including p53 and NF-κB, from the nucleus to cytoplasm. XPO1 mutations 
although not fully understood, are thought to be oncogenic and display an 
association with unmutated IGHV CLL91,93. KLHL6 is involved in GC formation 
during B cell maturation and SHM in CLL displays an association with mutated 
IGHV CLL88. FBXW7 is an ubiquitin ligase that targets several oncogenes such as 
c-Myc, myeloid cell leukaemia 1 (MCL-1) and Notch1 for degradation91. FBXW7 
mutations in CLL are thought to abrogate function resulting in an alternative 
mechanism for uncontrolled Notch1 activation94,95. MAPK1 kinase forms an 
integral part of many intracellular pathways such as proliferation, development, 
transcription regulation and differentiation. Mutations within MAPK1 in CLL are 
thought to encompass the kinase domain91.  
NOTCH1, SF3B1, MYD88 and BIRC3 have been the most extensively studied genes 
to date, due to their higher functional impact, association with prognostic 
outcome, high frequency of occurrence and their association with 
21 
 
chemotherapeutic resistance, and will be discussed in more detail below. Of the 
four genes MYD88 is the only recurrent gene mutation associated with improved 
prognostics88,89,94. 
NOTCH1 
NOTCH1 mutations (NOTCH1MUT) have been recently identified as an independent 
poor prognostic marker for CLL patients, present in approximately 10-12% of CLL 
cases96. The majority of mutations, greater than 80%, are generated from a 2 
base pair frameshift deletion c.7544_7545delCT88,97-99. In CLL a mutated Notch1 
results in constitutively active truncated protein lacking the C-terminal PEST 
domain. NOTCH1MUT, as well as being an independent poor prognostic marker, 
displays an association with high expression of CD38 and ZAP-70, increased 
incidence with advancing disease, trisomy 12 karyotype and unmutated 
IGHV97,100. The rate of incidence increases to 13-20% in CLL patients with 
progressive disease with increased chance of relapse. For NOTCH1MUT CLL 
patients, the time to first treatment is approximately 4.8 months from 
diagnosis101,102. Patients with NOTCH1MUT are observed to have a 21-45% OS to 10 
years compared to wild-type at 56-66% OS to 10 yrs103,104. NOTCH1MUT also 
demonstrate a propensity for being associated with Richter’s transformation. 
The rate of incidence of Richter’s transformation is 10% for CLL patients 5 years 
after diagnosis105. Richter’s transformation is a very aggressive disease which is 
lethal in almost all incidences; the disease is generally resistant to 
chemotherapy and displays rapid disease kinetics106,107. The most common 
mutation observed in Richter’s transformation is TP53 mutations, however in 30% 
of cases NOTCH1MUT are observed almost exclusively in the presence of 
oncogenic activation of c-MYC97.  
A retrospective study of the CLL8 trial identified which patients within the trial 
had NOTCH1MUT, and then determined how this predicted their response to 
fludarabine in combination with cyclophosphamide (FC) vs FC with rituximab 
(RTX) treatment. From these data it was determined that there was no 
advantage to combining RTX with FC treatment108. 17p del CLL patients 
displayed at least marginal improvement with the addition of RTX to FC 
treatment. At ASH 2013, research was presented from a trial investigating the 
effect of chlorambucil with or without ofatumumab (OFA) on PFS. They observed 
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an improvement in PFS with chlorambucil plus OFA in NOTCH1MUT patients up 
until 18 months, but after this the affect was lost and PFS becomes the same as 
chlorambucil alone for these patients109. This suggests therefore that NOTCH1MUT 
CLL cells have obtained resistance to type I anti-CD20 MAbs.  
SF3B1 
Mutations of splicing factor 3b subunit (SF3B1) have been observed in 3-10% of 
newly diagnosed CLL cases rising to 20% in relapsed refractory CLL 
patients89,91,110. Mutations are typically missense mutations limited to five codon 
hotspots (codons 662, 666, 700, 704 and 742) within the Heat domain89,91,110. 
These mutations are thought to modify the function of the protein instead of 
abrogating activity111. SF3B1 is a core component of the spliceosome machinery 
involved in the removal of introns from precursor mRNA. SF3B1 mutations are 
also an independent poor prognostic marker associated with an aggressive 
disease with the malignant SF3B1 clone expanding as the disease progresses112. 
SF3B1 mutations display an association with 11q del mutations, genomic 
instability and dysregulated epigenetic modification. OS to 10 years reduces 
from 60-77% in unmutated to 10-48% in SF3B1 mutated CLL cases with the time 
to first treatment being 2.4 months89,91,103,110. 
BIRC3 
Mutations within baculoviral IAP repeat containing protein 3 (BIRC3) result in an 
aggressive disease which is extensively observed within CLL patients relapsed 
refractory to fludarabine whom are p53 wild-type113. The rate of incidence rises 
from 5% in freshly diagnosed CLL cases to 25% in those that are relapsed 
refractory, with OS being 3.5 years113. In most cases mutations are either 
frameshift deletions/insertions or nonsense substitutions104. Mutations result in 
truncation of the C-terminal ring domain disrupting the function of the 
protein114. BIRC3 is a negative regulator of non-canonical NF-κB signalling. 
Mutations in BIRC3 usually result in abolishing the E3 ubiquitin ligase activity of 
the protein. Therefore the protein can no longer degrade its target MAP3KI4 
serine threonine kinase, the principle activator of the non-canonical NF-κB 
pathway115. 
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MYD88 
Myeloid differentiation primary response 88 (MYD88) has a very low observation 
rate in CLL, affecting approximately 3% of cases88. MYD88 mutations are 
typically associated with younger age at diagnosis, 83% ≤ 50 yrs. MYD88 
mutations are also associated with low expression levels of CD38 and ZAP-70, 
and a mutated IGHV phenotype. MYD88 mutations present a favourable 
prognostic outcome with 100% OS to 10 years compared to 62% wild-type 
cases116. Most mutations occur as a result of a SNP within exon 5, L265P91,94. 
MYD88 has a crucial role in B cell homeostasis and functions as the adaptor 
protein of interleukin-1 receptor (IL-1R)/ toll-like receptor (TLR) innate immune 
response117. Active TLR leads to the phosphorylation of MYD88 which in turn 
recruits IL-1R and other downstream proteins like TRAF6, resulting in NF-κB 
signalling116. CLL cells with MYD88 mutations display overexpression of several 
genes within the NF-κB pathway, which atypically confers improved prognosis. 
1.2.4 Origin of the CLL cell 
Determining the cell of origin in CLL remains a highly complex problem which is 
yet to be solved. New advances and breakthroughs in immunogenetics and gene 
expression profiling (GEPs) has resulted in a shift in the hypothesis as to the 
nature of CLL development. Part of the complexity in determining the cell of 
origin is due to the immunophenotype observed with CLL; CD5+, CD19+, CD23+ 
and low IgM which is not identifiable in any normal B cell subset107. With the 
identification of two different subsets of CLL, unmutated or mutated IGHV, it 
was proposed that there was a two cell origin model for CLL. However GEP data 
has demonstrated that unmutated and mutated CLL cells share large amount of 
GEP homology with few genes displaying differential expression118. This suggests 
that unmutated and mutated IGHV CLL cells are derived from the same antigen 
experienced progenitor cell. This lead to the hypothesis that CLL cell types are 
derived from marginal zone B cells. Marginal zone B cells surround the GC and 
typically have IgMhigh IgDlow expression, and are associated with responding to 
bacterial polysaccharides in a T cell-independent fashion119. Marginal zone B 
cells have been demonstrated to be antigen experienced through clonal 
expansion and can display either mutated or unmutated IGHV120,121.  
24 
 
Further evidence to suggest CLL cells are derived from antigen experienced cells 
is the observation that there is a skew in BCR use, approximately 30% of 
unmutated IGHV CLL patients express one of >150 grouped stereotyped BCR 
subsets122,123. Therefore it is thought that antigenic stimulation is involved in the 
processes of CLL pathogenesis. Unmutated IGHV CLL cases exhibit high degrees 
of homology of heavy chain complementarity-determining region (HCDR3), which 
often codes for identical IGHV, IGHD and IGHJ gene segments. This same bias is 
observed in stereotyped light chains with KCDR3 and LCDR3 displaying similar 
protein structure56,124-126. This bias in BCR expression suggests that common 
antigens are recognised by CLL cells and are a propagating factor in the 
development of the disease. Such level of similarity of BCR between CLL 
patients is striking, the probability of finding the same extent of similarities 
between the BCRs in two different individuals would be expected to be one in 
over a million cases56. Unmutated IGV marginal zone B cells are the first line of 
defence within the humoral immune response; they are also polyreactive and 
autoreactive Igs119. Unmutated IGV protect against invading microbes and 
catabolic debris such as non-muscle myosin heavy chain IIA, the latter of which 
has been proposed to be a propagating factor in CLL development56,127. However 
aside from expressing IgM and IgD like CLL cells, marginal zone B cells display a 
surface phenotype dissimilar to CLL cells as they are; CD5-,CD23- and CD22+.119 It 
has been proposed that these surface proteins become switched on, upon 
activation of CLL cells128. However this has not been unanimously agreed and so 
marginal zone B cells have not definitively been identified as the CLL cell of 
origin. 
CD5+ B cells have been identified in mice that also display stereotyped BCR use, 
termed B-1 cells129. B-1 cells display both unmutated and mutated IGV genes, 
and are polyreactive receptors, which can bind autoantigens from endogenous or 
exogenous proteins130. A population of CD5+ B cells in humans has been 
identified; however there were several conflicting factors in determining if they 
are the CLL cell of origin131. It was thought human CD5+ B cells are non 
polyreactive, do not mature or proliferate upon stimulation with T-cell type II 
independent antigens and displayed no stereotypy132. However recent research 
opposes this opinion; they demonstrate a statistically significant number of 
stereotyped BCRs in CD5+ B cells133,134. GEP data identified the CD5+ B cell 
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population as baring a closer resemblance to CLL cells when compared to 
marginal zone B cells. They also identified a population of CD5+ CD27+ B cells 
which displayed SHM, potentially representing the mutated CLL patient 
subset133,134. 
Another recent study showed HSCs of CLL patients are already primed to 
generate clonal B cells. Furthermore they identified a bias in IGHV genes 
independent of the original CLL clone in a xenograft mouse model, with the bias 
reflecting that seen in human CLL, indicating the importance of BCR signalling in 
clonal selection135. However the lymphoid expansions present in the mice were 
unrelated to the original patient, suggesting that the genetic lesions occurred de 
novo. These new findings need to be corroborated, but they add to the 
complexity of identifying the true progenitor cell of CLL107. 
1.3 CLL and the microenvironment 
The clinical efficacy of chemotherapeutic agents are limited in CLL by the pro-
survival and pro-proliferative signals received within the BM and LN. The 
dependency of CLL cells on microenvironmental stimulation is also observed in 
vitro, isolated CLL cells undergo spontaneous apoptosis unless rescued through 
co-culture with BM derived stromal cells136. CLL is no longer considered an 
indolent disease, with 1-2% of the entire clone being born per day28. CLL cells 
proliferate within pseudofollicles, located within the BM and LN137. Malignant 
CLL cells have been shown to modify the microenvironment to aid in their 
survival and proliferation138,139. The interaction of CLL cells with the other 
components of this niche, such as stromal cells, T cells and soluble factors, can 
also promote drug resistance137,138,140. A schematic overview of the interaction of 
CLL cells within the tissue microenvironment is shown in Figure 1.6. 
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Figure 1.6 Microenvironmental interaction of CLL cells within lymphoid organs.  
Modified from Ten Hacken. E., et.al. 2014. 
 
1.3.1 Stromal cells 
BM stromal cells provide important interaction with CLL cells to aid their 
survival. VLA-4 an integrin on the surface of CLL cells interacts with vascular cell 
adhesion molecule 1 (VCAM-1) expressed on the surface of endothelial cells, BM 
stromal cells, and extracellular matrix molecular fibronectin136. VLA-4 
stimulation results in the up-regulation of the Bcl-2 family of anti-apoptotic 
proteins; MCL-1 and T cell leukaemia/lymphoma 1 (TCL1)141,142. As described 
earlier CXCL12 is highly expressed by BM stromal cells. CXCL12 interacts with the 
chemokine receptor CXCR4 on CLL cells, providing an important chemokine 
gradient critical for the migration and homing of CLL cells towards the lymphoid 
organs. Migration of CLL cells is observed in vitro by the spontaneous migration 
of CLL cells below the stromal layer within culture, termed 
pseudoemperipoiesis, in a CXCR4 dependent fashion143. There is also some 
suggestion that BM stromal cells can lead to the down-regulation of CD20 on CLL 
cells144. 
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1.3.2 Nurse-like cells 
Nurse like cells (NLC), are located within the secondary lymphoid organs, 
including LNs of CLL patients145. The differentiation of NLC from peripheral 
blood mononuclear cells is still under investigation. However it has been 
established that in vitro CLL cells express the nuclear protein high mobility 
group box-1 (HMGB1) which when released by CLL cells results in NLC 
differentiation through the activation of the receptor for advanced glycation 
end-products (RAGE)- TLR9 pathway146. NLC are also able to activate BCR 
signalling and secrete CXCL12 and CXCL13 to attract circulating CLL cells to 
enter the tissue microenvironment145,147. NLC express tumour necrosis factor 
(TNF) family members; B cell activating factor (BAFF) and proliferation inducing 
ligand (APRIL)148. BAFF and APRIL activate B cell maturation (BCMA), 
transmembrane activator and calcium modulator and cyclophilin ligand 
interactor (TACI) and BAFF receptor which together aid the survival and 
proliferation of CLL cells148. CD31 expression on NLC interacts with CD38 from 
CLL cells to provide further pro-survival signals52. Chemokine receptors CXCR4 
and CXCR5 are expressed at high levels on CLL cells; making them highly adept 
at sensing and following the chemokine gradient produced by the release of 
CXCL12 and CXCL13 by NLC143. Aside from migration, CXCR4 and CXCR5 
stimulation activates the pro-survival pathways ERK1/2 and signal transducer 
and activator of transcription 3 (STAT3) signalling, which has been shown to 
prolong CLL cell survival in vitro149,150. Deuterium labelling of CLL cells has also 
provided insight into CXCR4+ CLL cells, which have an increased rate of lymphoid 
organ infiltration and subsequently inferior outcome for the patient151. VLA-4 
along with CD38 has been shown to provide a poor prognostic association for CLL 
patients, with higher expression linked with enhanced migration towards 
CXCL12152,153. Chemokine (C-C motif) ligand (CCL3) and CCL4 are secreted by CLL 
cells upon BCR stimulation and NLC co-culture in vitro154. Secretion of CCL3 and 
CCL4 attracts monocytes and T cells to the tissue microenvironment. Higher 
levels of CCL3 and CCL4 expression is associated with CD38+ VLA-4+ CLL cells155. 
Within normal B cells CCL3 and CCL4 expression is regulated by Bcl-6 
transcriptional repression156. The plasma levels of CCL3 provide an independent 
poor prognostic marker for CLL patients, with reduced time to first treatment157. 
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1.3.3 T cells 
As previously described, the association of B cells and T cells within the GC 
provide important signals to aid B cell survival. Interaction of CD154 on CD4+ T 
cells with CD40 on the surface of B cells is critical during antigen presentation. 
CD40 signalling is also important for CLL cells, as CD40 ligation promotes CLL 
survival158. In conjunction with CD40 stimulation, release of the pro-
inflammatory cytokine interleukin-4 (IL-4) by CD4+ T cells also propagates pro-
survival signals159,160. CLL disease also impacts upon the ability of T cells to 
function fully. The number of circulating oligoclonal CD4+ and CD8+ T cells is 
increased in CLL161. However their activity is de-regulated; they are unable to 
form functional immune synapses, have reduced T-cell motility mediated by Rho 
GTPase and have higher levels of exhaustion markers such as programmed cell 
death 1 (PD1)162-165. γδT cells, part of the innate immune system which respond 
to microbial pathogens, display reduced cytotoxicity activity within CLL 
patients166. T cells from CLL patients also express high levels of inhibitory 
receptor cytotoxic T lymphocyte associated antigen 4 (CTLA-4), resulting in 
impaired function167. 
1.3.3.1 CD40 signalling 
CD40 is a transmembrane glycoprotein receptor from the TNF-receptor (TNF-R) 
superfamily168. CD40 signalling through CD154 binding is important during 
antigen presentation for T cell-dependent B cell activation. CD154 is expressed 
on CD4+ T cells, monocytes and dendritic cells. CLL cells use CD40 signalling to 
mediate survival and proliferation169,170. CD40 displays no intrinsic catalytic 
activity, therefore TNF-R associated factors (TRAFs) act as adaptors for 
signalling. Upon CD154 engagement of CD40, CD40 clusters within lipid rafts to 
propagate intracellular signals168. TRAF adaptors when bound to CD40, couple 
CD40 with PI3K, PLCγ, MAPK-ERK, stress related protein kinase p38, JNK and NF-
κB171. NF-κB activation results in the activation of Bcl-2 anti-apoptotic proteins 
Bcl-XL, Bfl-1, A1 and MCL-1 and subsequently enhanced cell survival
168. Typically 
Bcl-2 and Bcl-XL expression results in Go/G1 cell-cycle arrest, however CD40 
signalling is able to bypass this in order to stimulate proliferation 172. CD40 
stimulation enhances the drive to proliferate in CLL cells through down-
regulation of the cell cycle inhibitory protein cyclin dependent kinase p27Kip-1 
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whilst enhancing the activation of cyclin dependent kinases Cdk4 and Cdk6173. 
Cdk4 and Cdk6 are both essential for G1 progression, they phosphorylate 
retinoblastoma (Rb) protein leading to the activation of E2F transcription 
factors168.  
Approximately 30% of CLL cases display expression of CD154 suggesting autocrine 
and paracrine signalling is present within CLL174. Noxa is a member of the Bcl-2 
family, but unlike the other proteins described, the expression of Noxa is 
associated with the induction of apoptosis in a caspase dependent fashion. 
Consequently with CD40 stimulation there is a reduction in NOXA gene 
expression both within the LN and following in vitro stimulation175. PLCγ2 
activation by CD40 signalling leads to the assembly of IP3. IP3 associates with IP3 
receptors on the surface of the ER causing cytoplasmic flux of Ca2+ from 
intracellular Ca2+ stores within the ER lumen. Elevated cytosolic Ca2+ levels 
result in a further cascade of Ca2+ release from store-operated calcium 
channels17. In an in vitro study investigating the efficacy of RTX against CLL cells 
stimulated through CD40 there was an increase in cytosolic Ca2+ levels when 
CD20 was bound by RTX, this caused an increase in reactive oxygen species (ROS) 
which enhanced the ability of RTX mediated direct cell death176. The use of a 
cross-linking antibody was required as RTX is not a potent inducer of direct cell 
death, with activity associated with complement dependent cytotoxicity (CDC) 
and antibody-dependent cellular cytotoxicity (ADCC) induction. The increase in 
direct cell death when stimulated with CD40 was not observed for alemtuzumab 
suggesting this is particular to anti-CD20 MAbs. It is not clear whether it is the 
role of CD20 as a store operated Ca2+ channel that causes this rise in cytosolic 
Ca2+ with RTX binding or whether CD20 couples with another Ca2+ channel. 
Importantly based on mRNA expression levels, the induction of direct cell death 
was not caused by typical apoptosis and therefore was p53 independent176. 
1.3.3.2 IL-4 signalling  
T cells secrete several different cytokines which can promote different cellular 
responses within B cells such as proliferation - IL-2 and TNFα, and survival - 
IFNα, IFNγ, IL-2 and IL-4.177 Within normal B cells binding of IL-4 to the IL-4 
receptor (IL-4R) on B cells results in the tyrosine phosphorylation and activation 
of Jak kinases Jak1/2/3178. Activation of Jak subsequently phosphorylates and 
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activates IL-4Rα. IL-4Rα then functions as a docking site for further signalling 
molecules such as insulin receptor substrate-1 (IRS-1) and IRS-2178. IRS1/2 
become phosphorylated after recruitment onto IL-4Rα, which in turn results in 
the association with the p85 subunit of PI3K. This interaction causes a 
conformational change within PI3K resulting in the activation of its catalytic 
ability, resulting in downstream activation of PKC and Akt kinase179,180. 
Activation of these signalling pathways results in increased proliferation and CLL 
survival. PI3K aids in CLL cell viability by protecting against apoptosis by up-
regulating anti-apoptotic proteins from the Bcl-2 family181. 
IL-4Rα also contains three tyrosine binding sites at residues 575, 603 and 631 for 
the docking of STAT6. STAT6 consequently becomes activated by Jak resulting in 
disengagement182. STAT6 then homodimerises and translocates to the nuclease 
where it binds to the promoters of certain genes either alone or in concert with 
other transcription factors. Other transcription factors include c-Jun, SP-1, 
c/EBPα and NF-κB which results in aiding cell survival and cellular 
differentiation183. IL-4 signalling within CLL is thought to be induced by both 
autocrine and paracrine signalling. PHA-activated CD2 purified T cells from the 
peripheral blood of CLL patients demonstrated increased secretion of IL-4 into 
culture when compared against those from normal individuals. CLL cells isolated 
from patients with early stage of disease also displayed elevated cytoplasmic 
levels of IL-4, in vitro they had IL-4 mRNA expression and demonstrated IL-4 
secretion following culture184-187. 
1.3.4 Tailored CLL microenvironment 
Aside from the factors already mentioned, NK cells, like T cells, display impaired 
cytotoxicity in CLL patients. Expression of the plasma molecule human leukocyte 
antigen G (HLA-G) within CLL patients results in the induction of NK cell 
apoptosis and impairs their cytotoxic ability188. NK cell cytotoxic response is 
described in more detail in section 1.4.4.6. CLL cells also release microvesicles 
which activate Akt within BM stromal cells, consequently leading to the 
production of vascular endothelial growth factor (VEGF) and enhancing CLL cell 
survival189. Microenvironmental stimulation clearly demonstrates a huge obstacle 
in the treatment of CLL. Chlorambucil and fludarabine in vitro demonstrate 
reduced efficacy at inducing apoptosis in CLL cells when co-cultured with BM 
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stromal cells141,190. The BM and LN microenvironment provides support to CLL 
cells that have escaped chemotherapy strategies propagating the appearance of 
minimal residual disease (MRD) within CLL191. Finding therapeutic agents 
effective against CLL cells hiding within the tissue microenvironment is crucial 
for the future treatment and management of CLL.  
BCR signalling within the tissue microenvironment is a key component to the 
survival and drug resistance observed within CLL139. Unmutated IGHV CLL cells 
are more responsive to BCR stimulation compared to mutated IGHV, which is 
enhanced by higher expression of ZAP-70 and CD3846,192. The signalling protein 
Lyn is also over expressed resulting in enhanced survival193. There is evidence to 
suggest both autonomous and antigen-dependent BCR signalling play important 
roles in the pathogenesis of CLL. The BCR signalling pathway was described in 
section 1.1.4. Dysregulation of tonic BCR signalling within CLL is observed by the 
hyperactivity of BCR signalling components Lyn, Syk, Btk, and PI3K138. 
Stereotyped BCRs within CLL highlight the importance of antigen stimulation in 
the pathogenesis of CLL. As previously stated unmutated IGHV CLL cells are 
polyreactive, possibly to catabolic debris, such as; non-muscle myosin heavy 
chain IIA, single stranded and double stranded DNA and 
lipopolysaccharides138,194. BCR from mutated CLL patients respond to yeast, fungi 
and β-glucans stimulation194. One stereotyped BCR subset from unmutated CLL 
cells, IGHV1-69 recognises HIV-1, Hepatitis C, viral antigens and commensal 
bacteria195. CLL cells also demonstrate autonomous signalling within some BCRs, 
with self-recognition of epitopes within the HCDR3 region of the BCR196. Unlike 
other malignancies like diffuse large B cell lymphoma, there are currently no 
activating mutations identified within the BCR of CLL patients to explain the 
reliance on BCR signalling197. This implies that both autonomous and antigen 
stimulation are important in receptor signalling and CLL cell survival and 
propagation. Inhibitors that target the BCR signalling pathway in CLL are 
currently in development to combat microenvironmental stimulation. Promising 
therapeutic agents are described in section 1.4.1.2. 
1.3.5 Notch signalling 
Oncogenic transformation of Notch signalling has been identified in several 
different cancer types; lungs, head and neck as well as in the haematological 
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malignancies, T cell acute lymphoblastic leukaemia (T-ALL), Hodgkin’s 
lymphoma and more recently CLL198. Advances in genome wide sequencing 
technologies has provided an insight into the role of Notch1 in CLL. The 
importance of Notch signalling within lymphocyte development has been well 
characterised199. NOTCH1MUT have been identified in approximately 12% of CLL 
patients and are an independent poor prognostic marker96. Notch signalling has 
been shown to suppress p53 and Jnk function, as well as the pro-apoptotic 
proteins Bax, Bim and Noxa200-202. Canonical and non-canonical Notch signalling 
also leads to elevated activation of PI3K/Akt and NF-κB signalling whilst also 
causing an increase in the anti-apoptotic proteins Bcl-2 and Bcl-XL
200,201,203.  
1.3.5.1 Notch receptors and ligands 
The Notch receptor was first identified in 1917 by Thomas Hunt Morgan, after 
the identification of a strain of Drosophila with notched wing phenotype198. 
Within mammals there are four members of the Notch family (Notch1-4). Notch 
receptors are cleaved within the Golgi by furin-like convertase (S1 cleavage) 
after which they transverse to the cellular membrane and as non-covalently 
linked heterodimers act as single pass type I transmembrane receptors204. 
Distinguishing features between the receptors include the number of epidermal 
growth factor (EGF)-like repeats - Notch1 and Notch2 both have 36 repeats 
whereas Notch3 has 34 and Notch4 has 29205. The EGF-repeats of the receptor 
become fucosylated by o-fucosyltransferase at specific serine threonine 
residues205-207. Notch receptors can also undergo post-translational modifications 
at the o-fucose moiety sites by Fringe family 1,3, N-
acetylglucosaminyltransferases addition of N-acetylglucosamine. EGF-like 
repeats and post-translational modifications impact upon the binding affinity of 
the Notch ligand208,209. There are five known canonical Notch signalling ligands; 
Delta-like ligand 1 (DLL1), DLL3 and DLL4 and Jagged 1 and 2. Notch ligands are 
also transmembrane proteins with large EGF-like repeats, and all, except DLL3, 
have a Delta, Serrate and Lag-2 (DSL) domain associated with receptor 
binding210. DLL3 acts as an inhibitory ligand211. Figure 1.7 provides a schematic 
representation of the Notch1 protein domains and Notch1 ligands Jagged 1 and 
DLL1. As the receptor and ligand are both membrane bound, Notch signalling is 
relatively short ranged and requires close cell to cell contact. 
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Figure 1.7 Notch1 receptor and ligand domains.  
Modified from Andersson. E.R., et.al. 2014
211
. 
 
The extracellular portion of the Notch1 receptor contains a signal peptide followed by 36 EGF-like 
repeats, EGF-like repeat 8 is associated with ligand specificity and repeats 11&12 are essential for 
ligand binding. EGF-repeats are followed by three Lin-Notch repeats (LNRs). The first two cleavage 
sites (S1&S2) are located within the heterodimerisation domain (HD), the third (S3) is located after 
the transmembrane domain (TD). After cleavage ICN is released. ICN contains RBPJ associated 
molecule domain followed by ankyrin repeats which are both important for protein-protein 
interactions. Nuclear localisation signals (NLS) are important for translocation to the nucleus 
whereby the transactivation domain (TAD) activates downstream events. At the C terminal the Pro-
Glu-Ser-Thr (PEST) domain is important for ICN degradation. Notch1 ligands Jagged1 and DLL1 
both contain amino-terminal Notch ligand motif, followed by DSL domain and two atypical EGF-like 
repeats termed Delta and OSM-11 (DOS). Jagged family ligands tend to have 15-16 EGF-like 
repeats whilst DLL family have approximately 6-8. Jagged family ligands also contain cysteine rich 
von Willebrand Factor (vWF) type C domain. Both ligands have TD and short C terminal fragments 
approximately 125 -155 amino acids in length
211
. 
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1.3.5.2 Canonical Notch1 signalling 
Canonical Notch1 signalling is activated when the receptor comes into contact 
with a Notch ligand on the signalling cell. This then activates S2 cleavage by 
ADAM10 metalloprotease, which in turn provides the substrate for S3 cleavage by 
γ secretase complex. The γ secretase complex consists of presenilin/APH1, PEN2 
and Nicastrin. Nicastrin is responsible for identifying the amino terminus of the 
cleaved Notch1 receptor for further cleavage210,212. After both rounds of 
cleavage, the truncated Notch1 is then able to translocate to the nucleus and is 
termed intracellular Notch1 (ICN). ICN then associates with the DNA binding 
protein CSL (Centromere Binding Factor 1, Suppressor of Hairless, Lag-1), which 
is also known as RBP-Jk
198,213,214. In the absence of ICN, CSL acts as a 
transcriptional repressor and associates with other co-repressors such as 
SMRT/NCOR, SHAPP and HDACs to enable epigenetic gene silencing. In active 
Notch signalling, ICN displaces the bound co-repressors so that mastermind-like 
protein (MAML) and HDACs such as p300 can take their place and form a 
transcriptional complex. The transcriptional complex produced in normal tissues 
is relatively short lived and gene expression is tissue specific, however key 
Notch1 target genes include hairy enhancer of split (HES) a transcriptional 
repressor, Notch-related ankyrin repeat protein (NARP), c-MYC and DELTEX203,214. 
Once target genes have been transcribed, ICN becomes marked for 
ubiquitination by the E3 ligase FBXW7215. In order for FBXW7, an F box protein, 
to mark ICN for proteasome degradation, the degron sequence within the 
carboxyl terminus of the PEST domain needs to be phosphorylated at a core 
threonine residue95. Cdk8 has been identified as being able to phosphorylate ICN 
and mark the protein for FBXW7 degradation216. The most frequent NOTCH1MUT 
identified in CLL cells is a 2 base pair frameshift deletion c.7544_7545delCT, 
observed in approximately 80% of NOTCH1MUT cases, which results in a truncated 
protein lacking the PEST domain. Therefore ICN is no longer recognised for 
ubiquitination leading to an accumulation of active ICN within the nucleus, 
causing deregulated activation of various different cellular pathways involved in 
cell cycle and cell survival such as NF-κB1 and c-Myc210,217. A representation of 
normal Notch1 and NOTCH1MUT signalling in CLL is shown in Figure 1.8. 
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Figure 1.8 Wild type and NOTCH1
MUT
 pathway 
 
1.3.5.3 Non-canonical Notch signalling. 
Non-canonical Notch signalling, which acts in a CSL independent fashion, is not 
as well understood and the ligands not as well defined as canonical signalling. 
The most studied non-canonical pathway is Notch regulation of Wnt/β catenin 
signalling218-220. Wnt/β catenin signalling is associated with embryonic 
development and homeostatic self-renewal within cells. Like Notch, 
dysregulated Wnt/β catenin signalling has been identified in several different 
cancer types from colorectal cancer to tumourigenesis within the skin, breast 
and BM221,222. Notch controls Wnt/β catenin signalling by binding to un-
phosphorylated active β catenin thus negatively regulating β catenin activity. 
Notch sequesters β catenin without the need for ligand dependent membrane 
Notch cleavage and glycogen synthase kinase -3β (GSK-3β)218,223. GSK-3β activity 
is associated with the β catenin destruction complex. In the presence of Wnt, β 
catenin becomes de-phosphorylated causing activation of the protein. Active β 
catenin joins the co-activator transcription factor T cell factor / lymphoid 
enhancer factor (TCF/LEF) to promote cell cycle and has been shown to aid CLL 
cell survival224,225.  
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1.3.5.4 Notch signalling, microenvironmental stimulation and resistance to 
treatment 
BM stromal cells express Notch1 ligands Jagged-1 and DLL1, which activate 
Notch1 signalling226,227. Enhanced Notch1 signalling is observed within the LN of 
CLL patients in vivo and with BM stromal cell co-culture in vitro. Notch1 
mutations within CLL patients were also more frequently observed within the LN 
compared to circulating cells within the peripheral blood. SF3B1 mutations 
displayed no such bias towards location within the tissue microenvironment228. 
CLL cells have also been found to express both DLL1 and Jagged-1, which within 
the close CLL to CLL cell contact of the LN and BM could provide enhanced 
activation of Notch1 signalling229. NF-κB levels are also elevated in CLL cells 
within the LN and BM microenvironment leading to increased CLL cell survival 
and chemotherapy resistance101,200. NF-κB signalling is able to induce Jagged-1 
expression on B cells during activation, resulting in Notch signalling and in turn 
further elevated NF-κB levels230. Elevated expression of MCL-1 has been 
identified in CLL as being an important protein in increased drug and apoptotic 
resistance of CLL cells within the LN. Notch1 signalling increases and sustains 
MCL-1 expression200. Further tumourigenesis activity of Notch1 signalling in CLL 
is observed by its association with glycolytic switch. Glycolytic switch causes the 
cell to switch from producing energy from mitochondrial respiration to gaining 
energy from glycolysis. Glycolytic switch is associated with growth advantage 
and chemoresistance of CLL cells231. BM stromal cells promoted a glycolytic 
switch in CLL cells in vitro, which was found to be dependent on Notch1 and its 
target gene c-Myc expression. Co-culture of CLL cells with BM stromal cells has 
been associated with increased chemoresistance to fludarabine, 
cyclophosphamide, bendamustine, prednisone and hydrocortisone in vitro. 
Antibodies against Notch1, Notch2 and Notch4 reverted this chemoresistance 
effect after 3 days of the inhibitors in co-culture232. This highlights the role of 
Notch1 mutations within CLL cells, suggesting that these cells rely heavily on 
stromal contact for enhanced malignancy and leads to the production of drug 
resistant clones of NOTCH1MUT within the LN. NOTCH1MUT within the LN of CLL 
patients could lead to ineffective CLL cell clearance by standard chemotherapy 
strategies resulting in the appearance of MRD and relapse following the 
expansion of the malignant NOTCH1MUT cell clone. Further to this NOTCH1MUT 
related chemoresistance, clinical trials of both RTX and OFA identified 
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resistance of NOTCH1MUT CLL cells to anti-CD20 MAbs108,109. One study has found 
that NOTCH1MUT CLL cells have lower expression levels of CD20, observed in 87 
NOTCH1MUT CLL patients from a total cohort of 692 CLL patients. ICN displaces 
HDACs from the CSL transcriptional complex, leaving the now free HDAC to bind 
to the promoter of CD20 epigenetically silencing transcription233. OFA is a potent 
inducer of CDC, however CDC induction is critically dependent on the 
concentration of the target antigen on the surface of the cell. Therefore low 
expression levels of CD20 within NOTCH1MUT CLL cells could lead to the observed 
OFA resistance. 
1.3.6 Cell cycle pathway   
Typical cell cycle progression is restricted in normal cells, only in the presence 
of mitogen signals will the cell undergo proliferation. Proliferation occurs in four 
stages, an initial growth phase G1, followed by DNA synthesis during (S phase), 
cells then enter a second growth phase where they prepare for mitosis (G2) and 
following G2 cells undergo mitosis (M phase), shown in Figure 1.9. Cells primed 
for proliferation enter the early growth phase (G1), if there is no stimulation to 
undergo proliferation then the cell exits the cycle and becomes a quiescent cell 
in G0 phase
83. Proliferation is dependent on the tight regulation of interactions 
between Cdks with their positive regulators Cyclins and negative regulators Cdk 
inhibitors. When mitogenic signals are present, they are detected by D-type 
Cyclins (Cyclin D1-D3). Cyclin D proteins bind and activate Cdk4 and Cdk6, which 
occurs during G1 phase for the initiation of DNA synthesis
234. The Cyclin D-Cdk4/6 
complexes lead to the partial inactivation of the negative regulators Rb, p107 
and p130. The partial inactivation allows Cyclins E1&2 to be released, which 
then bind and activate Cdk2234. This newly formed complex is essential for G1/S 
transition and results in the phosphorylation and complete inactivation of Rb, 
p107 and p130. Inactivation of Rb, p107 and p130 leads to the release of E2F 
which promotes the synthesis of proteins required for S phase235. Cyclin E 
expression is limited to early stages of DNA synthesis. G1/S check point is tightly 
controlled by complicated interplay between serine/threonine Cdks and Cdk 
inhibitors. Cdk2 expression is particularly important in determining whether 
there is DNA damage before progressing further. Under normal circumstances, in 
the presence of DNA damage the cell will either undergo DNA repair or 
apoptosis236. After passing the G1/S checkpoint the cell enters the S phase where 
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DNA is replicated, following this the cell enters G2
83. Cdk2 activation by Cyclin 
A2 is important at the later stages of DNA replication within the S phase to drive 
cells towards M phase. Following DNA replication, the cell enters G2 where the 
replicated DNA is checked83. After passing all the checkpoints the cell enters M 
phase. During M phase the nuclear membrane breaks down and compact 
duplicated chromosomes separate, with sister chromatids migrating to opposite 
poles of the cell. Once the chromosomes are separated, the nuclear membrane 
re-forms and two daughter cells are produced83. 
 
Figure 1.9 Cell cycle progression, identifying the key Cyclin-Cdk complexes. 
 
1.3.6.1 CLL and cell cycle 
Cell cycle progression is a tightly controlled process and dysregulation can result 
in uncontrolled proliferation and the generation of genetic mutations. Outside of 
the tissue microenvironment CLL cells are typically in the GO/G1 phase of the 
cell cycle237,238. CLL cells have been shown to overexpress Cyclin D2 and the 
inhibitor p27Kip-1, which are regulators during the early phases of cell cycle 
progression. Elevated expression of the Cdk inhibitor p27 Kip-1  is associated with 
a poorer outcome for CLL patients239. Progression through G1 is dependent on 
Cyclins D1/2/3, Cdk4 and Cdk6 resulting in the phosphorylation of Rb. In normal 
B cells it appears that Cyclin D3, Cdk6 and p27Kip-1 are the most important 
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regulators of G1 progression in vitro following anti-IgM and CD40 stimulation
240. 
Cyclin D1 is not typically present in either resting or active B cells and Cyclin D2 
is only very moderately regulated in active B cells. Mitogenic stimulation of CLL 
cells in vitro with CpG-ODN and IL-2 largely up-regulated Cyclin D2 and Cyclin D3 
and stimulation favoured Cdk4 as opposed to Cdk6. Despite having higher 
expression in circulating cells, p27Kip-1 was more readily down-regulated upon 
proliferation stimuli then B cells238. This highlights the finding that CLL cells are 
primed towards proliferation. Notch signalling has also been shown to influence 
proliferation in different cancers. Within pancreatic cells down-regulation of 
Notch1 results in growth inhibition with an increase in cells within G0/G1, 
associated with an increase in the Cdk inhibitors p21WAF1/CIP1 and p27Kip1 241. 
Within small cell lung cancer Notch signalling has been associated with cell cycle 
block at G0/G1 again due to p21
WAF1/CIP1 and p27Kip1 expression 242. T-ALL, like 
CLL, display activating mutations of Notch1, with Notch1 activation causing a 
decrease in p27Kip-1 inhibition for increased passage into G1/S phase
243. The 
influence of Notch on apoptosis has been the main focus of research within CLL 
as opposed to cell cycle progression. Interestingly one study identified over 
expression of several genes involved in cell cycle progression within NOTCH1MUT 
CLL patients244. NOTCH1MUT within CLL have favoured association with trisomy 12 
karyotype, and the cell cycle genes identified in this study as being over 
expressed were those located on chromosome 12. Although the study does not 
state which genes were elevated, cell cycle genes Cdk2 and Cdk4 are both 
located on chromosome 12245.  
Notch1 signalling within CLL demonstrates a pathway that deserves further 
investigation to determine its role in the pathogenesis of CLL and the 
appearance of MRD within CLL patients. 
1.4 CLL treatments 
While some CLL patients never require medical treatment, for the majority of 
patients diagnosed < 60 years treatment is required. Despite recent advances in 
chemotherapeutic agents CLL remains incurable to date.  
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1.4.1 Single agents 
Alkylating agents such as chlorambucil were previously considered the ‘Gold 
standard’ for treatment of CLL especially in those with reduced fitness, due to 
its relatively low levels of toxicity. Alkylating agents add alkyl groups onto DNA 
bases, DNA breaks are then caused by DNA repair enzymes. Alkylating agents can 
also generate DNA crosslinks which prevent DNA from being transcribed and 
replicated. The presence of DNA breaks then activates p53 mediated 
apoptosis246. Treatment of patients with chlorambucil alone demonstrates 
relatively low levels of complete remission (CR), with the most promising 
responses observed using combination therapy247. Purine analogues include 
fludarabine, pentostatin and cladribine. Purine analogues cause inhibition of 
both DNA synthesis and DNA repair mechanisms causing an accumulation of DNA 
breaks within the cell. Accumulation of DNA breaks results in p53 driven 
apoptosis and activation of poly (ADP-ribose) polymerase causing necrosis248. The 
most extensively used and assessed purine analogue is fludarbine which displays 
superior overall response rates (ORR), CR 7-40% more remission than CHOP 
(cyclophosphamide, doxorubicin, vincristine, prednisone), but does not improve 
OS as a single agent249,250. Bendamustine is an alkylating agent that has similar 
properties to both alkylating agents and purine analogues. Bendamustine can 
drive both p53 dependent and independent apoptosis and also cause inhibition of 
mitotic check point genes251. Bendamustine displays good responses but at a cost 
of increased toxicity. Bendamustine ORR and median PFS was 67% and 22 months 
respectively, which was an improvement upon the responses observed with 
chlormabucil252.  
1.4.1.1 MAbs 
MAbs against the cell surface protein CD20 have been used extensively in the 
treatment of CLL and their production, function and efficacy will be discussed in 
more detail in the following sections. RTX a chimeric MAb against CD20 is used 
comprehensively for the treatment of CD20 positive non-Hodgkin lymphomas253. 
CLL expression level of CD20 is low in comparison to other B cell malignancies. 
RTX is licenced as first line therapy for the treatment of CLL when used in 
combination with fludarabine and cyclophosphamide. RTX produces limited 
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responses as a single agent and displays highest efficacy when used in 
combination therapy.  
OFA is the next generation of MAb from RTX and binds to a novel epitope on 
CD20. The novel binding site results in increased binding affinity, prolonged 
dissociation rates and enhanced CDC254,255. OFA has currently been licensed for 
the treatment of CLL patients as a single agent in those refractory to both 
fludarabine and alemtuzumab (double refractory CLL patients), displaying ORR 
of 51% within these patients256,257. OFA has recently been given approval for 
treatment of previously untreated CLL patients when in combination with either 
chlorambucil or bendamustine.  
Obinutuzumab (GA101) is a humanised glycoengineered type II anti-CD20 MAb, 
which induces high levels of apoptosis with increased induction of ADCC, but 
reduced levels of CDC. Phase II of the GAUGUIN trial using 1,000 mg GA101 for 
20 CLL patients demonstrated ORR of 30% with 10.7 months PFS258,259.  
The other main MAb target for the treatment of CLL is CD52, with MAb 
alemtuzumab. CD52 expression is not limited to the B cell lineage and is found 
on the surface of thymocytes, T cells, B cells and monocytes. Alemtuzumab is a 
recombinant fully humanised MAb. Alemtuzumab is an effective second-line 
treatment strategy for CLL patients that have become refractory to fludarabine 
or have poor prognostic genetics like 17p del or TP53 mutations. Compared with 
chlorambucil, alemtuzumab displayed superior OR, CR, PFS and 42% reduction in 
the risk of disease progression86,260,261. 
Other MAbs have been assessed for their efficacy such as anti-CD19 and anti-
CD23 MAbs, but they displayed limited efficacy in pilot clinical trials262. Anti-
CD40 MAb lucatumumab (HCD122), which blocks the CD40 receptor disrupting 
microenvironmental signals and mediates ADCC, has also undergone a phase I 
clinical trial. Unfortunately despite acceptable tolerability of the drug there was 
minimal effect as a single agent within 26 relapsed CLL patients, however 
further research is required to determine if lucatumumab may prove beneficial 
when in combination with other therapies263. Early analysis of an anti-CD44 
humanised MAb (RG73S6) has shown promising results. RG73S6 displayed CLL 
only cytotoxicity and was able to induce caspase-dependent apoptosis in ZAP-70 
42 
 
positive CLL patients. When 1 mg/kg RG73S6 was used to treat mice engrafted 
with human CLL cells there was complete clearance of leukaemic cells, 
suggesting a novel immunotherapy option264.  
1.4.1.2 BCR targeting 
As previously described BCR signalling is important in CLL cell survival and 
therefore provides a promising target for the eradication of CLL, a schematic 
diagram of the currently used BCR inhibitors and MAb targets is shown in Figure 
1.10. Several different small molecule BCR inhibitors are currently being 
assessed and are showing great promise. Fostamatinib, a Syk inhibitor, is able to 
induce apoptosis through disrupting BCR signalling. A Phase I/II clinical trial 
demonstrated ORR of 54% in 6 out of 11 CLL patients and 6.4 months PFS265,266. 
Idelalisib (CAL101, GS101) is a specific inhibitor of the PI3Kδ, and in vitro 
displays effective activity against CLL cells interacting with the tissue 
microenvironment. A phase I idelalisib clinical trial of 54 patients with relapsed 
refractory CLL demonstrated an ORR of 72% and median PFS of 15.8 
months267,268. Other new inhibitors include ibrutinib, a BTK inhibitor, which 
induces apoptosis in vitro. Ibrutinib has been given FDA approval for the 
treatment of relapsed or refractory CLL patients and has shown clinical promise 
with estimated PFS of 90% and ORR of 42.6% at 12 months269,270. 
 
Figure 1.10 BCR inhibitors and MAb targets. 
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Other single agents include inhibitors of the key regulators of apoptosis in CLL 
cells- the Bcl-2 family, inhibitors of which include; AT-101 and ABT-199 the 
latter of which has shown good clinical promise25. Immunomodulatory agents 
include lenalidomide which has antiangiogenic properties, and has shown 
encouraging clinical results271. Harnessing T cell mediated cytotoxicity is also 
currently under development for the treatment of CLL. T cells can be genetically 
engineered to express chimeric antigen receptors (CAR) which are produced 
from an antigen recognition domain made into a single chimeric protein with the 
intracellular domain of CD3-zeta or FcγRI protein from T cells272. For the 
treatment of CLL CAR against CD19 are currently being investigated with early 
reports demonstrating high potency273. 
1.4.2 Combination therapy 
Current first line therapy for CLL involves the administration of purine analogue 
fludarabine in combination with the alkylating agent cyclophosphamide (FC) for 
patients determined fit enough to withstand this regime. The UK phase III CLL4 
trial identified vast improvement in CR with FC, 38%, compared to fludarabine 
single agent use, 7-15%274. They also observed improvements in ORR and PFS, 
and although a higher frequency of neutropenias was identified there was no 
significantly higher risk of severe infection275. The addition of RTX to FC (FCR) 
further increased the potency of the chemoimmunotherapy treatment. The CLL8 
trial investigated FC vs FCR in 817 CLL patients and identified ORR increased 
from 85.4% to 92.8% with the addition of RTX, CR went from 22.9% to 44.5% 
(p<0.001) and PFS went from 62.3% to 76.6% 25,276. FCR combination therapy 
represents a benchmark comparator to determine the effectiveness of new 
combination therapies. Other combination therapies include FCR plus 
alemtuzumab which went to phase II clinical trial and appeared promising for 
high risk CLL patients277. Bendamustine has been combined with RTX and 
assessed in 81 relapsed CLL patients producing a median of 14.7 months event 
free survival278. When compared against FCR the results were relatively 
comparable, although CR rates were lower there were fewer neutropenias 
observed. Other combinations tested include purine analogue cladribine with 
RTX and alemtuzumab with RTX25. OFA has also been combined with 
chlorambucil and displayed significantly improved PFS of 22.4 months vs 13.1 
months and higher ORR279. Small molecule inhibitors are also being tested for 
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additive and synergistic activity. Idelalisib in combination with OFA has gone to 
phase I clinical trial. Idelalisib on its own within 21 relapsed refractory CLL 
patients demonstrated 72% ORR and PFS of 15.8 months268. When in combination 
with OFA ORR was 76% and PFS 17.8 months in 21 relapsed refractory patients137. 
Although most patients exhibit an initial response to therapy nearly all relapse, 
due to the re-emergence of MRD, and many become refractory to fludarabine 
based regimes280-282. This group of CLL patients represents a small subset that 
have very poor prognosis, are difficult to treat with no clear standard therapy, 
with a median survival time of 8 months, underpinning the need for novel 
drugs283. 
1.4.3 MAb treatments 
MAbs exert anti-tumour activity by harnessing the body’s own natural immune 
response especially ADCC involving the recruitment of NK cells to cause 
phagocytosis and CDC requiring the activation of the classical complement 
pathway, and/or apoptosis284. 
1.4.3.1 CD20  
CD20, a B-cell marker, is a non-glycosylated phosphoprotein member of the 
MS4A family of proteins. This 33-37 kDa protein, is a tetraspan membrane bound 
protein. The extracellular portion of CD20 is marginal, 44 amino acids in length, 
and is the docking site for anti-CD20 MAbs binding, shown in Figure 1.11254,285-288. 
CD20 expression becomes activated at the pre-B cell stage of development and 
remains consistent until terminal differentiation into a plasma cell. The 
biological activity of CD20 is not fully elucidated, however it is thought to act as 
an ion channel and a store operated Ca2+ channel289,290. Although CD20 knockout 
mice lacked any obvious phenotype289, CD20 is also thought to function as a 
modulator of cell growth, differentiation and initiate intracellular signals. 
Binding of different MAbs to CD20 have identified differential responses in cell 
cycle progression, one MAb enhanced progression from GO to G1 phase, whereas 
the other inhibited progression from G1 to S/G2 stages
291. Binding of MAbs can 
also induce the activation of tyrosine and serine/threonine protein kinases non-
covalently associated with CD20, which in turn leads to the activation of PLCγ291. 
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As previously described PLCγ activation can lead to several different cellular 
responses such as survival, proliferation and migration. Hyper cross-linking of 
MAb bound to CD20 with a secondary Ab results in the mobilisation of Ca2+ from 
intracellular stores176. Although the function of CD20 is not fully understood it 
clearly has dynamic cellular activity and remains an ideal specific therapeutic 
target for B cell malignancies. 
 
Figure 1.11 CD20 structure with RTX and OFA binding sites. 
Modified from Ruuls. S.R., et.al. 2008
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1.4.3.2 MAb production 
MAbs can be produced in several different ways; the suffix of the MAb name 
indicates the production type. MAbs ending in ~ximab, such as RTX have been 
produced from splicing the antigen binding variable region of a mouse antibody 
with the constant Fc region of a human IgG. MAbs ending with ~ zumab, such as 
alemtuzumab, are humanised with murine hypervariable regions spliced into a 
human antibody. A suffix of ~mumab, such as OFA are fully humanised1.  
RTX was produced from the parent murine anti-CD20 MAb 2B8292. Light and 
heavy chain V regions were amplified using polymerase chain reaction (PCR) and 
then cloned into cDNA expression vector with human IgG1 heavy and κ-light 
chain C regions. High levels of C2BB (RTX) were then produced in hamster ovary 
cells. Activity was checked in human B cell lines and binding affinity, 
approximately 8.0 nM, to CD20 was similar to that observed with 2B8292,293. OFA 
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on the other hand was generated by human Ig transgenic mice being transfected 
with non- Ig secreting (NS/O) CD20 transfected cells using prime-boost 
strategy255,294. Hybridomas are a cell line used to produce a singular type of Ig 
protein. Hybridomas producing IgG1 MAbs from successfully immunised mice 
were isolated and the binding affinity to CD20 established. From this method 
three different MAbs were produced 2F2 (OFA), 7D8 and 11B8255. The superior 
binding and induction of CDC when compared to RTX lead to OFA being chosen 
for clinical practice. 
1.4.4 MAb activity 
1.4.4.1 Type 1 & 2 
Anti-CD20 MAbs fit into two categories, type I, which includes both RTX and OFA 
and type II, which includes GA101262. Type I MAbs are potent inducers of CDC but 
are less able to trigger programmed cell death, while type II MAbs are less 
competent at inducing CDC but are able to initiate direct cell death. However 
there are no differences in their ability to recruit NK cells for ADCC. These two 
types of MAbs are distinguished from each other by the ability to rearrange CD20 
into ‘microdomains’ or ‘lipid rafts’285,295,296. Type I MAbs, when bound to CD20, 
are able to effectively reorganise the plasma membrane into detergent insoluble 
lipid rafts whereas type II MAbs are not. The ability to induce lipid rafts is 
thought to aid type I MAbs to activate CDC, as the translocation of the 
CD20/anti-CD20 MAb complex provides an effective docking site for the globular 
head of C1q onto the Fc region of the CD20 Mab254,255,285. It is unclear what the 
differences are in binding of anti-CD20 MAbs that leads to such dramatically 
different functions255. The immune responses activated by type I MAbs are shown 
in Figure 1.12. 
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Figure 1.12 Innate immune responses activated by type I anti-CD20 MAbs.  
MAb binds to its target antigen activating three possible pathways to cause tumour lysis. CDC is 
activated when bound MAb is recognised by complement C1 activating the classical complement 
cascade resulting in the formation of membrane attack complex (MAC) and lysis. ADCC becomes 
activated when the Fc portion of the MAb is recognised by NK cells which activate targeted cell 
death. The Fc portion of the MAb can also be recognised by phagocytic cells, their ability to engulf 
the target cell is further enhanced by complement opsonisation on the surface of the cell.  
 
1.4.4.2 CDC 
The complement system is a fundamental part of the body’s innate immunity, 
providing a fast acting antimicrobial defence mechanism. Complement was first 
discovered in 1980 by Jules Bordet, whereby the activity was identified as 
‘complementing’ Ab activity by helping to opsonise the surface of the bacteria 
to mediate the killing of the invading pathogen. This pathway was termed the 
classical complement cascade. Since then two other complement activating 
pathways have been identified, alternative and lectin pathway1. The classical 
pathway is activated by antibody binding. Complement proteases are synthesised 
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as inactive pro-enzymes (zymogens), which become enzymatically active after 
proteolytic cleavage297,298. To activate the complement cascade either IgM or IgG 
MAb bound to an antigen on the surface of the target/cancer cell is then 
recognised by the complement component C1. The classical cascade becomes 
activated when C1 binds to an antigen on the surface of the target cell. C1 is 
comprised of three segments; C1q recognition segment, C1r and C1s serine 
proteases. C1q contains six globular heads that recognise the bound MAb (Figure 
1.13)1,284. When two or more of the globular heads bind to the MAb, a 
conformational change occurs within the C1 complex, resulting in C1r becoming 
autocatalytic, activating C1s serine protease function299.  
 
Figure 1.13 Schematic of C1 structure. 
Modified from Murphy. K., 2012. 
 
A catalytic cascade follows, of complement components being cleaved into 
active forms to eventually produce the membrane attack complex (MAC), which 
perforates the cell membrane creating a pore. C1s activates complement 
component C4 cleaving it into two components C4a, a peptide mediator of 
inflammation, and C4b which binds C2 so that C1s can then cleave C2 into two. 
C2a in combination with C4b forms the active C3 convertase complex, while C2b 
acts as a precursor of vasoactive C2 kinin300. Complement activation is confined 
to the target cell on which the MAb is bound, therefore it is crucial that MAb 
epitopes are located as close to the cellular membrane. C4b opsonises the target 
cell; if C4b does not efficiently form a covalent bond with carbohydrates on the 
surface of the target cell then the thioester bond within C4b is irreversibly 
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cleaved resulting in an inactive complement component. C3 convertase, 
covalently bound to the cell surface, then cleaves a large volume of C3 to 
generate C3b proteins1,301. C3a is also produced during C3 cleavage which is 
associated with inflammation induction. C3 cleavage is the critical step in the 
complement cascade and like C4b, C3b also forms a covalent bond with the 
surface of the target cell. Once again if the exposed thioester bond takes too 
long to attach then it also becomes inactive by hydrolysis. Large amounts of C3b 
opsonise the surface of the target cell. C3b opsonisation apart from being 
important for CDC can also signal the target cell to be engulfed by a phagocyte, 
described in section 1.4.3.4. Alternatively C3b can join C4b-C2a, to generate C5 
convertase, resulting in the release of subunits C5a and C5b. C5a release is 
highly inflammatory284,302. C5b is the first complement component to start the 
formation of the MAC (Figure 1.14).  
 
Figure 1.14 MAC complex. 
Modified from Murphy. K., 2012. 
 
C5b anchors the remaining MAC complement components to the cell membrane 
and initiates the assembly. C5b binds to one unit of C6, which in turn binds one 
C7 protein. This complex of C5b-C6-C7 then results in a conformational change 
in C7 allowing the hydrophobic site on C7 to become exposed so that it can be 
inserted into the lipid bilayer of the cell membrane. C8 and C9 complement 
components also contain hydrophobic domains allowing them to also transverse 
the lipid bilayer. C8 binds adjacent to the C5b-C6-C7 complex and once C9 also 
starts to bind then C8 activates the polymerisation of between 10-16 C9 
molecules to form a pore within the lipid bilayer of the cell1,303. The channel 
that is generated is approximately 100Å in diameter with the external part being 
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hydrophobic and the internal hydrophilic1,304. The channel allows passage of 
solutes and water out of the target cell destroying homeostasis and inducing 
cellular lysis. Naturally the body has strict control mechanisms to prevent 
uncontrolled activation of the complement cascade.  
1.4.4.3 Regulation of complement activation 
Understandably strict control is required to prevent excessive complement 
activation. As several of the subunits are opsonins and act as pro-inflammatory 
molecules, uncontrolled activation can cause unnecessary damage to 
surrounding tissues305. Complement activation can be controlled at several 
different points within the CDC pathway. The activity of C1 is controlled by C1 
inhibitor (C1INK), which is a plasma serine protease inhibitor, which binds to 
C1r:C1s causing its dissociation from C1q. Therefore C1INK provides a limited 
timeframe in which C1s is able to cleave C2 and C41,306. Plasma serine protease 
factor I works in conjunction with the co-factor membrane co-factor of 
proteolysis (MCP; CD46) acting together to cleave C3b/C4b into an inactive form. 
Plasma serine protease factor I also acts with complement receptor 1, to binds 
to C4b displacing C2a1,306. C4b is then cleaved and inactivated by factor I. 
Decay-accelerating factor (DAF; CD55) also competes for C4b binding, again 
causing C2a to be displaced so that C3 convertase can no longer be formed. DAF 
is associated with the plasma membrane of the cell through its 
glycosylphosphatidylinositol (GPI) tail307. Protectin (CD59) is also anchored to the 
membrane in this way. CD59 stops the MAC forming at the final stage by 
inhibiting the binding of C9 polymers. Therefore effective MAbs have to be able 
to overcome these complement inhibitory proteins308,309. The most critical factor 
for RTX activity is expression levels of CD20, although complement inhibitory 
protein expression in CLL has been studied their full effect upon MAb therapy 
remains ambiguous. Inhibitors of both CD55 and CD59 have been shown by some 
to aid the activity of RTX but have limited effect on OFA induced CDC310-314.  
1.4.4.4 CDC and CLL 
CDC induction is critically dependent on the distance between MAb binding and 
the plasma membrane, with closer binding associated with more efficient 
coating of active complement components onto the target cell315. The novel 
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epitope binding site of OFA brings the complex closer to the surface of the cell 
(Figure 1.11) making it more potent at inducing CDC then RTX254,255. This is of 
particular importance in CLL, as CD20 expression levels, are relatively low 
compared to other B-cell lymphomas. CD20 expression levels will then predict 
the response to MAbs310,311. One study estimated that on 14 CLL patient samples 
there were between 1,500-70,000 CD20 molecules per cell, compared to 100,000 
- 250,000 molecules per cell observed on normal B cells, demonstrating the vast 
down-regulation of CD20 in CLL262,310. OFA also demonstrates superior binding 
affinity to CD20 and C1q, with longer dissociation rates, increasing its activity in 
comparison to RTX316. In addition, recent studies demonstrate that CLL cells can 
evade RTX, through sequestration of CD20-RTX complexes by phagocytic cells, 
resulting in trogocytosis317. This enables CD20 depleted lymphocytes to remain in 
circulation, no longer responsive to RTX treatment318-320. These findings highlight 
the importance of generating a MAb capable of effectively inducing CDC. 
1.4.4.5 Complement deficiencies 
Complement deficiencies are generally quite rare; and have been linked with 
approximately 2% of primary immunodeficiency disorders321. C2 is the most 
commonly identified deficiency with a prevalence of 1/20,000 within Western 
countries300. Deficiencies within the classical complement cascade (C1, C2 and 
C4) have been well documented in their exacerbation of the pathogenesis of the 
autoimmune disorder systemic lupus erythematosus (SLE)322. Deficiencies within 
the classical cascade result in: impaired ability to clear circulating immune 
complexes and reduced clearance of apoptotic cells; increased tolerance to 
autoantigens, and dysregulation of cytokines. Individuals with impaired activity 
of the classical cascade and C3 are susceptible to infections with encapsulated 
bacteria due to ineffective clearance after Ab binding1. C2 deficiencies have 
been linked with recurrent Streptococcus pneumonia infections causing 
septicaemia or meningitis300,323. Deficiencies within the MAC result in increased 
susceptibility to the species Neisseria meningitidis324. Early reports in the 1980’s 
indicated that CLL patients harbour deficiencies in classical complement 
components C1 and C4 resulting in defective immune complex clearance. 
Deficiencies in classical complement components have also been linked to CLL 
patients being more susceptible to infections with S. pneumonia, and exhibiting 
a propensity to develop autoimmune syndromes325-328. Research has indicated 
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that complement is rapidly exhausted in vivo following the administration of 
both RTX and OFA independently319,329. Therefore the limited pool of available 
complement components and the potential for CLL patients to harbour 
complement deficiencies has important consequences for the efficacy of type I 
anti-CD20 MAbs.  
1.4.4.6 ADCC 
Target cells bound with Ab can also be destroyed by NK cells. NK cells contain 
prominent intracellular granules. NK cells have a limited repertoire of 
recognition sites for identifying invading pathogens and their action is generally 
carried out without the aid of Abs. However Abs can signal a cell for degradation 
by NK cells through the NK receptor FcγRIII (CD16), which recognises both IgG1 
and IgG3 antibody subclasses. Once associated with a bound Ab, NK cells release 
toxic cytoplasmic granules containing perforin and granzymes onto the surface of 
their target. Exocytosis causes the granules to be incorporated into the target 
cell resulting in cell death1,330. 
1.4.4.7 Phagocytosis 
Bound MAb can also cause the cell to be destroyed by phagocytosis. The Fc 
portion of the antibody is recognised by phagocytic cells. Phagocytic cells 
include; monocytic and myelocytic lineages, in particular macrophages and 
neutrophils. The Fcγ receptor engages the antibody on the surface of the target 
cell. Phagocytosis activity can also be synergised by complement opsonisation 
which interacts with the complement receptor CR1 on the effector cell. Through 
successive binding with the receptors on the effector cell the target cell 
gradually becomes engulfed. Once enclosed the target cell is sequestered into 
an acidified vesicle, the phagolysosome. Lysosomes are then released into the 
vesicle effectively destroying the target1,331,332.  
1.4.4.8 Direct cell death 
Although Type I MAbs are poor inducers of direct cell death, there is some 
evidence to support their ability to do so. There is some controversy over how 
clinically relevant the ability of type I to induce programme cell death is, as 
several studies demonstrate that cross-linking with a secondary reagent is 
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required to initiate the pathway176,333. It has been proposed that type I and type 
II anti-CD20 MAbs induce cell death via two different pathways. It is thought that 
type I MAbs when in a lipid raft as a CD20: anti-CD20 Mab complex also 
aggregate with the BCR, and type 1 anti-CD20 MABs then commandeer the Ca2+ 
flux pathway to trigger apoptosis334,335. Type II anti-CD20 MAbs can cause 
programmed cell death through the induction of the autophagy pathway. 
Autophagy results in the cytoplasmic material including organelles being 
enveloped by vesicles which are targets for recycling and destruction262,336. One 
of the benefits of using type II MAbs is through the avoidance of using the 
classical apoptotic pathway, as several proteins within the apoptotic pathway 
are deregulated in poor prognosis CLL. 
1.4.5 Rationale for investigating OFA efficacy in CLL 
RTX is currently used as first line therapy in the treatment of CLL in combination 
with FC. OFA has recently been given approval for the treatment of CLL patients 
in combination with chlorambucil for previously untreated CLL patients, when 
fludarabine based therapy is not suitable, and as a single agent for CLL patients 
that are double refractory. RTX as a single agent displays poor improvement in 
PFS and OS274. OFA on the other hand displays superior PFS and OS as a single 
agent and may therefore display a greater benefit for CLL patients if given 
approval as a first line therapy for all CLL patients337. The ability of OFA to 
produce a CDC response is important for its efficacy. We wanted to establish the 
limiting factors of OFA treatment in CLL. The exact role CDC induction plays in 
the efficacy of anti-CD20 MAbs remains controversial with some paying more 
emphasis towards the induction of ADCC and phagocytosis. However recent 
studies have identified that complement exhaustion has been observed in vivo, 
highlighting that CDC is an important pathway for the eradication of CLL 
cells319,329. Therefore we further investigated the prevalence and consequences 
complement deficiencies may or may not have upon the ability of CLL cells to 
elicit a CDC response. Complement is extremely important, enhancing the 
immune system ability to eradicate encapsulated bacteria. Therefore MAbs that 
cause large amount of complement exhaustion could result in CLL patients 
having an even more compromised immune system with greater risk of morbidity 
and mortality due to infection338.  
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The recent identification of recurrent NOTCH1MUT has given rise to the 
observation that dysregulation of different genetic pathways within CLL cells 
may impact upon the efficacy of anti-CD20 MAbs. As described a retrospective 
investigation of the CLL8 trial identified that there was no observable benefit of 
adding RTX to FC within NOTCH1MUT CLL patients108. This was also highlighted in 
a clinical trial investigating the effect of chlorambucil and OFA in NOTCH1MUT 
CLL patients. Unlike RTX there was an initial benefit of adding OFA to 
chlormabucil treatment but this only lasted 18 months109. Therefore it is 
important to further characterise the impact NOTCH1 and other genetic changes 
may have on anti-CD20 MAb efficacy. 
The microenvironment plays a critical role in the pathogenesis and drug 
resistance capabilities of CLL cells. Others have established that there is an 
increase in anti-CD20 MAb induced direct cell death when CLL cells are 
stimulated through CD40176. This was observed in both type I and type II anti-
CD20 MAbs, despite type I MAbs being poor inducers of programmed cell death. 
Therefore investigating the effect of CD40 stimulation has upon CDC maybe 
more clinically relevant for type I anti-CD20 MAbs. The Notch1 pathway becomes 
up-regulated within the tissue microenvironment227. Therefore it is also 
important to determine NOTCH1MUT CLL cells response to anti-CD20 MAbs when 
stimulated by IL-4 and stromal cells expressing CD154. When simulating the 
tissue microenvironment we aimed to determine whether CLL cells deregulate 
CD20 expression level and/or complement inhibitory proteins. It was also our 
aim to determine if CLL cells that survive OFA induced CDC activity displayed 
distinct gene signatures compared with untreated cells. If deregulation of 
certain pathways is apparent at the gene expression level this may provide a 
possible therapeutic avenue for enhancing the activity of anti-CD20 MAbs, 
providing more effective clearance of CLL cells.  
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1.5 Aims  
1. Establish the prevalence of complement deficiencies within our CLL 
patient cohort. 
2. Determine the functional consequences of complement deficiencies and 
exhaustion upon anti-CD20 MAb induced CDC. 
3. Define ADCC and CDC induction in our CLL patient cohort between RTX 
and OFA. Establish if there are any statistically significant trends between 
CD20, CD55 and CD59 and the induction of OFA CDC.  
4. Establish the impact mimicking microenvironmental signals in vitro has on 
our different CLL cytogenetic subsets and their ability to undergo anti-
CD20 MAb induced CDC. 
5. Characterise gene expression profiles in CLL cells that evade OFA induced 
CDC. 
6. Further define the efficacy of anti-CD20 MAbs upon NOTCH1MUT CLL cells 
in comparison to cytogenetically normal CLL cells. 
7. Delineate the mechanism surrounding NOTCH1MUT CLL cell resistance to 
anti-CD20 MAbs. 
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2 Materials and Methods 
The names and addresses of the suppliers of the reagents and materials used for 
this study are shown in Table 2.1. 
2.1 Serum collection and assessment 
Ethical approval for this study was obtained from the West of Scotland Research 
Ethics Committee, NHS Greater Glasgow and Clyde (United Kingdom). Peripheral 
blood samples were obtained following informed consent, from patients with a 
confirmed diagnosis of CLL (mean age 67.9 ± 6.78 years, range 48–88 years and 
percentage male 57.9%), the clinical parameters of CLL serum used in this study 
are shown in Table 2.2. Peripheral blood samples were also collected from 
healthy volunteers to isolate normal healthy serum (NHS; age range 25–50 years 
old) and age matched serum (AMS; mean age 64.8 ± 12.91 years, range 47–84 
years and percentage male 41.7%). Serum was separated from blood cells using 
serum clot activator, followed by centrifugation at 3000g for 10 min. Sera was 
immediately snap frozen on dry ice and stored at -80oC. Pooled NHS was 
prepared by isolating and mixing sera from 10 different healthy volunteers, prior 
to freezing. 
2.1.1 Complement assessment 
C1 and C2 levels in sera were determined by radial immunodiffusion (RID) (The 
Binding Site Group Ltd., Birmingham, UK) following the manufacturer’s protocol 
using the RID reference table provided. In order to use the RID reference table, 
the precipitin ring needs to develop to completion, for C1 this is at least 96 hr 
and for C2 at least 120 hr. C3c and C4 were determined by immunonephelometry 
in the clinical diagnostic immunology laboratory (Gartnavel General Hospital, 
NHS Greater Glasgow and Clyde). The activity of the classical complement 
cascade in serum was determined using a total haemolytic complement kit, 
CH100 assay (The Binding Site Group Ltd.) following the manufacturer’s 
instructions. 
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2.2 CLL samples and normal B cells  
2.2.1 CLL cells 
CLL cells were isolated from peripheral blood using RosetteSepTM human B cell 
enrichment cocktail (StemCell Technologies, Vancouver, Canada) following the 
manufacturer’s instructions. The clinical parameters of CLL patient cells used in 
this study are shown in Table 2.3. CLL cell purity was determined by flow 
cytometry using anti-CD19, -CD5 and -CD23 antibodies (Abs) and samples 
collected were >95% CD19+/CD5+. Of the CLL cells collected 2x107 cells were 
pelleted for RNA extraction, described in section 2.9.1, and stored long-term at 
-80oC. The remainder CLL cells were resuspended in freezing media (90% fetal 
bovine serum (FBS; Invitrogen Ltd., Paisley, UK) and 10% dimethylsulphoxide 
(DMSO; Sigma Aldrich, Dorset, UK). 1-10x107 CLL cells in 1 ml of freezing solution 
were then aliquoted into cryovials (Greiner Bio-One, Ltd., Gloucestershire, UK) 
for rate controlled freezing at around 1oC per hour in a -80oC freezer overnight. 
Frozen cells were then transferred into the vapour phase of a liquid nitrogen 
freezer for long term storage. 
2.2.2 Normal B cells 
Normal B lymphocytes used for gene expression analysis were isolated from buffy 
coat samples obtained from healthy individuals provided by the Scottish National 
Blood Transfusion Service (SNBTS), with approval from the SNBTS ethics 
committee. Standard virology screening was performed on the blood samples, 
which were received within 24 hrs of being collected. B cells were isolated by 
MACS human CD19 MicroBeads following the manufacturer’s protocol (Militenyi 
Biotec, Surrey, UK), B cell purity was >80% assessed by FACS staining 
(CD19+/CD20+). Buffy coat B cells were washed once in PBS and then pelleted for 
RNA extraction as described in section 2.9.1. B cells used for assessment of 
surface protein expression were obtained from peripheral blood samples from 10 
healthy volunteers, lymphocytes and mononuclear cells were isolated using 
density separation medium Histopaque®-1077 (Sigma Aldrich, Dorset, UK), 
following the manufacturer’s protocol. 
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2.3 Cell culture 
Cell culture was conducted under sterile conditions using a laminar air flow 
hood. All consumables used were purchased from either Fisher Scientific 
(Loughborough, U.K) or Greiner Bio-One Ltd unless otherwise stated.  
2.3.1  Thawing primary CLL cells 
CLL cells were thawed by warming the cryovial at 37oC in a water bath, cells 
were then gently transferred to the bottom of a sterile tube. 10 ml DAMP 
solution (DNAse 10000 units/L (Stemcell Technologies), MgCl2 2.5 mM, trisodium 
citrate 16 mM (both Sigma Aldrich), 1% Human Serum Albumin (SNBTS) in PBS) 
was added drop wise to the cells with gentle agitation over 10 min and then 
centrifuged at 300g for 5 min. Supernatant was discarded, CLL cells were 
resuspended in complete medium-RPMI-1640 containing 10% FBS, 50 U/mL 
penicillin, 50 mg/mL streptomycin and 2 mM L-glutamine (Invitrogen Ltd.), 
followed by centrifugation at 300g for 5 min. Supernatant was discarded and CLL 
cells were then re-suspended in complete medium at a concentration between 
5-10 x 106 cells/ml, CLL cells were then transferred to tissue culture 
plates/flasks and cultured in a humidified incubator at 37 oC and 5% (v/v) CO2.  
2.3.2 B cells from healthy volunteers 
Lymphocytes and mononuclear cells from healthy volunteers were cultured in 10 
ml complete medium in a T75 tissue culture flask and incubated at 37 oC and 5% 
(v/v) CO2 for 18 hr to enable the monocytes to adhere. Thereafter the non-
adherent lymphocytes were removed gently so as not to dislodge the adherent 
cells. B cells were then isolated from the suspension by FACS, described in 
section 2.6.1, for assessment of surface protein expression. 
2.3.3 Cell line cells 
2.3.3.1 CLL cell lines 
The HG3 cell line was used throughout this study. HG3 cells were originally 
produced from a Rai stage II individual with a deletion of 13q on both 
chromosomes339. Another CLL cell line WaC3CD5+ (WAC), was also used for CDC 
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optimisation of anti-CD20 MAbs OFA and RTX. WAC cells are characterised as 
being from a Rai stage I individual with deletions of both 13q and 17p340. CLL cell 
line cells were cultured in complete medium at a density of approximately 5 x 
105 cells/ml and cultured in a humidified incubator at 37 oC with 5% (v/v) CO2.  
2.3.3.2 Ramos cells 
Ramos cells are derived from a patient with Burkitt’s lymphoma, and were used 
for the optimisation of ADCC assay, described section 2.4.2341. Ramos cells were 
cultured in complete medium at a density of approximately 1 x 106 cells/ml and 
cultured in a humidified incubator at 37 oC with 5% (v/v) CO2.  
2.3.3.3 Stromal cell lines 
Mouse fibroblast L cells (NTL) and NTL cells transfected with CD154 (NTL/CD154) 
were used in co-culture experiments to simulate the CLL microenvironment and 
support CLL cell survival and proliferation as previously described140,342. NTL and 
NTL/CD154 cells were cultured in complete media, and cultured in a humidified 
incubator at 37 oC with 5% (v/v) CO2. When CLL cells were co-cultured on 
NTL/CD154 cells, complete media was supplemented with 10 ng/ml IL-4 
(Peprotech EC Ltd., London, UK) and referred to as NTL/CD154+IL-4.  
2.4 MAb treatment and assessment of cell death 
2.4.1 CDC 
CLL cell lines were split 1:2 with complete medium 24 hr prior to assessing CDC 
levels. Primary CLL cells were defrosted 18 hr before assessment of CDC. Unless 
otherwise stated 2.5 x 106 cells/ml were pelleted by centrifuging for 5 min, 300g 
at room temperature (RT), and then resuspended in CDC buffer - Hanks Buffered 
Saline Solution (HBSS; PAA Laboratories, Buckinghamshire, UK), 10 mM Hepes, 1 
mM sodium pyruvate and 10 μg/ml Gentamicin (Invitrogen Ltd.). OFA 
(GlaxoSmithKline, Brentford, UK) and RTX (Roche, West Sussex, UK) were diluted 
in CDC buffer and added to cells at 20 µg/ml, for 30 min at RT. Untreated 
control cells were treated equivalently except no MAb was added to the CDC 
buffer. CLL cells were then pelleted and the supernatant removed. Thawed 
human serum was diluted in CDC buffer (1:1) and added to cells and mixed 
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gently. CLL cells were then incubated with sera for 2 hr at 37oC. Following 
MAb/sera treatment, CLL cells were washed in CDC buffer, harvested and 
stained with 1 g/ml propidium iodide (PI) (BD Biosciences, Oxford, UK) to 
assess the levels of CDC, as described in section 2.6.2. 
2.4.1.1 Supplementing CLL sera 
For CLL patient sera supplementation assays, purified human complement 
components C2 and/or C4 (Complement Technology, Inc, Texas, USA) or NHS 
were added at the concentrations indicated and CDC performed. 
2.4.2 Assessment of ADCC 
The induction of ADCC was determined by using an ADCC Reporter Bioassay Kit 
provided by Promega (Southampton, UK) and following the manufactures 
protocol. Primary CLL cells were defrosted as described, and cultured for 18 hr 
at a concentration of 1.25 x 106 CLL cells/ml in complete media. Cell lines were 
split 1:2 with complete medium 24 hr prior to use. The effector: target cell ratio 
used was 6:1. OFA and RTX were prepared at a range of concentrations from 1 
ng/ml to 100 μg/ml. Luciferase luminescence was measured at 1500 ms on a 
Spectramax M5 plate reader (MDS Analytical Technologies, Berkshire, UK) and 
analysed with SoftMax Pro 5.2 software (MDS Analytical Technologies). 
2.5 Microenvironmental stimulation 
To assess how microenvironmental stimulation affected the susceptibility of CLL 
cells to anti-CD20 MAb activity, CLL cells were cultured normally or with stromal 
cells. CLL cells were cultured using three different systems; no stromal cells 
(plastic), NTL or NTL/CD154+IL-4. NTL and NTL/CD154+IL-4 cells were plated at 
a ratio of 25:1 for CLL: stromal cells. NTL and NTL/CD154 were plated into 6 
well plates to allow the stromal cells to adhere to the surface 4 hr prior to the 
start of experiment.  
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2.5.1 Assessment of CDC and surface protein expression 
After thawing, CLL cells were plated into a 6 well plate at a density of 4 x 106 
cells/well in complete medium using the three different culture systems, 
plastic, NTL and NTL/CD154+IL-4. For each of the different systems, cells were 
incubated with either no MAb (untreated) or 20 μg/ml of either RTX or OFA in a 
humidified incubator at 37oC with 5% (v/v) CO2. CLL cells were collected at time 
points; 24, 48 and 72 hr. For CLL cells cultured on stromal cells, CLL cells were 
gently washed from the well, taking care not to disturb the stromal layer. CLL 
cells cultured with either RTX or OFA then underwent CDC as previously 
described in section 2.4.1, omitting the incubation with OFA or RTX step. 
Untreated CLL cells (cultured without MAb), 2.5 x 105 cells were used for 
assessment of surface protein expression as described in section 2.6.1. The 
remaining untreated CLL cells underwent CDC as previously described, with 
some of the cells remaining untreated (control) and the cells treated with MAb 
named as control + MAb (either OFA or RTX) in the results section. 
2.5.2 Characterisation of CLL cells escaping OFA CDC 
To determine differentially expressed genes involved in CLL cells resistant to 
OFA induced CDC, Fluidigm (Fluidigm Ldt, London, UK) gene profiling was 
performed. The experimental design is shown in Figure 2.1. CLL cells were 
cultured in a 6 well plate at a density of 4 x 106 cells/well in complete medium 
with NTL/CD154+IL-4 cells and cultured in a humidified incubator at 37 oC with 
5% (v/v) CO2. After 24 hr of co-culture 20 μg/ml OFA was added to half of the 
CLL cells plated. After 24 hr incubation with OFA, CLL cells were removed from 
co-culture and pelleted by centrifuging for 5 min, 300g at RT. The supernatant 
was removed and cells were washed once in CDC buffer. After washing, CLL cells 
were pelleted and the supernatant removed. Half of the CLL cells from the OFA 
treated or untreated wells were then incubated for 2 hr at 37 oC with 50% NHS 
diluted in CDC buffer at a concentration of 2.5x106 cells/ml (CDC assay see 
section 2.4.1). At the same time CLL cells not undergoing CDC were incubated 
with complete medium at 37 oC for 2 hr. After incubation 2.5 x 105 cells were 
used to check the level of CDC by PI staining described in section 2.6.2. The 
remainder of cells were washed once in CDC buffer, once in complete medium 
and then re-cultured with NTL/CD154+IL-4 in a humidified incubator at 37 oC 
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with 5% (v/v) CO2 for an additional 24 hr. CLL cells were then gently washed 
from the NTL/CD154+IL-4 stromal layer and placed into a fresh 6 well plate to 
allow any stromal cells that may also have been removed to re-attach to the 
surface of the well. After 2 hr when NTL/CD154+IL-4 cells had adhered to the 
plate, CLL cells were removed, pelleted and washed twice with PBS, prior to 
RNA extraction for gene expression analysis, described in detail in section 2.9.1.  
2.5.3 Characterisation of the molecular response of CLL cells 
when stimulated with and without OFA on plastic and 
CD154/IL-4 
Thawed CLL cells were cultured as described either on plastic or with 
NTL/CD154+IL-4 in 6 well plates at a density of 4 x 106 cells/well, in the 
presence or absence of 20 μg/ml OFA for 48 hr. The cells cultured on 
NTL/CD154+IL-4 were then re-plated as described in 2.5.2 to remove any 
remaining NTL/CD154+IL-4 cells. CLL cells were then harvested, pelleted, and 
washed once in ice-cold PBS. CLL cell lysates were then prepared for either RNA 
extraction (section 2.6.1) or protein extraction (section 2.10.1). 
2.6 Flow cytometry 
2.6.1 Assessment of surface antigen expression 
Normal B cells and CLL cells in the CDC, ADCC and co-culture with plastic, NTL 
and NTL/CD154+IL-4 experiments were all assessed for the expression levels of 
CD19, CD20, CD52, CD55 and CD59, using FACS Abs shown in Table 2.4. In brief, 
2.5 x 105 cells were pelleted, washed once with PBS and centrifuged at 300g for 
5 min at RT. The supernatant was then removed and cells were gently re-
suspended in 200 μl PBS containing a mix of all five antibodies at 1/100 dilution. 
Staining of CD19 alone was also performed as an additional control in the 
experiments where CLL cells were assessed by PI staining following co-culture 
with NTL or NTL/CD154+IL-4. For this 5 x 105 cells were re-suspended in 200 μl 
PBS containing anti-CD19 Ab (1/100 dilution). Once Abs were added, cells were 
incubated on ice for 30 min in the dark. Cells were then washed once in PBS and 
re-suspended in 100 μl PBS for FACS analysis. FACS analysis was performed using 
a FACSCantoII flow cytometer (BD Biosciences), data was acquired using BD 
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FACSDiva (BD Biosciences) software and analysed using FlowJo (Tree Star Inc, 
Ashland, USA) software.  
2.6.2 PI staining 
PI staining was used for the assessment of cell death following induction of CDC. 
5 x 105 CLL cells were washed with 2 ml CDC buffer, and centrifuged for 5 min, 
300g at RT. CDC buffer was then removed and the cells re-suspended in 100 μl 1 
g/ml PI in CDC buffer. Immediately following PI staining the percentage of CDC 
was determined by acquiring the number of PI positive and PI negative cells 
within the PE fluorochrome channel using a FACSCanto II flow cytometer (BD 
Biosciences). PI- cells were considered viable, as indicated in Figure 2.2. If CLL 
cells were co-cultured on NTL or NTL/CD154+IL-4 then CD19 staining was 
performed first as described in section 2.6.1, 30 min prior to PI being added, and 
only CD19+ PI+  cells were then used to determine the percentage of CDC.  
2.7 Genomic DNA extraction 
For the identification of NOTCH1MUT from our CLL cell bank, 1-5 x 106 cells were 
pelleted and re-suspended in 200 μl PBS. DNA was isolated using DNeasy Kit 
(Qiagen, West Sussex, UK) following the manufacturer’s protocol, DNA was then 
dissolved in AE buffer (10 mM Tris-Cl, 0.5 mM EDTA pH9) supplied by Qiagen. 
DNA concentration was determined on a spectrophotometer (Nanodrop ND1000 
Spectrophotometer; Labtech International Ltd, East Sussex, UK), using 2 μl of 
the sample at 260 nm. DNA samples were stored at -20 oC. 
2.7.1 ARMS PCR 
ARMS PCR was used to identify the presence of the c.7544_6545delCT mutation 
of the NOTCH1 PEST domain. The PCR reaction was performed using 25 ng DNA 
and 1 U Go Taq (Promega) with 1 mM MgCl2, 0.4 mM dNTP and primers (Eurofins 
MWG Operon,London, UK) as indicated in Table 2.5, in a 30 μl reaction, 
following a previously described protocol98. Cycling conditions were as follows; 
initial denaturing step of 95 oC for 3 min and then 30 cycle of; 95 oC for 30 sec, 
57 oC for 40 sec and 72 oC for 40 sec. Products were resolved on a 1% agarose gel 
by electrophoresis using TBE buffer containing 10 μg/ml of Ethidium Bromide 
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(EtBr), visualisation was performed under Ultra Violet (UV) illumination of the 
Molecular Imager® ChemiDocTM XRS system (BioRad, West Sussex, UK). 
2.8 Sequencing (Oxford University) 
ARMS positive NOTCH1MUT CLL samples (n=8) and NOTCH1WT CLL samples (n=13) 
were sent to Oxford University for sequencing. DNA concentrations were 
measured by Oxford BRC Molecular Diagnostic Laboratory using Qubit® 2.0 
Fluorometer and Qubit® assays (Invitrogen), two samples failed this quality 
control. The 19/21 samples were sequenced on the Miseq (Illumina, Inc., Essex, 
UK) using a 300 cycle MiSeq Reagent Kit v2. Library preparation was performed 
using TruSeq Custom Amplicon Kit (Illumina, Inc) v 1.5. The kit was designed to 
target >400 amplicons across 24 genes, including NOTCH1 2-bp frameshift 
deletion (ΔCT7544-7545, P2515fs). The cluster density was 1000/kmm2. Total 
yield was around 5.6 G and total % >= Q30 was 91.5. Four CLL samples (CLL041, 
CLL044, CLL068, and CLL101) showed very low percentage of Reads Identified 
across all amplicons and failed. Data analysis was performed on Illumina MiSeq 
Reporter Software version 2.4 or an earlier version, applying two different 
variant callers: GATK and somatic caller for low variant allele frequency (VAF) 
(Illumina, Inc). The annotation and filtering was performed using Variant Studio 
tool ((Illumina, Inc). The filter includes: filtering out all VAFs with read depth > 
20, quality > 99, and filter in all consequences (Missense, framshift, Stop gain 
and loss and splice site). VAF present in > 5% of 1000 genome database was 
filtered out. An additional filter was then applied to filter out all VAF > 5% and 
which were then visually inspected by IGV viewer in order to remove false 
mutations. This analysis detected 53 mutations in total from the 15 CLL patients 
screened (described in more detail in Chapter 6; Figure 6.1). A simplified flow 
chart of the mutation screening process is shown in Figure 2.3. 
2.9 Gene expression analysis 
2.9.1 RNA extraction 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) following the 
manufacturer’s protocol, and RNA was re-suspended in RNase free H2O. RNA 
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concentration was determined on a Nanodrop spectrophotometer, using 2 μl of 
the sample at 260 nm and remaining sample stored at -80oC. 
2.9.2 Reverse transcription of RNA 
RNA (450 ng) was used for cDNA synthesis using SuperScript III Reverse 
Transcriptase (Invitrogen) following the manufacturer’s protocol. SuperScript III, 
involves a two-step programme. The first step involves incubating RNA, 50-250 
ng random primers and 0.5mM dNTP mix made up to 13 μl in total using RNase 
free H2O, at 65
oC for 5 min then 1 min on ice. The remaining reagents (1x First-
Strand Buffer, 0 5 mM DTT, 40 U of RNaseOUT™ and 200 of U SuperScript™ III RT) 
were then added, totalling a reaction mix of 20 μl. The second step reaction 
then involved incubating the samples at 25oC for 5 min, 50oC for 60 min, the 
reaction was then inactivated by heating at 70oC for 15 min. 
2.9.3 Fluidigm analysis 
Prior to quantification of gene expression levels by Fluidigm analysis, cDNA 
templates were pre-amplified for chosen genes using Qiagen® Multiplex PCR Plus 
kit following the manufacturer’s protocol. Pre-amp cycling conditions involved 
an initial PCR activation step for 5 min at 95oC, then 14 cycles of; 30 sec at 95oC, 
90 sec at 60oC and 90 sec at 72oC, the reaction was then finished with a final 
extension of 10 min at 68oC. Unincorporated primers were removed using 
Exonuclease I (New England BioLabs, Hertfordshire, UK), following the 
manufacturer’s protocol. Exonuclease I thermal cycling conditions were 30 min 
at 37oC (digestion step), then 15 min at 80oC (enzyme inactivation step). Gene 
expression levels were determined by 48:48 Dynamic Array BioMarkTM (Fluidigm, 
London, UK), following the manufacturer’s defined protocols for either primer or 
probe based assays, depending on which was being analysed. Cycling conditions 
for primers involved 60 sec hot start at 95oC and then 30 cycles of; 5 sec at 96oC 
and 20 sec at 60oC, followed by a melting curve step for 3 sec at 60oC. Cycling 
conditions for probes were as follows, 120 sec at 50oC, hot start for 600 sec at 
95oC, then 40 PCR cycles of; 15 sec at 95oC then 60 sec at 60oC. Relative gene 
expressions were analysed by the ΔΔCt method using an average of six 
housekeeping genes (UBE2D2, B2M, ENOX2, GN2B1, TYW1 and CYC1) for primers 
and four housekeeping genes for probes (B2M, UBE2D2, GUSB and TBP) as a 
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reference control and an assigned calibrator. Primers were purchased from 
Eurofins MWG Operon (Germany) shown in Table 2.6, housekeeping genes in 
Table 2.7, and probes from Invitrogen shown in Table 2.8. PCR buffers were 
purchased from Applied Biosystems (Warrington, UK). Heat maps were produced 
using PermutMatrix software (ATGC, France) using Pearson distance for 
dissimilarity and Complete linkage for hierarchical clustering343. 
2.10 Western Blotting 
CLL cells (1 x 107  cells) pelleted from the 48 hr co-culture experiment (section 
2.5.3), were washed in ice-cold PBS and re-suspended in 50 μl lysis buffer (20 
mM Tris pH7.5, 137 mM NaCl, 10% glycerol, 1% NP40) containing protease 
inhibitor cocktail (Roche) and phosphatase inhibitor cocktail (Roche) on ice for 
30 min. Lysates were then centrifuged at 12 000g for 30 min at 4 oC and the 
supernatant transferred to a fresh eppendorf (Eppendorf, Cambridge, UK). 
2.10.1 Protein quantification 
Protein lysates were quantified using Quickstart Bradford Dye Reagent (BioRad), 
following the manufacturer’s protocol, standard curve was prepared using BSA 
protein (BioRad), at concentrations ranging from 0 to 20 μg/ml. Absorbance was 
read at 595 nM on a Spectramax M5 plate reader and analysed with SoftMax Pro 
5.2 software. 
2.10.2 Sample preparation 
Protein lysates (15-20 μg) were made up to a final volume of 12 l in 
solubilisation buffer and 3l of Sample buffer (5x; 10% (w/v) Sodium Dodecyl 
Sulphate (SDS) (Sigma-Aldrich), Milli Q ultrapure water, 200 mM Tris-HCl pH6.8, 
50% (v/v) glycerol, Bromophenol blue and 5% (v/v) 2-mercaptoethanol (50 μl/ml) 
reducing agent (Sigma-Aldrich) was added. Samples were then boiled for 5 min 
at 95oC. Samples were stored long-term at -80oC, before being thawed on ice 
and then boiled for 1 min at 95oC prior to Sodium Dodecyl Sulphate – 
Polyacrylamide gel electrophoresis (SDS-PAGE). 
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2.10.3 SDS-PAGE 
Samples were then resolved by SDS-PAGE, 7.5% gels were used to separate 
proteins larger than 50 kDa and 10% gels for proteins smaller than 50 kDa (Table 
2.8). Cell lysates were fractioned by SDS-PAGE in 1 x Running buffer (25 mM 
Trizma base (Sigma-Aldrich), 192 mM Glycine (Sigma-Aldrich) and 0.1% (w/v) 
SDS) at 80 V for 30 min and 180 V for 45 min. Separated proteins were then 
transferred onto Immun-Blot polyvinyliden difluoride (PVDF) membrane (BioRad) 
using a semi-dry transfer method. PVDF was immersed in 100% methanol for 1 
min, before being saturated in 1 x semi-dry transfer buffer (39 mM Glycine, 48 
mM Tris-base, 0.04% (w/v) SDS). Four 1.0 mm Whatman paper strips were placed 
below the PVDF membrane, the gel was then added on top of the membrane 
followed by four more paper strips, the stack was then compressed to remove 
any air bubbles. Proteins were transferred onto the membrane at 40 mA/gel for 
60 min. Blots were washed with 1 x TBST (20 mM Tris HCl pH 7.4, 150 mM NaCl, 
0.01% Tween 20 (Sigma-Aldrich)), blocked in TBST containing either 5% BSA or 5% 
milk for 1 hr at RT. Following block the blots were incubated with primary 
antibody overnight at 4oC as outlined in Table 2.10. Blots were then washed four 
times with TBST and incubated with horseradish-peroxidase (HRP)-labelled 
secondary antibodies for 1 hr at RT. Secondary antibody was then washed four 
times with TBST, followed by two washes with TBS and then blots were 
developed using Bio-Rad ECL and developed on a SRX-101A Medical Film 
Processor (Konica Minolta Medical Graphic, Inc., Banbury, UK). 
2.10.4 Membrane re-probing 
PVDF membranes were stripped if multiple proteins of similar molecular weights 
were being viewed. Blots were incubated in stripping solution (10% (w/v) SDS, 
62.5 mM Tris-HCl pH7.4, 108 mM 2-Mercaptoethanol) for 30 min at 65oC, with 
vigorous shaking every 10 min. After stripping the blots were washed with TBST 
and then blocked with the appropriate blocking solution and incubated with 
primary antibody as previously described. 
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2.11 Calcium Signalling 
Fluo-4 AM cell permeant (Invitrogen) was used as a calcium indicator. Fluo-4 
stock solution was prepared at 5 mM in DMSO. Calcium buffer was prepared by 1 
x HBSS (Invitrogen), 10 mM Hepes and 0.2 % BSA. CLL cells (2-3 x 106 cells) were 
cultured overnight in complete medium on plastic, after which cells were 
pelleted by centrifuging for 5 min, 300g at RT and re-suspended in RPMI media 
with 0.5% BSA and cultured on plastic for a further 2 hr. CLL cells were pelleted 
by centrifuging as previously described, washed once with calcium buffer and re-
suspended in 9 ml calcium buffer with 2 μM fluo-4. Cells were protected from 
light and incubated at 37oC for 45 min. Cells were then washed twice with 
calcium buffer and then re-suspended in 9 ml calcium buffer, 2.6 ml of cell 
suspension was treated with 20 μg/ml of either OFA or RTX for 15 min at 37oC 
and then pelleted and re-suspended in 2.6 ml calcium buffer. Cells in suspension 
were left to incubate at 37oC for 30 min to allow complete de-esterification of 
intracellular AM esters. Calcium signalling was measured on the FACSCantoII flow 
cytometer for 2 min. Stimulation with the addition of 10 µg/ml F(ab’)2 (Jackson 
ImmunoResearch Laboratories Inc., Suffolk, UK), 10 µg/ml IgM (BDBiosciences), 
500 nM Ionomycin (Iono; Sigma-Aldrich), OFA (20 μg/ml) and RTX (20 μg/ml) was 
carried out by adding the reagent directly to the CLL cell suspension 
immediately prior to measuring fluo-4 signal. 
2.12 Statistical analysis and Software 
All statistical analysis was performed using GraphPad Prism 4 software 
(GraphPad Software Inc., CA, USA), P values were determined by students paired 
or unpaired t-test as indicated. Mean ± standard error of mean (SEM) or mean ± 
standard deviation (SD) are shown as indicated. Flow cytometry data were 
acquired using FACSDiva software (BD Biosciences) and analysed using FlowJo 
(Tree Star Inc., Ashland, OR) software. 
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Table 2.1 List of suppliers 
 
Company Address 
Applied Biosystems Lingley House, 120 Birchwood Boulevard, 
Warrington, WA3 7QH, UK 
ATGC South of France bioinformatics platform 
BD Biosciences The Danby Building, Edmund Halley Road, Oxford, 
OX4 4DQ, UK 
The Binding Site Group Ltd. 8 Calthorpe Road, Edgbaston, Birmingham, B15 
1QT, UK. 
BioRad Maxted Rd, Hemmel Hempstead, West Sussex, HP2 
7DX, UK 
Bioscience Lifescience Ltd. 10 Orchard Place, Nottingham Business Park, 
Nottingham, NG8 6PX, UK 
Cell Signaling Technology c/o New 
England Biolabs 
75-77 Knowl Piece, Wilbury Way, Hitchin, Herts SG4 
0TY, UK 
Complement Technology, Inc. 4801 Troup Hwy, Suite 701, Tyler, Texas, 75703, 
USA 
Eppendorf UK Ltd. Endurance House, Vision Park, Histon, Cambridge, 
CB24 9ZR 
Eurofins MWG Operon Westway Estate 28-32 Brunel Road, Acton, London, 
W3 7XR, UK 
Fisher Scientific UK Bishop Meadow Road, Loughborough, 
Leicestershire, LE1 5RG, UK 
Fluidigm UK Ltd 90 Fetter Lane, London, EC4A 1EQ, UK  
GlaxoSmithKline (GSK) GSK House, 980 Great West Rd, Brentford, 
Middlesex, TW8 9GS, UK 
GraphPad Software, Inc. 7825 Fay Avenue, Suite 230 La Jolla, CA 92037 
USA 
Greiner Bio-One Ltd. Unit 5, Stroudwater Business Park, Gloucestershire, 
GL10 3SX, UK 
Illumina, Inc. Chesterfield Research Park, Essex, CB10 1XL, UK 
Invitrogen, Paisley, UK Ltd. Part of Life 
Technologies 
3 Foundation Drive, Paisley, UK 
Jackson ImmunoResearch, 
Laboratories, Inc. 
UK distributor; Stratech Scientific Limited,  
Konica Minolta, Inc. Konica Minolta Medical & Graphic Imaging Europe 
B.V. Barford Road, Banbury, OX15 4FF, UK 
Labtech International Ltd. Acorn House, The Broyle, Ringmer, East Sussex, 
BN8 5NN, UK 
Merk Chemicals Ltd. Boulevard Industrial Park, Padge Road, Beeston, 
Nottingham, NG9 2JR, UK 
Millipore (U.K.) Limited Suite 3 & 5, Croxley Green Buisiness Pakr, Watford, 
WD18 8YH, UK. 
Miltenyi Biotec Ltd. Almac House, Church Lane, Bisley, Surrey, GU24 
9DR, UK 
PAA Laboratories (now part of GE 
Healthcare Life Sciences)  
Amersham Place, Little Chalfont, 
Buckinghamshire,HP7 9NA, UK 
Peprotech EC Ltd. Peprotech House, 29 Margavine Road, London, W6 
8LL, UK 
Promega UK Delta House, Southampton Science Park, 
Southampton, SO16 7NS, UK 
Qiagen Fleming Way, Crawley, West Sussex, RH10 9NQ, 
UK 
R&D Systems 19 Barton Lane, Abingdon Science Park, Abingdon, 
OX14 3NB, UK 
Roche Roche, West Sussex, Charles Avenue, Burgess Hill, 
RH15 9RY, UK 
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Company Address 
Sigma-Aldrich The Old Brickyard, New Rd, Gillingham, Dorset, SP8 
4XT, UK 
Stemcell Technologies 40 Rues des Berges, Miniparc Polytec, Bâtiment 
Sirocco, 38000 Genoble, France 
Stratech Scientific Limited Oaks Drive, Newmarket, Suffolk, CB8 7SY, UK 
Tree Star, Inc. 340 A Street #101 Ashland, OR97520, USA 
Whatman plc Springfield Mill, James Whatman Way, Maidstone, 
Kent, ME14 2LE, UK 
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Table 2.2 Summary of the CLL patient clinical parameters for the CLL serum samples 
a
 Previously undergone treatment but not within three months prior to sample collection 
b
 Received RTX immunotherapy. Patients (except CLL 105) have not been previously exposed to RTX and received at least 5 cycles of FCR. CLL105 had previously 
received FCR, and received R-CHOP, with RTX given as a split dose over two days. Absolute lymphocyte count prior to treatment ranged from 44.5 – 430 and was 
reduced to 0.9 – 29.1 prior to the second cycle of RTX. 
c
 ZAP-70 analysis was conducted by immunohistochemistry in the regional haematology laboratory. 
Bolding indicates subnormal levels of complement component, or complement activity as appropriate. 
CLL 
sample ID 
Treatment
a 
 
RIT 
treatment
b
 
Sex Stage Zap-70 
status
c 
Cytogenetics C1q (g/L) 
NR: 0.119-0.24 
C2 (g/L) 
NR: 0.018 – 0.035 
C3 (g/L) 
NR: 0.88-1.82 
C4 (g/L) 
NR: 0.16-0.45 
CH100 units 
NR: 80-100 U 
Exhaustion 
(%) 
5 N  M A Neg 13q del 0.1428 0.0425 1.34 0.290 92 -1.12 
8 N  F A Neg 11q del 0.1194 0.0190 1.15 0.181 100 52.58 
11 N  M A Neg 13q del & Tr 12 0.1950 0.0379 1.19 0.283 100 7.5 
16 Y  F A Pos Normal 0.1097 0.0311 1.27 0.427 85 27.09 
18 Y  F B Pos 11q del 0.0839 0.0131 0.46 0.061 70 - 
26 Y  M A Pos 13q del - - 0.44 0.052 60 54.12 
28 N  F A Pos 17p del 0.1260 0.0299 1.10 0.205 94 9.3 
29 Y  M C Pos Normal 0.1310 0.0104 1.13 0.238 86 68.84 
32 N  F C Pos Normal - 0.0311 0.88 0.200 98 41.48 
35 N  M A Pos 11q - - 0.86 0.131 100 - 
41 N  M A Neg Normal - - 1.51 0.305 100 28.54 
42 Y  F B Pos Normal 0.1760 0.0131 0.87 0.070 78 77.14 
44 N  F A Neg Normal - - 0.86 0.040 0 - 
50 Y  M C Pos Normal 0.1950 0.0227 1.20 0.221 93 0.44 
52 Y  F B Neg 11q del 0.1003 0.0282 1.04 0.324 100 14.67 
53 N  F A   0.1227 0.0237 1.39 0.191 100 51.5 
54 N  F A Neg Normal 0.1950 0.0165 1.55 0.326 89 35 
57 N  M C Pos Normal 0.1161 0.0347 1.15 0.316 100 31.57 
67 N  M A Pos Normal 0.1326 0.0305 1.15 0.370 100 8.29 
68 Y  F C Pos Normal 0.1785 0.0360 0.94 0.255 100 28.8 
69 Y  M A Pos Normal 0.1515 0.0109 1.27 0.246 100 - 
70 N  F C Neg Normal - - 1.25 0.478 100 54.01 
72 N  F A Pos Normal 0.1445 0.0379 1.17 0.330 100 23.36 
73 Y  F A Pos Normal 0.2845 0.0091 1.02 0.236 100 38.84 
74 Y  F A Neg  0.1604 0.0288 1.15 0.209 92 32.6 
76 N  F A Pos 6q del 0.1725 0.0305 0.94 0.302 100 - 
79 Y  M C Pos 17p del - - 0.90 0.188 100 58.3 
81 Y  M C Pos Normal - 0.0373 0.95 0.194 92 -4.12 
82 Y  F B Pos  0.1950 0.0341 1.45 0.395 100 7.8 
83 Y  M B Pos Normal - - 0.98 0.122 85 66.34 
84 Y  M B Neg 11q del 0.1532 0.0392 0.91 0.425 92 - 
85 Y  F A  11q del 0.1480 0.0341 1.21 0.159 100 17.04 
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CLL 
sample ID 
Treatment
a 
 
RIT 
treatment
b
 
Sex Stage Zap-70 
status
c 
Cytogenetics C1q (g/L) 
NR: 0.119-0.24 
C2 (g/L) 
NR: 0.018 – 0.035 
C3 (g/L) 
NR: 0.88-1.82 
C4 (g/L) 
NR: 0.16-0.45 
CH100 units 
NR;80-100 U 
Exhaustion 
(%) 
86 N Y F A Pos 11q del 0.1194 0.0341 1.18 0.338 100 9.1 
87 N  M C Neg Normal 0.1394 0.0254 1.02 0.187 - 42.74 
91 Y  M C Pos 11q del 0.1533 0.0493 1.57 0.264 93 27.5 
92 Y  M C Pos 11q del 0.1935 0.0452 1.17 0.363 100 3.4 
93 Y  M C Pos 17p del 0.1990 0.0109 0.88 0.092 22 60.94 
94 N  M B Pos 11q del 0.1326 0.0360 1.04 0.356 25 8.18 
96 Y  M  Pos 11q del 0.1550 0.0265 1.21 0.214 100 30.55 
97 Y  M C   0.1360 0.0305 1.39 0.382 100 9.1 
98 N  M B Neg 17p del 0.0911 0.0254 1.33 0.402 100 50 
101 Y  M C   0.1604 0.0271 1.58 0.517 100 14.65 
102 Y  F C Pos 11q del 0.1326 0.0299 1.42 0.376 100 15.15 
104 N  M    0.1428 0.0360 1.01 0.284 100 6.8 
105 Y Y M C Pos Normal 0.1394 0.0425 0.95 0.173 62 9.9 
106 N Y M B Pos Normal 0.1245 0.0150 1.19 0.153 100 72.9 
107 Y  F C Neg Normal 0.1515 0.0323 1.25 0.152 100 - 
108 Y Y F C Pos  - 0.0341 1.22 0.300 100 8.4 
109   M   17p del 0.1310 0.0032 0.87 0.111 58 43 
111 Y  M C  11q del 0.2025 0.0367 1.06 0.299 76 1.8 
112 N  M    0.1990 0.0221 1.09 0.323 94 13.2 
113 Y  F C 
 
17p del 0.1280 0.0360 1.14 0.173 50 12.5 
114 Y  M B Pos Normal 0.1550 0.0385 1.01 0.276 100 0.8 
115 Y  M C Pos  0.1150 0.0242 1.07 0.118 100 14.8 
117   M    0.1550 0.0179 1.15 0.274 100 70.6 
118   M    0.1725 0.0398 1.19 0.225 100 -0.1 
119 N  F   17p del 0.2800 0.0392 1.28 0.231 100 -3 
120 Y  M C Pos Normal - 0.0265 1.13 0.187 100 34.9 
121 N Y M C Pos Normal 0.0762 0.0354 1.24 0.069 42 47.6 
123       0.1480 0.0282 0.84 0.195 94  
124 Y Y M B Pos Normal 0.1638 0.0329 1.52 0.278 100  
127 Y  M   17p del  0.0626 1.81 0.414  -1.3 
129       0.2800 0.0418 1.31 0.248 69.5  
131       0.0529 0.0360 1.36 0.166 92  
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Table 2.3 Summary of the CLL patient clinical parameters of CLL cell samples 
a
 Previously undergone treatment but not within three months prior to sample collection 
b
  ZAP-70 analysis was conducted by immunohistochemistry in the regional haematology 
laboratory 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLL sample ID Treatment
a 
 
Sex Stage Zap-70 
status
b 
Cytogenetics 
14 Y M C Pos 17p del 
23 N F A  NOTCH1
MUT
 
28 N F A Pos 17p del 
41 N M A Neg Normal 
42 Y F B Pos Normal 
44 N F A Neg Normal 
51 N M A+C Neg Normal 
54 N F A Neg Normal 
57 N M C Pos Normal 
65 Y F C Neg Partial NOTCH1
MUT
 
67 N M A Pos NOTCH1
MUT
 
68 Y F C Pos NOTCH1
MUT
 
69 Y M A Pos Normal 
70 N F C Neg Normal 
73 Y F A Pos NOTCH1
MUT
 
78 Y M  Pos 17p del 
81 Y M C Pos Normal 
84 Y M B Neg 11q del 
86 N F A Pos 11q del 
90 N F B Pos Normal 
91 Y M C Pos 11q del 
92 Y M C Pos 11q del 
93 Y M C Pos 17p del 
94 N M B Pos 11q del 
95 Y M    
101 Y M C  NOTCH1
MUT
 
104 N M A Neg Normal 
105 Y M C Pos Normal 
106 N M B Pos Normal 
107 Y F C Neg Partial NOTCH1
MUT
 
108 Y F C Pos NOTCH1
MUT 
109  M   17p del 
112 N M    
113 Y F C 
 
17p del 
114 Y M B Pos Normal 
121 N M C  Normal 
122 M    17p del/ partial 
NOTCH1
MUT
 
124 Y M B Pos Normal 
125 N M C Low Normal 
126 N M B Pos Normal 
130 (Oxford 
Sample) 
    NOTCH1
MUT
 
133 N F C Neg NOTCH1
MUT
 
162 (Oxford 
Sample) 
    NOTCH1
MUT
 
190 (Oxford 
Sample) 
    NOTCH1
MUT
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Table 2.4 FACS antibodies 
 
Antibody name Clone Fluorochrome Manufacturer’s 
reference 
CD5 UCHT2 PE BD 555353 
CD19 SJ25C1 APC-Cy7 BD 555791 
CD20 L27 V450 BD 561164 
CD23 M-L233 APC BD 558690 
CD45 2D1 APC-Cy7 BD 557833 
CD52 HI186 PE Bio-legend 316006 
CD55 JS11 APC Bio-legend 311312 
CD59 p282 (H19) FITC Bio-legend 304706 
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Table 2.5 ARMS DNA primer sequences and concentrations 
 
Primer Sequence Concentration (μM) 
Forward control GTGACCGCACGGGACTT 0.1 
Forward mutation TCCTCACCCCGTCCCGA 0.4 
Reverse AAGGCTTGGGAAAGGAAGC 0.5 
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Table 2.6 cDNA primer sequences and product size 
 
Gene Forward sequence Reverse sequence Product 
size (bp) 
HES1 CCAAAGACAGCATCTGAGC TTCTCCAGCTTGGAATGCC 149 
HES3 ACGCATCAATGTGTCACTGG GCTTCTCATGTACTTCACG 125 
HES5 CATCCTGGAGATGGCTGTC GAGCGTCAGGAACTGCAC 136 
HES6 AAGCTGGAGAACGCCGAAGT CGTGCATGCACTGGATGTAG 138 
HEY1 CCGTGGATCACCTGAAAATGC GGCATCTAGTCCTTCAATGATGC 149 
HEY2 GAAGATGCTCCAGGCTACAGG CCTTCCACTGAGCTTAGGTACC 126 
TLE1 TAACCTCCTCAATGCTTGGC AGACTGTAGCCTTCTTGTCC 140 
TLE4 ACTTGGTGGTTGACGTTTCC ATAGAGGCTGGACTAATCGG 130 
DELTEX AATCCCGAGGATGTGGTTCG GTAGCCTGATGCTGTGACCA 102 
CDKN1A GTGGACCTGGAGACTCTCAG CCTCTTGGAGAAGATCAGCCG 92 
RUNX3 GGCAATGACGAGAACTACTC GTTGGTGAACACAGTGATGG 144 
C-FMS CAAGTTCATTCAGAGCCAGG CTGGGATGACTTTCTGCACT 101 
FBXW7 CCTTCTCTGGAGAGAGAAATGC CTGTCTGATGTATGCACTTTTCC 121 
NUMB CCAAACCAGTGACAGTGGTGGC CCCAAGGGTTGGTTTCACGC 141 
MAML GCAACAGCAGTTCCTTCAGAGG GTGAACTGTCCAACCTGCTGTG 141 
LFNG GCCACAAGGAGATGACGTT GAGCAGTTTGTGATGACCACG 88 
MFNG CTGGTACAGTTCTGGTTTGC ATGTGTCCATGAAACGGGAGC 106 
ADAM19 GTTTACACAACAGACCAAGAAGC CTTGTGTTTGGTGGCGTCC 142 
C-JUN CTTGAAAGCTCAGAACTCGGAG CTGCGTTAGCATGAGTTGGC 121 
VEGF AGAAGGAGGAGGGCAGAATCA AGGGTACTCCTGGAAGATGTCC 109 
DKK3 GCATCATCGACGAGGACTGT GTCTCCACAGCACTCACTGT 122 
DLL1 GCCTGGATGTGATGAGCAGC ACAGCCTGGATAGCGGATACAC 109 
STAT3 CCTAGATCGGCTAGAAAACTGG GGGTCCCCTTTGTAGGAAAC 114 
NFKB1 AGATGATCCATATTTGGGAAGGC TTGCTCTAATATTTGAAGGTATGGGC 142 
JAG1 TGGGATTCCAGTAATGACACCG GTAGTCATCACAGGTCACGC 156 
JAG2 CAAAAACCTGATTGGCGGCT CACACACTGGTACCCGTTCA 142 
ADAM17 CTTCTACAGATACATGGGCAGAG CTCTATCTGTATTCCATAGCCTTTAA 139 
ADAM10 ATGGCAAAGATGATAAAGAATTATGCC AATCGTTGCAAGGGGATCC 147 
FURIN CCACATGACTACTCCGCAGAT TACGAGGGTGAACTTGGTCAG 150 
PSEN GGTGGTTCTGTATAAATACAGGTGC AACAGTAATGTAGTCCACAGCAA 145 
CCND1 CAGAAGGAGATTGTGCCATCC GAAGCGGTCCAGGTAGTTCA 120 
TP53 TTCTTGCATTCTGGGACAGCC GGGGGTGTGGAATCAACCC 119 
MYC GACTCTGAGGAGGAACAAGA TTGGCAGCAGGATAGTCCTT 218 
NOTCH1 TCCACTGTGAGAACAACACGC ACTCATTGACATCGTGCTGGC 141 
NOTCH2 GCAAAGTGTATCGATCACCCGA TGCAGGTGTAGGAATCAATACCATC 148 
NOTCH3 TACTGGTAGCCACTGTGAGCAG CAGTTATCACCATTGTAGCCAGG 129 
NOTCH4 TTCCACTGTCCTCCTGCCAGAA TGGCACAGGCTGCCTTGGAATC 142 
DLL3 CACTCAACAACCTAAGGACGCAG GAGCGTAGATGGAAGGAGCAGA 126 
DLL4 TCGCTCATCATCGAAGCTTGG CAGTTCTGACCCACAGCTAGG 119 
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Table 2.7 cDNA primer sequences for housekeeping genes and product size 
 
Gene Forward sequence Reverse sequence Product 
size (bp) 
B2M TTGTCTTTCAGCAAGGACTGG ATCCGGCATCTTCAAACCTCC 172 
CYC1 ACTGCGGGAAGGTCTCTACTT GGGTGCCATCGTCAAACTCTA 101 
ENOX2 GAGCTGGAGGGAACCTGATTT CACTGGCACTACCAAACTGCA 182 
GNB2L1 TCCATACCTTGACCAGCTTG GCAGATTGTCTCTGGATCTC 179 
TYW1 ATTGTCATCAAGACGCAGGGC GTTGCGAATCCCTTCGCTGTT 167 
UBE2D2 CCATGGCTCTGAAGAGAATCC GATAGGGACTGTCATTTGGCC 302 
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Table 2.8 cDNA gene expression probes 
 
Gene ID Gene ID 
APC Hs00181051_m1 HDAC4 Hs00195814_m1 
AXIN1 Hs00394718_m1 HDAC5 Hs00608366_m1 
AXIN2 Hs00610344_m1 JUN Hs99999141_s1 
B2M Hs00984230_m1 JUNB Hs00357891_s1 
BAD Hs00188930_m1 LEF1 Hs00212390_m1 
BCL2 Hs00608023_m1 LYN Hs00176719_m1 
BCL9L Hs00699441_m1 MAML2 Hs00287205_m1 
CCL4 Hs99999148_m1 MAPK8IP2 Hs00183753_m1 
CCND1 Hs00765553_m1 MAX Hs00231142_m1 
CCND3 Hs00236949_m1 MCL1 Hs01050896_m1 
CCNE1 Hs01026536_m1 MMP7 Hs01042796_m1 
CCNE2 Hs00180319_m1 MMP9 Hs00957555_m1 
CD247 Hs00167901_m1 NCAM1 Hs00941830_m1 
CD38 Hs01120071_m1 NFATC1 Hs00542678_m1 
CD44 Hs00153304_m1 NFATC3 Hs00190046_m1 
CDC25C Hs00156411_m1 NFATC4 Hs00190037_m1 
CDK1 Hs00364293_m1 NOXA Hs00736699_m1 
CDK2 Hs01548894_m1 PECAM1 Hs00169777_m1 
CDKN1B Hs01597588_m1 PRDM1 Hs00153357_m1 
CDKN2A Hs99999189_m1 PRKCa Hs00176973_m1 
DAPK1 Hs00234480_m1 PRKCb Hs00176998_m1 
DELTEX1 Hs01092201_m1 PRKCd Hs01090047_m1 
DV1 Hs00182896_m1 PRKCe Hs00178455_m1 
E2F1 Hs00153451_m1 PRKCz Hs00177051_m1 
E2F2 Hs00231667_m1 ROR1 Hs00178178_m1 
E2F3 Hs00605457_m1 ROR2 Hs00171695_m1 
FASLG Hs00181225_m1 RRAD Hs00188163_m1 
FOS Hs00170630_m1 SYK Hs00374292_m1 
FOXO3 Hs00818121_m1 TBP Hs00427620_m1 
GATA3 Hs00231122_m1 TP73 Hs01056231_m1 
GLI1 Hs01110766_m1 VEGFA Hs00900055_m1 
GUSB Hs99999908_m1 UBE2D2 Hs00366152_m1 
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Table 2.9 SDS-PAGE Running and stacking gel preparation 
 
Gel (%) 5.5 7.5 10 
Gel type Stacking Running Running 
30% bis-Acrylamide 5.5%  7.5%  10 %  
Milli Q Ultrapure water 667 μl/ml  373 μl/ml ) 290 μl/ml  
1M Tris-HCl pH 8.8 - 373 mM  373 mM  
1M Tris-HCl ph 6.8 139 mM  -  
10% (w/v) SDS 0.17%  0.17%  0.17%  
10% (w/v) Ammonium 
Persulphate 
0.06%  0.07%  0.07%  
Temed 2.2 μl/ml  1.3 μl/ml  1.3 μl/ml  
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Table 2.10 Western blot antibodies 
 
Antibody name Reactive 
Species 
Dilution Block Manufacturer’s reference 
ADAM10, C-terminus Rabbit 1:1000 5 % Milk Millipore AB19026 
Akt (pan) (C67E7) Rabbit 1:1000 5 % BSA Cell Signaling 4691 
Phospho-Akt 
(Ser473)(D9E) 
Rabbit 1:1000 5 % BSA Cell Signaling 4060 
Cyclin E1 (HE12) Mouse 1:1000 5 % Milk Cell Signaling 4129 
Cyclin E2 Rabbit 1:1000 5 % BSA Cell signaling 4132 
GAPDH (D16H11) Rabbit 1:1000 5 % Milk Cell Signaling 5174 
GSK-3β (27C10) Rabbit 1:1000 5 % BSA Cell Signaling 9315 
Phospho-GSK-3β 
(Ser9) 
Rabbit 1:1000 5 % BSA Cell Signaling 9336 
Notch1 (A-8) Mouse 1:500 5 % BSA Santa Cruz Biotechnology, 
sc-376403 
Notch2 (D67C8) Rabbit 1:1000 5 % BSA Cell Signaling 4530 
Notch3 (D11B8) Rabbit 1:1000 5 % Milk Cell Signaling 5276 
Notch4 (L5C5) Mouse 1:1000 5 % Milk Cell Signaling 2423 
Anti-rabbit IgG (H+L) – 
HRP conjugated 
Goat 1:10000 5 % BSA Cell Signalling 7074 
Anti-mouse IgG (H+L) 
– HRP conjugated 
Horse 1:10000 5 % BSA Cell Signalling 7076 
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Figure 2.1 Experimental outline for molecular characterisation of CLL cells escaping OFA 
induced CDC 
 
CLL cells were cultured on NTL/CD154+IL-4 for 24 hr, cells were then either left untreated or 20 
μg/ml OFA was added for a further 24 hr. CLL cells were then collected and half underwent CDC 
and the remaining half incubated with complete medium. The surviving CLL cells were then co-
cultured with NTL/CD154+IL-4 for a further 24 hr. After co-culture the CLL cells were separated 
from the stromal layer and gene expression analysis performed as described in section 2.9. 
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Figure 2.2 Cell death assessed by PI staining 
 
CLL cells were stained with PI as described in section 2.6.2, and the gating is shown above. Debris 
was at first gated out and then the percentage of dead cells determined by the number of cells 
positive for PI staining. A. CLL sample (121) untreated. B. CLL sample (121) treated with 20 μg/ml 
OFA. 
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Figure 2.3 Flow chart of the mutation screening process carried out by Oxford University. 
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3 Complement levels effect MAb efficacy 
3.1 Introduction 
MAb therapies form an integral part of the treatment regime for CLL patients. 
MAbs exert anti-tumour activity by harnessing the body’s own natural immune 
response especially ADCC involving the recruitment of NK cells to cause 
phagocytosis and CDC requiring the activation of the classical complement 
pathway, and/or apoptosis284.  
Type 1 MAbs, such as RTX and OFA, are potent inducers of CDC as they are able 
to localise CD20 into lipid rafts enhancing C1q recruitment255. CDC induction is 
critically dependent on the distance between MAb binding site and the plasma 
membrane, close binding allows efficient coating of active complement 
components onto the target cell1. OFA is a more potent inducer of CDC than 
RTX. OFA more readily binds to C1q, has a longer disassociation rate and the 
novel binding site allows more effective deposition of C3b onto the surface of 
the membrane254,255,315,316. The ability to induce CDC is of particular importance 
in CLL, as CD20 expression levels, which are relatively low compared to B-cell 
lymphomas, linearly correlate with the lytic response of RTX310,311. In addition, 
recent studies demonstrate that CLL cells can evade RTX, through sequestration 
of CD20-RTX complexes by phagocytic cells, resulting in trogocytosis. 
Trogocytosis causes CD20 depletion from the surface of the lymphocytes in 
circulation, which are no longer responsive to OFA or RTX treatment318-320. These 
findings highlight the importance of generating a MAb capable of effectively 
inducing CDC and ADCC.  
To maximise the clinical effect, it is important to consider whether the patient 
will be able to elicit a healthy CDC and ADCC responses to MAb immunotherapy. 
Early reports indicated that CLL patients harbour deficiencies in classical 
complement components C1 and C4 resulting in defective immune complex 
clearance326. Deficiencies in classical complement components have also been 
linked to CLL patients being more susceptible to infections with organisms such 
as S. pneumonia, and exhibiting a propensity to developing autoimmune 
syndromes325-327. Complement deficiencies could greatly impact upon the clinical 
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efficacy of OFA and RTX. Therefore it is important to establish the prevalence 
and impact of complement deficiencies within CLL patients. 
3.2 Aim 
The main focus of this research is to establish whether CLL patients are prone to 
deficiencies in classical complement components. If complement deficiencies do 
occur then we also aim to determine: 
 How frequently they occur;  
 How they impact upon the efficacy of MAb treatment; 
 If CDC activity is reduced, can we enhance it?; 
 Is a reduction in complement levels or CDC activity observed in vivo 
following MAb therapy.  
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3.3 Results 
3.3.1 CLL patient sera display multiple deficiencies in 
components of the classical complement cascade 
Complement component levels C1, C2, C3 and C4 were assessed in CLL patient 
sera alongside NHS and sera from AMS controls. NHS was provided by healthy 
volunteers with an age range of 22-50 years, similar to those donating fresh 
frozen plasma (FFP). CLL is a late onset disease therefore the age range for our 
CLL sera cohort was 67.9 years ± 6.78 years (age range 48-88 years, 57.9% 
males). To determine whether the predominance of any complement 
deficiencies were CLL related and not age related AMS was used. AMS had an 
average age of 64.8 years ± 12.91 (age range 47-84 years, 41.7% males).  
Patients displaying single deficiencies/reduced levels were noted in all 
complement components screened (Figure 3.1A). In the AMS samples (n=12), 
complement deficiencies slightly below normal range for C1, C2 and C3/C4 were 
observed in a minority of donors (n=3), a single deficiency in C4 was also 
observed in one NHS control sera. The CLL sera screened displayed a much wider 
range of complement values than either controls, with complement 
concentrations falling outside the normal range. Of the CLL patients screened, 
15.4% exhibited levels lower than the normal range of C1q in their sera (n=52) 
and approximately 20% of patients displayed deficiencies in the levels of C2 and 
C4 (17.5%, n=57 and 20.3% n=64 respectively). Analysis of C3 levels revealed that 
10.9% of patient sera (n=64) were deficient in this component. Double 
deficiencies of C1/C4, C2/C4 and C3/C4 also occurred, at a frequency of 3.1%, 
3.1% and 4.7% respectively. Triple deficiency of C2/C3/C4 was seen in 3.1% of 
CLL patients screened, and deficiency of C1q/C2/C3/C4 was observed in one 
patient within our cohort. Due to the large range of CLL sera complement levels, 
no statistically significant differences were observed between the mean 
complement levels from CLL sera and either NHS or AMS. In total 37.5% of CLL 
sera tested were deficient in at least one complement component (n=64; Figure 
3.1A). To determine how these deficiencies impacted on the sequential 
activation of the classical complement cascade in the CLL sera we performed a 
CH100 assay. Surprisingly only 19.4% of CLL sera exhibited reduced complement 
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activity levels (Figure 3.1B), despite the high proportion displaying at least one 
component deficiency.  
To establish whether there was an association with abnormal complement 
levels, either above or below the normal range, we compared complement levels 
vs different prognostic markers in CLL. Complement concentrations and 
prognostic information for each CLL patient sera screened is shown in Table 2.2. 
Firstly complement levels were stratified against the Binet stage of disease at 
the point of sample collection. We observed no correlation between the 
different clinical stages and complement levels (Figure 3.2). Interestingly when 
the different mutational or cytogenetic sub-groups in CLL were compared to 
complement levels, we observed an elevation of C1q and C4 concentrations in 
NOTCH1MUT CLL patients. When comparing the mean complement levels for 
NOTCH1MUT vs. cytogenetically normal CLL patients the values were near 
significance using a two-tailed unpaired t-test, p= 0.069 (C1q) and p=0.056 (C4), 
however a larger sample size is required to determine if this is a significant 
trend (Figure 3.3). ZAP-70 status groups revealed no statistical significance 
between complement levels for our CLL patient cohort (Figure 3.4). However the 
majority of C2 and C4 complement deficiencies were observed in the ZAP-70 
positive cohort, but again a larger sample size is required to determine if this is 
a significant trend.  
3.3.2 Optimisation of CDC in CLL cell lines 
Two CLL cell lines, HG3 and WAC were used to determine the optimal 
experimental conditions to achieve maximal CDC with OFA using RTX as a 
comparator. CDC was determined by the percentage of cells positive for PI 
staining (Figure 3.5). We determined that the highest efficacy was reached at 20 
μg/ml for OFA in HG3 cells (Figure 3.5A) and using 50% NHS (to approximate 
physiological conditions; Figure 3.5B) in both CLL cell lines. Longer serum 
incubation times made no significant difference to enhancing CDC levels (Figure 
3.5C), therefore 2 hr incubation time was used for maximal CDC. These 
conditions were then used for all subsequent CDC experiments unless stated. 
HG3 cell line was also used for all subsequent experiments due to the high levels 
of CDC observed. These optimisation results also corroborate the increased 
efficacy of OFA to induce CDC in comparison to RTX, as seen by others254,255,344. 
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3.3.3 High exhaustion levels associate with increasing tumour 
burden 
To determine whether CDC was affected by high tumour load, we carried out 
exhaustion assays using NHS exposed to increasing numbers of primary CLL cells. 
The efficiency of CDC in primary CLL cells did not decline significantly until 
10000 cells/μl were present, at which point CDC activity dropped by 48.1% in the 
NHS from the primary use (Figure 3.6). Given that CLL sera is more depleted of 
complement than NHS, CLL sera exhaustion assays carried out in subsequent 
experiments were performed using 2500 HG3 cells/μl. These findings indicate 
that tumour load will also have a significant negative impact on CDC activity.  
3.3.4 CLL sera readily exhaust of complement activity following 
MAb therapy 
Our findings indicated that low levels of individual complement components 
observed in CLL patient sera did not always directly impact on CH100 
complement activity. We therefore hypothesised that CLL patient serum might 
exhaust the available complement components more readily after eliciting an 
initial CDC response. This is an important consideration given the repeated 
scheduling of MAbs in CLL patients undergoing immunotherapy. To validate 
complement exhaustion, OFA-mediated CDC was performed on the CLL cell line 
HG3 using 50% CLL patient sera (n=52), with a NHS control included for 
comparison. Following 2 hr incubation, cells were pelleted and CDC levels 
measured by PI staining (Figure 3.7A). The sera removed from this experiment 
was then re-used to promote a second CDC response on fresh OFA bound HG3 
cells (Figure 3.7B). Serum exhaustion was performed on 52 CLL patient sera. The 
difference between CDC cell kill from the first to the second round of serum use 
was then plotted (Figure 3.8A), with representative data from three individual 
patient samples with poor (CLL08), medium (CLL32) and good (CLL85) CDC 
activity shown (Figure 3.8B). Our results clearly demonstrate that CLL patient 
sera show significantly more complement exhaustion compared to NHS controls, 
with 42.3% of CLL patient sera showing more than 30% reduction in CDC activity 
from primary to secondary use.  
As previously shown with complement levels, we determined whether exhaustion 
levels were associated with poor prognostic markers, also shown in Table 2.2. 
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Similar to our findings with complement concentration levels, there was no 
significant correlation between exhaustion and Binet stage (Figure 3.9A) and 
ZAP-70 status (Figure 3.9C). Interestingly 11q del patients, which had marginally 
elevated C2 and C4 levels compared to cytogenetically normal CLL samples, also 
had lower levels of exhaustion bordering on statistical significance when 
compared against cytogenetically normal CLL sera (p= 0.056, using two-tailed 
paired t-test; Figure 3.9B). This suggests that there is possibly genetic interplay 
between the different cytogenetic sub-groups and the expression and activity of 
complement components; however more samples would be required to confirm 
this.  
3.3.5 CLL sera exhaustion is most strongly linked with 
complement C2 concentration levels 
To establish whether complement exhaustion could be attributed to individual 
complement components, we performed linear regression analysis comparing 
individual complement components against exhaustion levels (Figure 3.10). The 
concentration of C2 displayed a significant negative correlation with sera 
exhaustion levels in CLL patients (Figure 3.10B; r2= 0.5260, p <0.0001). The 
levels of C4 also displayed a significant negative correlation with sera exhaustion 
in CLL patients (Figure 3.10D; r2= 0.1559, p= 0.0192), albeit to a lesser degree 
than C2. The concentrations of C1 and C3 appeared to have marginal influence 
over the level of CDC exhaustion observed. 
3.3.6 CLL sera exhaustion can be reduced by the addition of a 
complement source 
To determine whether CDC could be improved in patients deficient in one or 
more complement component, individual components were added back to CLL 
patient sera. We added back both C2 and C4 as they showed significant 
correlation with exhaustion levels. Similar to a report by Kennedy A.D., et al., 
we identified C2 as being the limiting factor 319. Upon addition of C2 to patient 
sera we were able to abrogate complement exhaustion (Figure 3.11A). Only C2 
alone or in combination with C4 was able to augment CDC in deficient sera, 
supporting previous findings that C2 is the limiting factor. Interestingly C2 was 
also important for improving CDC in CLL patients deficient in C4 alone (Figure 
3.11B). In a larger patient cohort, supplementing the sera with C2 restored CDC 
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cell kill from primary to secondary sera use to levels observed for the NHS 
control (Figure 3.12), whereas the addition of C4 only showed improvement in 
CDC levels during the primary sera use. To determine whether we could protect 
against complement consumption in a clinically-relevant manner, we added back 
10% and 20% NHS (equivalent to FFP, an available source of complement for CLL 
sera), prior to the first round of CDC. Our results clearly demonstrate that 
adding back 20% NHS not only gave significant improvement to the initial level of 
CDC but also decreased the amount of complement exhaustion on secondary use 
(Figure 3.13).  
3.3.7 CLL sera exhaustion is observed in vivo with RTX 
Next we screened the sera of CLL patients undergoing RTX immunotherapy to 
establish whether complement levels were severely diminished following RTX 
treatment in vivo. The standard dosing schedule for RTX is shown in Figure 
3.14A, along with sera collection points. All except one CLL patient displayed 
complement levels falling below the expected normal range 24 hr post RTX 
infusion (Figure 3.14B-D). For the majority of patients, 28 days was sufficient for 
complement levels to be replenished following treatment, however this was not 
true for the patient already deficient in C2 (CLL106). In addition, in vitro CDC 
assays were carried out using OFA treated HG3 cells, using the RTX treated 
patient sera. OFA was chosen due to its ability to elicit higher levels of CDC in 
vitro than RTX, enabling a better range of CDC response to be measured. 
Analysis 24 hr following RTX infusion revealed that reduced complements levels 
correlated with an inability to elicit a CDC response (Figure 3.15A). The one CLL 
patient serum sample (CLL108) which did not have reduced complement levels 
also demonstrated good CDC activity on OFA treated HG3 cells which correlated 
with no complement exhaustion following RTX treatment (Figure 3.14B-D and 
Figure 3.15). Interestingly CLL108 was identified as being positive for 
NOTCH1MUT. Retrospective analysis of the CLL8 trial demonstrated that the 
addition of RTX to FC provided no additional benefit to NOTCH1MUT CLL 
patients108. Therefore it was not surprising that very little RTX CDC activity was 
observed for this patient within their sera. Individual complement component 
levels also reflected how readily patient sera exhausted following subsequent 
CDC challenge on OFA treated HG3 cells, with CLL106 displaying a marked 
reduction in CDC cell kill in vitro prior to RTX infusion (Figure 3.15Bi). This was 
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more apparent post RTX infusion with the majority of patients showing complete 
ablation of complement activity in vivo (Figure 3.15Bii). These findings highlight 
important implications for the future management of CLL patients receiving MAb 
therapy. 
3.3.8 OFA also induces complement consumption in vivo 
When this study was carried out, pre-April 2014, OFA was registered for use only 
in patients that were double refractory to both fludarabine and alemtuzumab 
treatment. Therefore the number of CLL patients receiving OFA treatment was 
scarce in the Glasgow area, however we were fortunate to receive sera from two 
CLL patients undergoing OFA immunotherapy. As we and others have shown OFA 
is a more potent inducer of CDC than RTX due to its novel epitope binding site 
(Figure 3.5). The scheduling for OFA is different from RTX with weekly cycles of 
MAb infusion followed by monthly doses. This scheduling, in combination with 
OFA’s potent CDC induction could therefore potentially lead to more excessive 
complement exhaustion. The standard dosing schedule for OFA is show in Figure 
3.16A, including the time points at which serum samples were collected for 
CLL111. 24 hr post the first 300 mg infusion of OFA, complement levels C2 and 
C4 were completely abolished, and C3 dropped below the normal range (Figure 
3.16B-D). For this patient OFA demonstrates excessive complement consumption 
similar to what we observe with CLL patients receiving RTX immunotherapy 
(Figure 3.14). 7 days after the 300 mg small dose of OFA complement levels 
were restored back to within the normal range. Interestingly when the dose of 
OFA increased to 2000 mg, 7 days post this infusion CLL111 still had no 
detectable C2 or C4 complement levels and C3 remained below the normal range 
(Figure3.16B-D). The reduction in complement levels were reflected in the CDC 
activity of the sera, with no detectable CDC observed in the primary or 
secondary use of the sera following OFA infusion (Figure 3.17). These in vitro 
findings potentially have a clinical impact, as they highlight that any further 
dose of OFA would likely have little effect on CDC lysis of tumour cells.  
The serum collection points for the second CLL patient that underwent OFA 
immunotherapy, CLL127, are shown in Figure 3.18A. CLL127 displayed a very 
high expression of complement components C2, C3 and C4, and after the start of 
OFA treatment, while complement levels dropped, they remained within the 
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normal range (Figure 3.18B-D). CDC analysis of the sera revealed that serum 
extracted from CLL127 still showed no complement exhaustion (Figure 3.19). 
CLL127 CDC results also demonstrated that there was enough OFA circulating 
within the peripheral blood to induce high levels of CDC in vitro upon HG3 cells 
incubated with this patient’s serum (i.e. no additional OFA added in vitro) to be 
used as a control. After the first 300 mg dose of OFA we observed an increase in 
CDC by 33.7% on untreated HG3 cells and 7 days after the large 2000 mg dose of 
OFA, CDC on untreated HG3 cells was maximal. This data shows that OFA is 
likely to be stable and circulate within the body for at least 7 days post 
treatment. 
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3.4 Discussion 
MAbs are now firmly established in the treatment of CLL, both as a first-line 
therapy and in the relapse setting. Type 1 anti-CD20 MAbs mediate their toxicity 
effects against CLL cells by using the patient’s natural immune responses to 
induce cell death through ADCC and CDC. Previous reports have shown that CDC 
is a finite process with complement becoming exhausted following MAb induced 
cell lysis329. Earlier research indicated that around 50% of CLL patients are 
deficient in C1 and C4, key components of the classical complement cascade, 
and this low complement activity is associated with advanced disease and 
shorter survival time325,326,328,338. Despite these early reports there has been little 
follow up to determine how these complement deficiencies influence the 
efficacy of MAb treatment, with immunotherapies such as OFA and RTX that are 
potent inducers of CDC.   
3.4.1 CLL patients have lower classical complement levels 
Our comprehensive assessment of the levels of all complement components 
involved in the first stage of the classical cascade in CLL patient sera revealed 
that a high proportion of CLL patients harbour deficiencies, with 37.5% 
displaying a reduced level of either C1, C2, C3 or C4. Patients exhibited a range 
of deficiencies from one to multiple complement components, with one 
individual demonstrating a deficiency in all classical complement components 
examined. Levels of C1 and C3 were often within the normal range, whereas 
subnormal levels of C2 (17.5% deficient) and C4 (20.3% deficient) were more 
prevalent in the CLL patient cohort examined. We were unable to define any 
significant differences in complement concentration within CLL patient clinical 
stage, or ZAP-70 status. Interestingly NOTCH1MUT CLL samples displayed a trend 
towards elevated concentration levels of C1 and C4. NOTCH1MUT CLL cells have 
previously been reported to be resistant against anti-CD20 MAb therapies; 
therefore our data indicates that impaired complement levels are not limiting 
CDC activity108,109. C2 and C4 are both cleaved into two fragments during 
classical complement activation, with C4b and C2a then forming a complex 
termed C3-convertase. C3-convertase is essential for cleaving C3, which enables 
the C3b fragment to opsonise the target cell and act as a scaffold for the MAC to 
assemble so that the target cell can be lysed. C3b also functions to opsonise 
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bacteria strains, for clearance by the classical pathway284. CLL patients are 
frequently unable to effectively coat bacterial pathogens with C3b, making them 
more susceptible to infection327. Therefore these deficiencies could increase the 
risk of life threatening infection, already a major concern in CLL patients338,345.  
3.4.2 CLL patient sera more readily exhaust of complement, 
abrogating CDC activity 
Although the high frequency of defects in complement levels did not correlate 
closely to overall classical complement activity in vitro, analysis of patient sera 
revealed that significantly more CLL patient sera samples underwent 
complement exhaustion on secondary challenge with bound MAb, compared to 
the NHS controls (42.3%; n=52). CLL patients with 11q del have been shown to 
respond well to RTX when added to FC treatment346, this could be in part due to 
the reduced level of complement exhaustion we observed in this cytogenetic 
subset. 11q del patients show 16.9% less complement exhaustion than CLL 
patients with no cytogenetic abnormalities (p=0.0529), suggesting there will be 
more effective clearance of cancer cells via RTX induced CDC. 
In addition tumour burden impacted on CDC efficiency, with high levels of sera 
exhaustion observed at medium-low tumour burden levels typically observed for 
CLL, 1 x 104 CLL cells/l. These findings are corroborated by Beurskens F.J. et 
al., who also observed an elevated complement consumption with high cell 
counts. Moreover they demonstrated that administering high concentrations of 
OFA did not substantially augment initial CDC induction, but did affect the 
ability to induce a second round of CDC due to exaggerated complement 
activation and consumption329. Therefore any MAb treatments requiring CDC for 
potency will be limited by tumour burden, and low complement component 
levels within CLL patient sera.  
3.4.3 CDC activity can be restored in CLL patient sera with limited 
complement levels  
Complement exhaustion has important implications for the dosing schedule of 
MAb treatment within CLL as frequent dosing, which in addition to limiting the 
efficacy of the drug, will lead to sustained complement exhaustion making 
patients more susceptible to infections. Having confirmed previous findings that 
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C2 was depleted at a high frequency in CLL319, we established that impaired CDC 
could be restored to a normal NHS level by supplementing patient sera with C2. 
In addition, supplementing patient sera with 10 and 20% NHS was also sufficient 
to substantially improve OFA mediated CDC and enable protection against 
complement exhaustion. Other studies suggest that RTX is not as effective at 
depositing C3b onto the surface of cancer cells and is not as effective as OFA as 
a single agent in CLL254,255,344. Despite this, RTX still showed significant 
improvement when administered together with FFP in a clinical trial of 
fludarabine-refractory CLL patients, with minimal toxicity255,347-349. This suggests 
that complement could be one of the limiting factors in RTX efficacy as a single 
agent.  
OFA is currently licensed for treatment in combination with chlorambucil for 
previously untreated CLL patients, when fludarabine based therapy is not 
suitable and as a single agent for CLL patients that are double refractory. OFA 
shows significant activity as a single agent, effectively targeting CLL cells 
previously treated with RTX256,257. The improvement reported for the small 
cohort of patients treated with RTX in combination with FFP, lend support for 
further investigation of MAb therapy in combination with FFP infusions in clinical 
trials in the context of enhancing classical complement pathway activity. This 
would be of particular importance for MAbs like OFA, which are highly effective 
at using the complement system to induce cell death. Moreover, enhancement 
of CDC by supplementing MAb therapy with FFP may also reduce the level of 
trogocytosis thus preventing immune evasion of CLL cells. Indeed, our data 
highlight the importance of considering tumour burden and patient complement 
levels prior to MAb therapy, as these factors could negatively impact on the 
ability of the patient’s natural immune system to clear the malignant cells, thus 
reducing clinical efficiency of the administered MAbs. Significantly, we 
demonstrate that complement exhaustion can occur following RTX therapy in 
vivo, reducing both complement activity as shown previously319, and the serum 
concentrations of complement components, particularly C2 and C4. Analysis of 
sera from CLL patients undergoing RTX immunotherapy, showed that 24 hr post 
RTX infusion, complement was rapidly consumed by OFA treated HG3 cells, 
leading to a substantial decrease in CDC activity. Only one CLL patient, 
identified as being NOTCH1MUT, did not display depleted complement levels with 
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high CDC activity and marginal exhaustion with secondary sera use. This was not 
surprising as NOTCH1MUT patients have previously been shown to display no 
improvement in PFS or OS when RTX was added to FC108. Therefore it is 
understandable that there would be no complement consumption if the cells are 
resistant to RTX. We have shown that the lack of RTX activity for this NOTCH1MUT 
CLL patient is not due to low complement levels or the inability to elicit CDC 
following OFA binding to HG3 cells. This suggests that the inhibitory mechanism 
for anti-CD20 MAb CDC efficacy is cellular rather than serum based. However in 
the majority of patients by day 28 CDC activity was restored, in line with 
complement levels. Interestingly the patient whose CDC activity remained low at 
day 28 was deficient in C2, which dropped even lower following RTX treatment 
and remained at low levels by day 28. We observed that sera from this patient, 
CLL106, exhausted readily in vitro, corroborating what was observed in vivo. In 
contrast to RTX, OFA is typically administered as 8 weekly doses followed by 4 
monthly treatments256,257.  
In one of the two CLL patients undergoing OFA treatment, 7 days after the 
infusion of OFA complement levels still were not restored to normal. This 
suggests that complement levels take between 7-28 days after MAb infusion to 
be restored, leaving CLL patients vulnerable to infection during these depleted 
periods and calls into question the effectiveness of the dosing schedule for OFA. 
In a previous study, patient complement levels were also reduced considerably 
following OFA infusion, especially after the first dose when CD20 levels were 
initially high23. These findings have recently been confirmed by Baig et al., who 
demonstrate that there is a rapid decrease in serum complement levels 
following OFA treatment, which is sustained 24h post-treatment. In addition CLL 
cells lose CD20 expression and become insensitive to in vitro OFA-mediated CDC, 
whilst retaining their ability to undergo alemtuzumab-mediated CDC when 
supplemented with 10% NHS28. The higher dose-intensity, coupled with the 
greater induction of CDC with OFA, suggests that sustained complement 
depletion is more likely to occur during OFA treatment, in susceptible patients. 
As observed in our second CLL patient undergoing OFA immunotherapy, OFA 
appears to be stable within peripheral blood up to and possibly exceeding 7 
days. Therefore the addition of FFP could lead to more effective clearance of 
CLL cells that are entering the peripheral blood from the LNs several days after 
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OFA infusion. In patients with complement deficiencies, ineffective CDC may 
also result in non-lethal complement deposition on CLL cells, allowing excessive 
CD20 depletion through trogocytosis by effector cells, and subsequent resistance 
to OFA-mediated CDC.  
This research demonstrates how important complement levels are in CLL and 
how this will limit the efficacy of MAb therapies, and gives warrant to a clinical 
study to assess the impact of complement replenishment using FFP in CLL 
patients receiving MAb therapy. 
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Figure 3.1 CLL patient sera exhibit deficiencies in key components of the classical 
complement cascade and reduced complement activity 
 
A. The concentrations of complement components of the classical cascade were assessed. Mean 
of individual patient samples, NHS and AMS controls is shown. NR: Normal Range. i. C1q levels 
were determined by RID. NR was established from the manufacturer's guidelines (NHS, n=4; AMS, 
n=12; CLL sera, n=52).  ii, C2 levels were determined by RID. NR was established from our AMS 
controls (NHS, n=6; AMS, n=12; CLL sera, n=57). iii & iv. C3 & C4 concentrations respectively 
were determined by immunonephelometry performed by the clinical diagnostic laboratory (NHS, 
n=13; AMS, n=12; CLL sera, n=64). B. Activity of the classical complement cascade was measured 
using the CH100 assay in CLL sera (n=62), NHS (n=10) and AMS control (n=12). CH100 units 
were determined against a standard curve following lytic ring measurement produced by serum 
measured against a calibrator of known activity levels. An unpaired t test revealed no significant 
difference in the mean complement levels and complement activity when comparing AMS controls 
with CLL patient sera.  
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Figure 3.2 Complement concentrations in CLL patient sera are not significantly affected by 
Binet stage 
 
The concentrations of complement components of the classical cascade were compared against 
Binet stage of disease at the point of sample collection. Mean of individual patient samples is 
shown. A. C1q levels compared against clinical stage (n=42). B. C2 levels compared against 
clinical stage (n=46). C. C3 levels compared against clinical stage (n=53). D. C4 levels compared 
against clinical stage (n=53). An unpaired t test was performed, with no significant difference 
observed between the mean complement levels or the level of CLL sera exhaustion and the 
different clinical stages of disease. 
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Figure 3.3 Complement concentrations in CLL patient sera are not significantly affected by 
poor prognosis cytogenetics/mutation 
 
The concentrations of complement components of the classical cascade were compared against 
the different CLL cytogenetic subgroups normal/13q, 11q del 17p del and NOTCH1
MUT
. Mean of 
individual patient samples is shown. A. C1q levels compared against cytogenetic subgroups 
(n=41). B. C2 levels compared against cytogenetic subgroups (n=46). C. C3 levels compared 
against cytogenetic subgroups (n=52). D. C4 levels compared against cytogenetic subgroups 
(n=52). An unpaired t test was performed, with no significant difference observed between the 
mean complement levels or the level of CLL sera exhaustion and the different cytogenetic 
subgroups. 
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Figure 3.4 Complement concentrations in CLL patient sera are not significantly affected by 
ZAP-70 status 
 
The concentrations of complement components of the classical cascade were compared against 
the ZAP-70 status. Mean of individual patient samples is shown. A. C1q levels compared against 
ZAP-70 status (n=37). B. C2 levels compared against ZAP-70 status (n=41), 25% ZAP-70 positive 
CLL patients are deficient in C2 compared to 10% that are ZAP-70 negative. C. C3 levels 
compared against ZAP-70 status (n=48). D. C4 levels compared against ZAP-70 status (n=48). An 
unpaired t test was performed, with no significant difference observed between the mean 
complement levels or the level of CLL sera exhaustion and ZAP-70 status.  
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Figure 3.5 Optimisation of experimental conditions using two CLL cell lines 
 
Optimisation of CDC was carried out using two CLL cell lines, HG3 and WAC. 2.5 x 10
6
 cells/ml 
were cultured with different concentrations of MAb and the optimal concentration was then used to 
determine the % NHS required to produce maximal CDC, once the % NHS was defined the time in 
which CLL cells incubated with NHS was altered. The level of CDC cell death was measured by 
flow cytometry (% PI+ cells). The percentage of dead cells is expressed relative to untreated 
control. A. Varying MAb concentrations with 50% pooled NHS and 2 hr incubation. i. HG3 cell line. 
ii. WAC cell line. B From these results (A) 20 μg/ml of OFA or RTX was decided as optimal, and 
cells were then incubated for 2 hr with different percentages of NHS. i. HG3 cell line. ii. WAC cell 
line. C. From (B) 50% pooled NHS was chosen as optimal and incubation time with NHS was 
varied between 1 and 24 hr. All experiment conditions were repeated in duplicate and 
representative data is shown. Each data point has been repeated in triplicate, with mean ± S.D 
shown. 
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Figure 3.6 Increasing tumour burden results in excessive complement consumption 
 
CLL primary cells (n=4 ± SEM) of different cell densities were treated with 20 μg/ml OFA. Sera 
were removed and re-challenged with fresh CLL cells of matching cell density treated with 20 μg/ml 
OFA. CDC was measured at both stages. The level of CDC cell death was measured by flow 
cytometry (% PI+ cells). p values were determined by a paired t-test (*, p<0.05).  
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Figure 3.7 CLL patient sera displays reduced CDC activity when used for a second time 
 
HG3 cells were treated with 20 μg/ml OFA and then incubated with 50% CLL patient sera or NHS 
and the level of CDC cell death measured by flow cytometry (% PI+ cells). The percentage of dead 
cells is expressed relative to untreated control. A. Induction of CDC from CLL patient sera for the 
first set of OFA-treated HG3 cells was assessed by PI staining (NHS, n=12; CLL, n=48). Serum 
that caused ≥40% CDC was used for secondary CDC. B. Sera from the first set of OFA-treated 
HG3 cells were removed from the cells and used for a second time to determine the CDC activity 
induced on fresh HG3 cells treated with 20 μg/ml OFA (2° use) (NHS, n=12; CLL, n=48). p values 
were determined by an unpaired t-test (** p<0.01). 
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Figure 3.8 CLL patient sera exhausts more readily than NHS 
 
HG3 cells were treated with 20 μg/ml OFA and then incubated with 50% CLL patient sera or NHS 
and the level of CDC cell death measured by flow cytometry (% PI+ cells). The percentage of dead 
cells is expressed relative to untreated control. A. CLL serum that caused ≥40% CDC in OFA 
treated HG3 cells in 1° use, was used again (2° use) and the percentage difference in CDC from 1° 
to 2° sera use enabled calculation of exhaustion levels (n=52 CLL patient sera vs. n=12 individual 
NHS). p values were determined by an unpaired t-test (** p<0.01). B. After induction of CDC from 
the first set of OFA-treated HG3 cells (1° use) sera were removed from the cells and used for a 
second time to determine the CDC activity induced on fresh HG3 cells treated with 20 μg/ml OFA 
(2° use). Representative data are shown from the sera of 3 CLL patients and NHS control. p values 
were determined by a paired t-test (*, p<0.05). 
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Figure 3.9 Exhaustion levels are not significantly linked with any poor prognostic markers in 
CLL  
 
CLL patient sera exhaustion levels were compared against different poor prognostic markers. 
Mean of individual patient samples is shown. A. Binet stage of the disease at the point of sample 
collection (n=54). B. CLL cytogenetic subgroups normal/13q, 11q del,17p del and NOTCH1
MUT
 
(n=46). C. ZAP-70 status (n=40). An unpaired t test was performed, with no significant difference 
observed between the mean CLL sera exhaustion levels and the different poor prognostic markers.  
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Figure 3.10 Complement C2 levels strongly correlates with CLL sera exhaustion 
 
Complement concentration levels were compared against the levels of CLL sera exhaustion to 
determine whether one or more complement component displayed the strongest association.  A. 
C1q levels in CLL patient sera were compared against CLL patient sera exhaustion (n=43). Linear 
regression was applied to obtain values for r
2
, 0.01681 and p value, 0.4073. B. C2 levels in CLL 
patient sera were compared against CLL patient sera exhaustion (n=47). Linear regression was 
applied to obtain values for r
2
, 0.5260 and p value, <0.0001. B. C3 levels in CLL patient sera were 
compared against CLL patient sera exhaustion (n=47). Linear regression was applied to obtain 
values for r
2
, 0.02727 and p value, 0.2673. C. C4 levels in CLL patient sera were compared against 
CLL patient sera exhaustion (n=43). Linear regression was applied to obtain values for r
2
, 0.1559 
and p value, 0.0192.  
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Figure 3.11 CLL sera exhaustion in complement deficient serum can be restored with the 
addition of complement components  
 
CLL sera that had complement deficiencies in C2, C3 and/or C4 were supplemented with C2 (50 
μg/ml), C4 (700 μg/ml) or both C2/C4 (25 μg/ml/350 μg/ml respectively), before being used to 
induce CDC in HG3 cells treated with 20 μg/ml OFA (1° use). After the incubation period, sera was 
removed and re-challenged with HG3 cells treated with 20 μg/ml OFA (2° use). Percentage of dead 
cells is relative to untreated control. A. Representative CLL patient serum sample deficient in C2 
alone. B. Representative CLL patient serum sample deficient in C4 alone. C. Representative CLL 
patient serum sample deficient in C2 and C4.  
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Figure 3.12 CDC activity in complement deficient serum can be restored with the addition of 
C2 alone 
 
CLL sera that exhibited high levels of serum exhaustion was supplemented with C2 (50 μg/ml), C4 
(700 μg/ml) or both C2/C4 (25 μg/ml/350 μg/ml respectively), before being used to induce CDC in 
HG3 cells treated with 20 μg/ml OFA (1° use). After the incubation period, sera was removed and 
re-challenged with HG3 cells treated with 20 μg/ml OFA (2° use). Percentage of dead cells is 
relative to untreated control. A. CLL sera (n=16) were supplemented with C2 (n=14), C4 (n=9), C2 
and C4 combined (n=8). Mean cell death 
+
 SEM are shown. p value were obtained by paired t test 
(* p<0.05, ** p<0.01, *** p<0.001). B. CLL sera were supplemented with C2 alone. Analysis is 
shown for the percentage change in CDC from the 1° to 2° use.  p value was obtained from a 
paired t-test (*** p<0.001). 
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Figure 3.13 The addition of NHS to CLL sera significantly abrogates serum exhaustion 
 
CLL sera that exhibited high levels of serum exhaustion was supplemented with 10 or 20% NHS 
(n=9 ± SEM), before being used to induce CDC in HG3 cells treated with 20 μg/ml OFA (1° use). 
After the incubation period, sera was removed and re-challenged with HG3 cells treated with 20 
μg/ml OFA (2° use). Percentage of dead cells is relative to untreated control. p value was obtained 
from paired t test. (* p<0.05; ** p<0.01; *** p<0.001). Percentage of dead cells is relative to 
untreated control. 
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Figure 3.14 Complement levels are exhausted in vivo following RTX immunotherapy 
 
A. RTX dosing schedule and serum sample collection points. B-D. Concentrations of complement 
levels from sera samples collected from CLL patients undergoing RTX immunotherapy 
(concentration shown in Table 3.1; n=6). Sera were collected prior to RTX therapy (pre – RTX dose 
1), 24 hr after treatment (post – RTX dose 1) and prior to the second dose of RTX, 28 days after 
dose 1 (pre – RTX dose 2). A. C2 levels were determined by RID. B. & C. C3 & C4 concentrations 
were determined by immunonephelometry. p value was obtained from paired t test (* p<0.05; ** 
p<0.01).  
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Figure 3.15 CDC activity is exhausted in vivo following RTX immunotherapy 
 
CDC activity of sera from CLL patients undergoing RTX immunotherapy (concentration shown in 
Table 3.1; n=6). Sera were collected prior to RTX therapy (pre – RTX dose 1), 24 hr after treatment 
(post – RTX dose 1) and prior to the second dose of RTX, 28 days after dose 1 (pre – RTX dose 
2). A. CDC was measured on HG3 cells treated with 20 μg/ml OFA in 50% CLL sera. p value was 
obtained from paired t test (* p<0.05; ** p<0.01). B. Exhaustion was measured in sera collected i, 
prior to RTX therapy and ii, post – RTX dose 1. After induction of CDC from the first set of OFA 
treated HG3 cells (1° use) sera were removed from the cells and re-challenged with HG3 cells 
treated with 20 μg/ml OFA and CDC measured (2° use). Percentage of dead cells is relative to 
untreated control. 
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Figure 3.16 Complement levels are exhausted in vivo following OFA immunotherapy 
 
A. OFA dosing schedule and serum sample collection points B-D. Concentrations of complement 
levels from sera collected from one CLL patient (CLL111) undergoing OFA immunotherapy. Sera 
were collected prior to OFA therapy (pre – OFA dose 1), 24 hr after treatment (post – OFA dose 1), 
prior to the second dose of OFA, 7 days after dose 1 (pre – OFA dose 2) and 7 days after the 
fourth dose of OFA (Pre-OFA dose 5). A. C2 levels were determined by RID. B. & C. C3 & C4 
concentrations were determined by immunonephelometry. 
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Figure 3.17 CDC activity is exhausted in vivo following OFA immunotherapy 
 
CDC activity of sera from one CLL patient (CLL111) undergoing OFA immunotherapy. Sera were 
collected prior to OFA therapy (pre – OFA dose 1), 24 hr after treatment (post – OFA dose 1), prior 
to the second dose of OFA, 7 days after dose 1 (pre – OFA dose 2) and 7 days after the fourth 
dose of OFA (pre-OFA dose 5). Exhaustion was measured in sera collected at each time point, 
after induction of CDC from the first set of OFA treated HG3 cells (1° use) sera were removed from 
the cells and re-challenged with HG3 cells treated with 20 μg/ml OFA and CDC measured (2° use). 
Percentage of dead cells is relative to untreated control. 
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Figure 3.18 Complement levels are reduced in vivo following OFA immunotherapy 
 
A. OFA dosing schedule and serum sample collection points. B-D. Concentrations of complement 
levels from sera collected from one CLL patient (CLL127) undergoing OFA immunotherapy. Sera 
were collected prior to OFA therapy (pre – OFA dose 1), prior to the second dose of OFA, 7 days 
after dose 1 (pre – OFA dose 2), 7 days after dose 2 (Pre-OFA dose 3), 7 days after dose 3 (pre- 
OFA dose 4) and 7 days after the sixth dose of OFA (pre-OFA dose 7). A. C2 levels were 
determined by RID. B. & C. C3 & C4 concentrations were determined by immunonephelometry. 
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Figure 3.19 OFA is stable within peripheral blood for up to 7 days in vivo following OFA 
immunotherapy 
 
CDC activity of sera from one CLL patient (CLL127) undergoing OFA immunotherapy. Sera were 
collected prior to OFA therapy (pre – OFA dose 1), prior to the second dose of OFA, 7 days after 
dose 1 (pre – OFA dose 2), 7 days after dose 2 (Pre-OFA dose 3), 7 days after dose 3 (pre- OFA 
dose 4) and 7 days after the sixth dose of OFA (pre-OFA dose 7). Exhaustion was measured in 
sera collected at each time point. A. CDC induction from the first set of OFA treated HG3 cells (1° 
use). B After the induction of CDC from the 1° use sera were removed from the cells and re-
challenged with HG3 cells treated with 20 μg/ml OFA and CDC measured (2° use). 
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4 Anti-CD20 MAb activity on CLL cells 
4.1 Introduction 
As described in the previous chapter MAbs exert anti-tumour activity via 
harnessing the body’s own natural immune response especially ADCC involving 
the recruitment of NK cells to cause phagocytosis and CDC requiring the 
activation of the classical complement pathway, and/or apoptosis284. RTX and 
OFA are Type 1 MAbs which exert anti-tumour activity mainly through ADCC and 
CDC induction and rarely through apoptosis. Therefore the focus of this chapter 
is to assess CDC and ADCC induction in CLL cells following RTX and OFA 
treatment. 
4.1.1 Surface expression markers and anti-CD20 MAb activity 
Research has shown that RTX induced CDC is greatly hindered by low CD20 
expression levels and high expression of complement inhibitory proteins CD55 
and CD59, which aid CLL cells resistance to RTX mediated killing. CD55 and CD59 
both prevent uncontrolled complement activation311,319,350. CD55 acts to 
accelerate the decay of C3 convertase, whereas CD59 inhibits the formation of 
the MAC pore thus preventing cell lysis by CDC306. However, in the case of RTX, 
the most important determinant in inducing CDC is the expression levels of 
CD20310,311. In CLL patients that had low CD20 expression levels, CDC induction 
by RTX was improved with the use of inhibitor molecules against one or both of 
these proteins310,311. Further research has also suggested that OFA is less 
dependent on these inhibitory proteins and is more effective at inducing CDC at 
lower CD20 levels. This is important as CLL cells are known to express lower 
levels of CD20 than other B-cell malignancies254,255,315,344,351,352. CD52 
glycoprotein is the target for alemtuzumab MAb. CD52 displays high expression 
on both B and T cells, there are thought to be around 500,000 CD52 
molecules/cell, encompassing 5% of the cells surface353. The physiological 
function of CD52 is relatively unknown, however it is thought to function in T 
cell activation, cell to cell adhesion and signal transduction353. CD55 and CD59 
both possess GPI tails, CD52 is also anchored to the cellular membrane through 
the GPI tail354. One research group postulated that it may also function as a 
complement inhibitor354. When they created RTX resistant cell lines from Raji 
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and RL cells, it was found that CD52 expression was up-regulated. Complete 
inhibition of CD52 resulted in partial rescue of RTX CDC sensitivity in these cell 
lines354. Therefore although CD52 does not appear to be a potent complement 
inhibitory protein it may function in conjunction with CD55 and CD59 expression 
to increase OFA/RTX related resistance. Although substantial research has been 
carried out to determine the effect of these surface proteins on RTX activity 
little is known about the effect they have on OFA activity in CLL. 
Well documented cytogenetic aberrations such as 17p (targeting TP53) and 11q 
(targeting ATM) deletions have long provided a difficult paradigm for the 
treatment of CLL. ATM is a key component of the DNA damage response pathway 
and p53 is a critical component for driving apoptosis in the presence of DNA 
damage83. Chemotherapeutic agents such as alkylating agents and purine 
analogues rely upon this pathway for their clinical efficacy246,248. Therefore it is 
not surprising that 17p del CLL displays aggressive clinical course with limited 
therapeutic options. Alemtuzumab is most commonly used for CLL patients with 
either a TP53 mutation and/or refractory to fludarabine based 
treatment86,354,355. Recent identifications of novel genetic mutations are also 
shedding light upon chemotherapy resistance not contributable to 17p del. BIRC3 
mutations for instance are extensively observed within CLL patients relapsed 
refractory to fludarabine whom are p53 wild-type113.  
Emerging data is now contributing NOTCH1MUT with resistance against type I anti-
CD20 MAbs. NOTCH1MUT were recently identified as an independent poor 
prognostic marker for CLL patients, present in approximately 10-12% of CLL 
cases96. The majority of mutations, 80%, are generated from a 2 base pair 
frameshift deletion c.7544_7545delCT, resulting in a truncated protein lacking 
the C-terminal PEST domain98. This mutation results in Notch1 escaping 
ubiquitination leading to an accumulation of active Notch1 in the nucleus. Active 
Notch1 in the nucleus is known to result in deregulated activation of various 
different cellular pathways, especially those involved in cell cycle and cell 
survival such as NF-κB1 and MYC210,217.  
A retrospective study of the CLL8 trial identified the patients within the trial 
which had NOTCH1MUT, and then determined how this predicted their response to 
FC vs FCR treatment. From these data it was determined that there was no 
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advantage to combining RTX with FC treatment, similar to results obtained from 
the 17p deleted cohort108. Interestingly, research presented from a trial 
investigating the effect of chlorambucil with or without OFA on PFS, observed an 
improvement in PFS with chlorambucil plus OFA in NOTCH1MUT. However this 
response only occurred during the first 18 months, after which the affect was 
lost and PFS followed patients treated with chlorambucil alone in the NOTCH1MUT 
cohort109. Although the initial response was lost, it is important to identify why 
the NOTCH1MUT patients respond briefly to OFA treatment and not RTX. 
Especially since other poor prognostic cytogenetics such as 11q del respond well 
to this type of treatment346. 
4.2 Aim 
The main focus was to investigate anti-CD20 MAb activity in poor prognosis 
NOTCH1MUT CLL patient cells. In order to do this the differences in CDC and ADCC 
activation in CLL cells between RTX and OFA was characterised, and analysis of 
surface protein expression markers CD20, CD52, CD55 and CD59 linked to anti-
CD20 MAb activity was performed. Key aims: 
 Distinguish surface protein expression levels between normal healthy B-
cells and CLL cells and the different cytogenetic sub-groups; 
 Determine whether OFA displays significantly improved CDC compared to 
RTX in all the different CLL cytogenetic sub-groups; 
o If so are CDC levels limited by CD20, CD52, CD55 and CD59 
expression levels? 
 Establish ADCC induction levels in NOTCH1MUT CLL cells and if induction is 
lower than in the other cytogenetic groups. 
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4.3 Results 
4.3.1 Identification of NOTCH1MUT CLL patients 
FISH analysis was performed on CLL patients at the point of diagnosis by the 
regional haematology laboratory, to determine whether patients harboured 11q 
del or 17p del. Identification of NOTCH1MUT was carried out in the laboratory 
using ARMS PCR screening. Of the 89 patients screened by ARMS PCR (Figure 4.1) 
NOTCH1 mutations were identified in 8.0% of our CLL patients that had no 11q or 
17p de. Surprisingly we also identified a small cohort of CLL patients harboured 
both 17p del and NOTCH1MUT (3.3%). This assay is sensitive enough to detect the 
mutation allele if present in at least 10% of the clonal population; we detected 
samples that had a stronger band present in the wild type allele, and a faint 
band for the mutant allele (CLL122; Figure 4.1). These samples were excluded 
from further analysis. Cytogenetically normal CLL cells were classified as CLL 
cells with no detectable 17p or 11q del or NOTCH1MUT. 
4.3.2 Surface expression levels for specific proteins differ 
between healthy B-cells and CLL cells 
We next investigated how surface protein expression levels of CD20, CD52, CD55 
and CD59 differ between CLL cells and those from healthy B-cells (n=10). Protein 
expression levels were determined by mean fluorescent intensity (MFI) ratio (MFI 
stained cells / MFI unstained cells). CD20 expression levels show the most 
marked difference in expression between B cells and CLL cells (Figure 4.2A), 
with healthy B cells having approximately 30 fold higher expression of CD20 
compared with CLL cells. It is widely known that CLL cells have reduced CD20 
expression levels compared to other B cell malignancies such as non-Hodgkins 
lymphomas. These results further highlight the low levels of CD20 expression and 
the importance of antibody binding affinity and its proximity to the cell surface 
when considering anti-CD20 MAb treatment in CLL254,311. As observed with CD20 
expression, levels of CD52, another protein targeted frequently in the treatment 
of CLL patients, also had significantly less expression, with around 3 fold less 
observed in CLL cells compared to healthy B cells (Figure 4.2B). This finding 
implies that the MAbs used in CLL will also target any healthy B cells present in 
CLL patients. Interestingly comparing expression levels of the two complement 
inhibitory proteins CD55 and CD59, expression was variable with CD55 having an 
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approximate 2 fold higher expression in CLL cells than B cells, while there was 
little difference between the two populations for CD59 expression (Figure 
4.2C&D). Higher expression levels of CD55 may act to further inhibit the classical 
complement pathway making CLL cells less susceptible to CDC induction by 
MAbs.  
4.3.3 Different cytogenetic sub-groups de-regulate surface 
protein expression 
To further characterise CD20, CD52, CD55 and CD59 expression in our CLL 
patient cohort we separated the CLL samples based on cytogenetic status. 
Interestingly when we compared CD20 expression levels, CLL cells with no 
reported cytogenetic abnormalities or those with 11q del had the highest 
expression levels, and 17p del had significantly lower expression of CD20 (Figure 
4.3A). Similar to other reports356, we also found NOTCH1MUT CLL patients to have 
lower expression levels of CD20, having on average 30% lower expression levels 
than cytogenetically normal CLL cells. Although with a larger NOTCH1MUT patient 
cohort this may become statistically significant. Our findings demonstrate that 
although NOTCH1MUT patients do have lower CD20 expression levels this is 
unlikely to be the only contributing factor leading to their reduced CDC activity 
with anti-CD20 MAb’s. 17p del patients also express lower CD20 expression levels 
and reports have shown that these patients still show slight improvement in PFS 
and OS when RTX is added to FC, albeit not to the extent observed with 11q del 
or cytogenetically normal CLL patients108,346. When we compared CD52 
expression levels, CLL samples with no cytogenetic abnormalities exhibited the 
highest expression levels, whilst 11q del CLL cells had the lowest expression 
levels observed with approximately 40% lower expression than normal CLL cells 
(p=0.0795), which may be a contributing factor to the effectiveness of RTX 
treatment in 11q del patients346. CD55 expression was relatively similar between 
the different cytogenetic groups with NOTCH1MUT having slightly higher 
expression than the other cytogenetic groups, (Figure 4.3C) and CD59 displayed 
no difference between the cytogenetic groups (Figure 4.3D). 
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4.3.4 OFA displays significantly higher efficacy at inducing CDC 
in all cytogenetic sub-groups 
CDC was induced for both OFA and RTX in CLL cells from all of the different 
cytogenetic groups, on average the level of CDC observed with RTX was low at 
0.93%, whereas OFA produced significantly more CDC with a mean of 23.13% 
(Figure 4.4). When we compare the level of CDC produced by OFA between the 
different prognostic groups we observe that NOTCH1MUT CLL cells produced the 
lowest levels of CDC, with CDC levels being nearly half that of cytogenetically 
normal CLL cells (Figure 4.5). These findings are in line with a previous report 
which also showed that NOTCH1MUT CLL cells exhibited less CDC in response to 
MAb233. Although there are no statistically significant differences between the 
groups in our study, this is likely due to the small sample size; a larger cohort is 
required to determine if these findings are statistically significant. 
4.3.5 OFA CDC levels display a positive linear correlation with 
CD20 expression levels only 
Next we determined if there was any correlation between CD surface proteins 
levels and the level of OFA induced CDC. Firstly CD20 MFI ratio was plotted 
against OFA CDC levels, this showed a strong positive correlation between CDC 
levels and CD20 expression levels (r2= 0.4506; p= <0.001) (Figure 4.6A). Analysing 
these data by the different cytogenetic groups demonstrated that 
cytogenetically normal CLL cells displayed a significant correlation with CD20 
expression levels (r2= 0.6898; p= 0.01). While 11q and 17p del patients displayed 
a positive linear correlation, this was not statistically significant, although the 
results are close to being so (r2= 0.4342; p= 0.11 and r2= 0.4881; p= 0.081 
respectively) (Figure 4.6Bi-iii). This is in contrast to NOTCH1MUT CLL cells which 
displayed no correlation (r2= 0.098; p= 0.49), again corroborating our earlier 
results that the lack of anti-CD20 MAb activity can not solely be contributed to 
low CD20 expression levels (Figure 4.6Biv). Comparing CD52, CD55 and CD59 
expression levels produced no correlation with % of dead cells from OFA induced 
CDC. Others have also shown that RTX CDC activity does not correlate with 
complement inhibitory proteins, but CDC activity was improved with inhibitors of 
CD55 and CD59 for CLL cells that displayed reduced efficacy towards RTX (Figure 
4.7)308,310,311. 
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4.3.6 OFA has greater efficacy at inducing ADCC in CLL cells 
An ADCC assay was performed on our CLL samples to address potential 
mechanisms of NOTCH1MUT mediated resistance to RTX108. To determine the 
range of concentrations to use for RTX and OFA the assay was optimised in two 
cell lines HG3 and Ramos (Burkitt’s lymphoma cell line with high expression 
levels of CD20). We analysed the results in two ways; using the luminescence 
read and calculating the fold of induction of ADCC (MAb luminescence/no drug 
control (NDC) luminescence –background luminescence). As the fold of induction 
was more informative this was used for all further analysis. Ramos displayed a 
greater induction of ADCC than HG3 cells, with OFA being more potent at a 
lower concentration than RTX (OFA at 100 ng/ml as opposed to RTX at 1 µg/ml). 
However RTX induced a higher fold of induction than OFA (Figure 4.8).  
Comparing the response of cytogenetically normal CLL cells with RTX and OFA 
(Figure 4.9), there was a slightly higher induction of ADCC for OFA than RTX and 
OFA was more potent, with maximal fold of induction observed at 100 ng/ml as 
opposed to RTX at 1 µg/ml, as seen with the cell lines. A similar trend with OFA 
being more potent at lower concentrations was observed in our 11q del CLL 
patients (Figure 4.10), although only 1 of 3 patients displayed a clear induction 
of ADCC. Minimal ADCC induction was observed for both RTX and OFA in our 17p 
del patients (Figure 4.11). Comparing the MAbs in our NOTCH1MUT samples 
(Figure 4.12), there was a slightly higher maximal fold of induction for OFA and 
again OFA had higher potency at 100 ng/ml. To determine if there was 
significant difference in the efficacy at inducing ADCC between OFA and RTX the 
fold induction at the highest potency for the two MAbs was compared, for OFA 
100 ng/ml and RTX 1 µg/ml. For all the different cytogenetic groups, OFA had 
the higher fold of induction, but this was only statistically significant for 11q del 
CLL cells (p=0.0057) (Figure 4.13A-D). Comparing all the CLL samples together, 
OFA significantly induced higher amounts of ADCC than RTX, with approximately 
30% more ADCC observed with OFA than RTX (p=0.0068). When the maximal fold 
of induction for both RTX and OFA was compared between the different 
cytogenetic groups, cytogenetically normal CLL cells had the higher ADCC 
induction, similar to our findings for CDC activation in this group. However 
unlike with CDC, 17p del patients had the lowest levels of induction, lower than 
NOTCH1MUT CLL cell ADCC induction, although a larger patient cohort is required 
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to determine if there are any statistically significant differences between the 
different cytogenetic subsets (Figure 4.14). 
4.3.7 ADCC induction does not correlate with expression levels of 
CD20 nor CDC induction. 
Comparing CD20 expression levels against CDC demonstrated there was a strong 
positive linear correlation between CD20 expression levels and the % of dead 
cells produced by CDC induction. However, the same was not true for ADCC. 
Comparing the maximal fold of ADCC induction produced with OFA at 100 ng/ml 
for all the CLL samples in comparison to CD20 expression levels produced no 
correlation (Figure 4.15A). To determine whether the higher levels of CDC 
activation would relate to higher ADCC induction this was also plotted, however 
no correlation was found (Figure 4.15B). Therefore our results indicate that 
when CLL samples are susceptible to OFA induced CDC, this does not necessarily 
result in similar susceptibly to OFA induced ADCC.  
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4.4 Discussion 
Notch1 mutations are a recently identified independent poor prognostic marker 
in CLL, with mutations resulting in increased CLL cell survival and 
proliferation98,229,357. Notch expression has been shown to result in suppression of 
p53 and pro-apoptotic proteins Bax, Bim and Noxa, whilst activating PI3K/Akt, 
NF-κB and anti-apoptotic proteins Bcl-2 and Bcl-XL
210. Over activation of pro-
survival pathways in NOTCH1MUT CLL cells, presents an obstacle for 
chemotherapeutic agents, especially through the suppression of p53 activity 
limiting the induction of apoptosis. However immunotherapeutic agents such as 
RTX, that induce CDC and ADCC and have limited efficacy at inducing 
programmed cell death, could have provided a viable treatment option for 
NOTCH1MUT CLL cells. Therefore it was surprising that a retrospective 
investigation of the CLL8 trial identified that NOTCH1MUT confers a resistance to 
RTX when RTX is added to FC treatment strategy, which is not observed in any 
other poor cytogenetic subset108. Importantly there was improvement in PFS 
observed in NOTCH1MUT patients treated with chlorambucil plus OFA, although 
this improvement was relatively short lived, 18 months. Therefore, it is 
important to understand the mechanism surrounding CD20 MAb treatments that 
result in diminished efficacy in NOTCH1MUT CLL patients and whether a potent 
inducer of CDC may be able to overcome this resistance109.  
4.4.1 The level of CD20 expression is the most important 
determinant in CDC induction with RTX/OFA 
Comparing surface expression levels of CD20 from healthy B cell donors and CLL 
cells demonstrated as expected that CLL cells had significantly lower levels of 
CD20, which is a well-documented phenotype of CLL cells310,318. Interestingly 
there was also lower expression levels of CD52. However the mean CD52 MFI 
ratio in CLL cells was 67.29, which was still substantially larger than the mean 
MFI ratio for CD20 which was 4.388. Therefore although expression levels are 
lower, it would seem likely that the number of CD52 molecules on the surface of 
the CLL cell are still above a critical level required for CDC and ADCC activation, 
which makes alemtuzumab such a successful treatment regime86,358. Interestingly 
only CD55 displayed a significant up-regulation in CLL cells, whereas with CD59 
there was little difference in expression levels from normal B cells to CLL cells. 
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Others have also observed a skew in CLL cells towards up-regulating CD55 more 
than CD59311.  
4.4.2 Surface protein expression levels do not fully explain the 
lack of activity of RTX and OFA against NOTCH1MUT  
When CD20 expression levels were separated based on CLL cytogenetic subsets, 
17p del CLL cells displayed significantly less CD20 expression than CLL cells with 
no cytogenetic abnormality. Although NOTCH1MUT cells also had lower levels of 
CD20 than normal CLL cells this was not statistically significant, with a larger 
population of NOTCH1MUT CLL cells this may change. Importantly 11q del patients 
did not display reduced CD20 expression levels, and responded well to OFA 
induced CDC, therefore low CD20 expression levels are not uniformly observed in 
all poor prognostic CLL patients. The retrospective CLL8 trial demonstrated no 
improvement in PFS or OS in NOTCH1MUT CLL cells with FC vs FCR. However there 
was a slight improvement observed in PFS and OS within 17p del patients 
receiving FCR compared to FC108. When the mean OFA induced CDC levels were 
compared between all cytogenetic sub-groups, NOTCH1MUT CLL cells 
demonstrated the lowest CDC induction of all the cytogenetic subgroups. This 
indicates that low CD20 expression levels alone do not entirely contribute to the 
lack of activity of anti-CD20 MAb in NOTCH1MUT CLL cells. Recent research of a 
large cohort of CLL patients (n=692) of which 87 were NOTCH1MUT suggests the 
reduced activity of anti-CD20 MAbs in NOTCH1MUT CLL cells is due to reduced 
expression of CD20356. When CLL samples were sorted for lowest and highest 
expression of CD20 they identified that the population with the lowest CD20 
expression was enriched for NOTCH1MUT. They attributed the lower expression of 
CD20 to increased expression at the mRNA and protein level of HDAC1 and 
HDAC2356. HDACs act as epigenetic regulators of gene expression by catalysing 
the removal of acetyl groups from core histones. This in turn results in 
chromatin compaction leading to the repression of gene transcription359,360. 
HDAC inhibitors, such as valporic acid (VPA) have been shown to result in the up-
regulation of CD20 expression and potentiate the activity of RTX mediated CDC 
in B cell lymphoma cell lines361. Low CD20 expression levels have been 
associated with innate and acquired RTX related resistance, and HDAC inhibitors 
have been shown to augment the CDC activity of RTX. However our results would 
suggest that even if CD20 expression levels were able to be raised in NOTCH1MUT 
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CLL cells this would not necessarily result in the complete return in activity of 
OFA/RTX. This is highlighted when comparing CD20 expression and CDC linear 
regression, with no detectable correlation between the two in NOTCH1MUT CLL 
cells. 
CD55 was the only other molecular marker investigated that could contribute to 
reduced MAb activity in NOTCH1MUT CLL cells, as CD55 expression was highest 
within NOTCH1MUT CLL samples. Higher CD55 complement inhibitory protein 
expression in conjunction with low CD20 expression levels could result in 
resistance to RTX. Although OFA CDC levels did not display any correlation with 
expression of CD55 or CD59, others have also observed similar results with RTX 
311. Despite a lack of correlation between CD55 and CD59 expression with RTX 
induced CDC within their study, in CLL cells with basal response to RTX there 
was improvement in RTX CDC induction when antibodies against CD55 and CD59 
were used. The improved efficacy was cumulative when antibodies against both 
proteins were used in conjunction with RTX, displaying a 6-fold increase in CDC 
induction in the previously basal level responders311. In the CLL cells that 
responded well to RTX within the first instance, inhibition of either CD55 or 
CD59 was sufficient to produce maximal CDC induction311. The lack of correlation 
with expression levels and induction of CDC suggests that even the lowest 
expression of these complement inhibitors is sufficient for them to limit 
complement activation and higher expression levels provide no further inhibitory 
effect. As NOTCH1MUT CLL cells demonstrate poor CDC induction with OFA, 
inhibition of CD55 and CD59 may lead to increased efficacy. RTX displays little 
efficacy as a single agent, whereas when in combination with FC superior 
responses are produced349. One of the mechanisms behind this is thought to be 
that fludarabine may potentially cause the down-regulation of CD55. Within a 
non-Hodgkin’s lymphoma cell line resistant to RTX it was identified that 
exposure to fludarabine caused a reduction in CD55 from 96% to 55% positive 
cells and synergised with the efficacy of RTX362. OFA however does not 
demonstrate the same level in improvement in CDC induction with inhibitors 
against CD55 and CD59, presumably because it is a more effective inducer of 
CDC in the presence of low CD20 expression levels363. CD55 competes for binding 
to complement component C4b so that C2a is displaced and C3 convertase can 
no longer be formed, whereas CD59 prevents the formation of the MAC through 
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stopping the polymerisation of complement C91. This suggests that the closer 
binding site of OFA allows more effective deposition of active complement 
components onto the surface of the cell so even in the presence of these 
complement inhibitory proteins CDC is still induced. The brief time period in 
which OFA showed clinical efficacy in NOTCH1MIUT CLL patients could be 
explained by the heterogeneous population of CLL cell being treated254,255,315,316. 
Within NOTCH1MUT CLL patients OFA infusion could effectively have cleared the 
CLL cells not expressing NOTCH1MUT which had higher levels of CD20 expression. 
This would leave the malignant NOTCH1MUT clone to escape into the BM/LN. 
Within the BM/LN microenvironment stimulation of the Notch pathway would 
provide enhanced activation of the NOTCH1MUT clone leading to its expansion. 
After 18 months the NOTCH1MUT clone would then represent the majority of the 
CLL cell population resulting in a loss of susceptibility against OFA activity. 
4.4.3 ADCC levels do not correlate with CD20 expression 
Investigating the efficacy of RTX and OFA at inducing ADCC in CLL cells 
demonstrated that OFA is more potent than RTX and also shows significantly 
higher ADCC induction, although this induction is not as notable as with CDC. 
Others have seen that OFA is marginally more effective than RTX at inducing 
ADCC364. Interestingly 17p del displayed the lowest levels of ADCC induction, 
lower than results obtained from NOTCH1MUT CLL cells, but a larger patient 
cohort would be required to determine if this is a significant trend. Again 
NOTCH1MUT CLL cells displayed less ADCC induction with RTX/OFA than 
cytogenetically normal CLL cells, indicating that the resistance observed in vivo 
is also observed in vitro without Notch1 stimulation. Interestingly, unlike CDC 
activation the ADCC fold of induction did not correlate with CD20 expression 
levels. The Ramos cell line has a much higher expression level of CD20 than CLL 
cells, and it displays a strong fold of induction with RTX/OFA. Therefore it is 
possible that the surface expression of CD20 on CLL cells is too low and only 
above a certain threshold can CD20 expression levels affect the level of ADCC 
induction. Furthermore high CDC activation did not correlate with high ADCC 
induction, others have also found this characteristic of ADCC with RTX365. This 
indicates that CLL cells may be susceptible to either CD20 MAb induced 
CDC/ADCC but not necessarily both of these pathways. 
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This work provides important evidence that CD20 expression levels could be to 
blame for some, but not all of the reduced activity of anti-CD20 MAb in 
NOTCH1MUT CLL cells. Therefore further research is required to determine the 
precise mechanisms responsible for poor activity of these MAbs against 
NOTCH1MUT CLL cells.  
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Figure 4.1 Identification of NOTCH1
MUT
 by ARMS PCR 
 
ARMS PCR detects NOTCH1 c.7544_7545delCT mutation using two forward primers, one for the 
normal NOTCH1 sequence producing a band at 284 bp and one for the NOTCH1 mutation giving a 
band at 183 bp. Representative data is shown here from twelve of our CLL patients along with two 
NOTCH1
MUT
 positive samples received from Oxford University (+ve OX_CLL). A total of 89 CLL 
patients were screened, with seven found to be NOTCH1
MUT
 positive with no 11q or 17p deletions 
detected by FISH. 
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Figure 4.2 Cluster of differentiation surface protein expression is skewed in CLL patients 
 
Normal healthy B cells were selected by gating on the CD19
+
 and CD20
+
 population of cells. B 
cells and CLL cells were either unstained or stained with Ab, cells were left on ice with Ab for 30 
min and then washed with PBS. All cells then underwent flow cytometry analysis. MFI ratio was 
obtained by taking the ratio of unstained vs stained cells. A. CD20 expression in normal B cells 
(n=10) vs CLL cells (n= 37). B. CD52 expression in normal B cells (n=10) vs CLL cells (n= 33). C. 
CD55 expression in normal B cells (n=10) vs CLL cells (n= 36). D. CD59 expression in normal B 
cells (n=10) vs CLL cells (n= 36). p values were determined by an unpaired t-test (*** p<0.001).  
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Figure 4.3 Only CD20 expression levels display significant differences between the different 
CLL cytogenetic subsets 
 
CLL cells were either unstained or stained with Ab, cells were left on ice with Ab for 30 min and 
then washed with PBS. All cells then underwent flow cytometry analysis. MFI ratio was obtained 
from taking the ratio of unstained vs stained cells. A. CD20 expression in cytogenetically normal 
(n=8), 11q del (n= 7), 17p del (n=7) and NOTCH1
MUT
 (n=7) CLL cells. B. CD52 expression in 
cytogenetically normal (n=8), 11q del (n= 6), 17p del (n=6) and NOTCH1
MUT
 (n=7) CLL cells. C. 
CD55 expression in cytogenetically normal (n=8), 11q del (n= 7), 17p del (n=7) and NOTCH1
MUT
 
(n=7) CLL cells. D. CD59 expression in cytogenetically normal (n=8), 11q del (n= 7), 17p del (n=7) 
and NOTCH1
MUT
 (n=7) CLL cells. p values were determined by an unpaired t-test (* p<0.05). MFI 
ratio ± SEM is shown. 
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Figure 4.4 OFA is a superior inducer of CDC than RTX in all cytogenetic sub-groups of CLL 
 
CLL patient cells were treated with 20 μg/ml OFA or RTX and then incubated with 50% NHS and 
the level of CDC cell death measured by flow cytometry (% PI+ cells). The percentage of dead 
cells is expressed relative to untreated control, p values were determined by a paired t-test (*, 
p<0.05, ** p<0.01, *** p<0.001). A. Cytogenetically normal CLL cells (n=11). B. 11q del CLL cells 
(n=6). C. 17p del CLL cells (n=7).D. NOTCH1
MUT
 CLL cells (n=8). Mean cell death ± SEM is 
shown.  
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Figure 4.5 OFA has higher CDC potency in cytogenetically normal and 11q del CLL patients 
 
CLL patient cells (n=32) were treated with 20 μg/ml OFA and then incubated with 50% NHS and 
the level of CDC cell death measured by flow cytometry (% PI+ cells). The percentage of dead 
cells is expressed relative to untreated control. CLL samples are categorised by the type of 
cytogenetic abnormalities they harbour. Mean cell death ± SEM is shown.  
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Figure 4.6 NOTCH1
MUT
 CLL cells display no correlation with CD20 expression levels and 
OFA induced CDC 
 
CD20 expression levels was determined by flow cytometry and MFI ratio was calculated from the 
MFI signal from stained divided by unstained CLL cells and plotted against the CDC percentage 
dead cells observed with 20 μg/ml OFA. Linear regression analysis was applied. A. All CLL cells 
(n=31), r
2
, 0.4506 and p value, <0.0001. B. CDC vs CD20 expression separated by CLL 
cytogenetics. i. Cytogenetically normal CLL cells (n=8), r
2
, 0.6898 and p value, 0.0107. ii. 11q del 
CLL cells (n=7), r
2
, 0.4342 and p value, 0.1075 (not statistically significant). iii. 17p del CLL cells 
(n=7), r
2
, 0.4881 and p value, 0.0808 (not statistically significant). iv. NOTCH1
MUT
 CLL cells (n=7), 
r
2
, 0.09824 and p value, 0.4937 (not statistically significant). 
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Figure 4.7 No correlation was observed with surface expression levels of complement 
inhibitory proteins and OFA induced CDC 
 
Surface expression levels were determined by flow cytometry and MFI ratio was calculated from 
the MFI signal from stained divided by unstained CLL cells and plotted against the CDC 
percentage dead cells observed with 20 μg/ml OFA. Linear regression analysis was applied and no 
statistical significance was observed.  A. CD52 expression vs CDC induction in CLL cells (n=29), 
r
2
, 0.0048 and p value, 0.712. B. CD55 expression vs CDC induction in CLL cells (n=31), r
2
, 0.012 
and p value, 0.558. C. CD59 expression vs CDC induction in CLL cells (n=31), r
2
, 0.0054 and p 
value, 0.705. 
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Figure 4.8 ADCC optimisation in two cell lines 
 
HG3 and Ramos cell line were cultured on plastic for 18 hr. ADCC luciferase reporter bioassay was 
performed with a ratio of effector: target cells of 6:1. A. Luminescence signal. B. Fold of induction 
was calculated by dividing the luminescence signal from MAb treatments by the luminescence 
signal from NDC. Mean ±
 
SD are shown. 
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Figure 4.9 OFA has higher ADCC efficacy in normal CLL cells than RTX 
 
Cytogenetically normal CLL cells (n=5) were cultured on plastic for 18 hr. ADCC luciferase reporter 
bioassay was performed with a ratio of effector: target cells of 6:1. Fold of induction was calculated 
by dividing the luminescence signal from MAb treatments by the luminescence signal from NDC. A. 
RTX treatment. B. OFA treatment. Mean ± SD are shown.
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Figure 4.10 OFA has higher ADCC efficacy in 11q del CLL cells than RTX 
 
11q del CLL cells (n=3) were cultured on plastic for 18 hr. ADCC luciferase reporter bioassay was 
performed with a ratio of effector: target cells of 6:1. Fold of induction was calculated by dividing 
the luminescence signal from MAb treatments by the luminescence signal from NDC. A. RTX 
treatment. B. OFA treatment. Mean ± SD are shown.
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Figure 4.11 CLL cells with 17p del display minimal ADCC induction 
 
17p del CLL cells (n=3) were cultured on plastic for 18 hr. ADCC luciferase reporter bioassay was 
performed with a ratio of effector: target cells of 6:1. Fold of induction was calculated by dividing 
the luminescence signal from MAb treatments by the luminescence signal from NDC. A. RTX 
treatment. B. OFA treatment. Mean ± SD are shown. 
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Figure 4.12 OFA has higher ADCC efficacy in NOTCH1
MUT
 CLL cells than RTX 
 
NOTCH1
MUT
 CLL cells (n=7) were cultured on plastic for 18 hr. ADCC luciferase reporter bioassay 
was performed with a ratio of effector: target cells of 6:1. Fold of induction was calculated by 
dividing the luminescence signal from MAb treatments by the luminescence signal from NDC. A. 
RTX treatment. B. OFA treatment. Mean ± SD are shown. 
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Figure 4.13 OFA is a more potent inducer of ADCC than RTX in CLL cells 
 
CLL cells (n=18) were cultured on plastic for 18 hr. ADCC luciferase reporter bioassay was 
performed with a ratio of effector: target cells of 6:1. Fold of induction was calculated by dividing 
the luminescence signal from MAb treatments by the luminescence signal from NDC. The fold of 
induction at the optimal concentration of RTX (1 µg/ml) and OFA (100 ng/ml) is plotted, p values 
were determined by a paired t-test ( ** p<0.01) A. Cytogenetically normal CLL cells (n=5). B. 11q 
del CLL cells (n=3). C. 17p del CLL cells (n=3). D. NOTCH1
MUT
 CLL cells (n=7). E. All CLL cells 
(n=18). Mean ± SEM are shown. 
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Figure 4.14 17p del patients display lowest levels of ADCC induction 
 
CLL cells were cultured on plastic for 18 hr. ADCC luciferase reporter bioassay was performed with 
a ratio of effector: target cells of 6:1. Fold of induction was calculated by dividing the luminescence 
signal from MAb treatments by the luminescence signal from NDC. The fold of induction at the 
optimal concentration of OFA (100 ng/ml) is plotted for each of the cytogenetic sub-groups, normal 
(n=5), 11q del (n=3), 17p del (n=3), NOTCH1
MUT
 (n=7) CLL cells. Mean ± SEM are shown. 
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Figure 4.15 ADCC induction displays no correlation with CD20 expression levels or CDC 
activation 
 
CLL cells (n=18) were cultured on plastic for 18 hr. ADCC luciferase reporter bioassay was 
performed with a ratio of effector: target cells of 6:1. Fold of induction was calculated by dividing 
the luminescence signal from MAb treatments by the luminescence signal from NDC. The fold of 
induction at the optimal concentration of OFA (100 ng/ml) is plotted. A. CD20 expression levels 
was determined by flow cytometry and MFI ratio was calculated from the MFI signal from stained 
divided by unstained CLL cells and plotted against ADCC fold of induction. B. CLL patient cells 
were treated with 20 μg/ml OFA and then incubated with 50% NHS and the level of CDC cell death 
measured by flow cytometry (% PI+ cells). The percentage of dead cells is expressed relative to 
untreated control and plotted against the ADCC fold of induction. 
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5 Microenvironmental stimulation and anti-CD20 
MAb activity 
5.1 Introduction 
CLL cells are known to migrate between the BM, LN and the peripheral blood. 
Within the BM and LN CLL cells gain pro-survival and pro-proliferative signals. 
CLL cells are also dependent on microenvironmental stimulation in vitro, with 
isolated CLL cells undergoing spontaneous apoptosis unless rescued through co-
culture with stromal-derived cells136. Malignant CLL cells have been shown to 
tailor their microenvironment to aid in their survival and proliferation138. The 
interaction of CLL cells with the other components of this niche, such as stromal 
cells, T cells and soluble factors, can also promote drug resistance140,231. 
Chlorambucil and fludarabine in vitro demonstrate reduced efficacy at inducing 
apoptosis in CLL cells when co-cultured with BM stromal cells141,190. This close 
association of CLL cells with the microenvironment leads to CLL cells interacting 
with other cell types and secreted factors which aid malignant CLL cell survival 
and proliferation. T cells expressing CD154, support the proliferation of CLL cells 
and cytokine IL-4 secretion by T cells promotes the expansion of CLL cell clones 
and aids survival138,139,366. CD40 stimulation in combination with IL-4R signalling 
causes the up-regulation of anti-apoptotic Bcl-2 family proteins, Bcl-XL, Bfl-1, A1 
and MCL-1168. Therefore with the up-regulation of anti-apoptotic proteins it is 
not surprising that drug resistance is observed in vitro141,190. Fludarabine and 
chlorambucil also induce DNA damage to cause CLL cell death246,248. Cytogenetic 
abnormalities 17p and 11q del encompasses genes TP53 and ATM respectively, 
which results in impaired DNA damage response pathway, limiting the efficacy of 
agents that cause DNA damage77,367. This highlights the need for treatments such 
as anti-CD20 MAbs that do not cause cell death through DNA damage and do not 
function principally through the induction of apoptosis. 
LN/BM interactions could therefore greatly impact on the efficacy of MAb 
treatment. CLL cells may differentially regulate the surface expression of CD20 
or complement inhibitory proteins upon cross-talk within the LN or BM. A recent 
publication suggested that long term culture of CLL cells with BM derived 
stromal cells causes both a reduction in CD20 expression and an increase in CD59 
expression, which resulted in a reduced susceptibility to RTX144. Different 
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cytogenetic abnormalities or mutations may also alter the way CLL cells respond 
to their microenvironment232,368. Our lab has previously established that upon 
NTL/CD154+IL-4 stimulation of CLL cells, there is increased activation of the NF-
κB pathway369. Others have identified that NF-κB is able to induce the expression 
of the Notch1 receptor ligand, Jagged1, in B cells, which results in the activation 
of Notch1217,230. BM stromal cells are known to express Notch ligands Jagged 1 
and DLL1, and an up-regulation of Notch is observed in vivo within the LN and in 
vitro with microenvironmental stimulation226-228,232,368. Therefore chronic 
activation of Notch1 within LN/BM microenvironment may be a cause of 
impaired susceptibility of CLL cells to anti-CD20 MAbs in patient lymphoid 
organs.  
To further investigate the action of anti-CD20 MAbs and why they are ineffective 
against NOTCH1MUT CLL cells, analysis of the effect the tissue microenvironment 
has on anti-CD20 MAb activity will be assessed. For microenvironmental 
stimulation we will use three different culture systems; plastic (containing no 
stromal cell support), NTL (stromal cells) and NTL/CD154+IL-4 (NTL stromal cells 
expressing CD154 supplemented with IL-4).   
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5.2 Aim 
The focus was to determine whether the microenvironment played a role in the 
mechanism behind NOTCH1MUT mediated resistance to anti-CD20 MAbs, and what 
effects microenvironmental stimulation has on the efficacy of MAbs against other 
poor cytogenetic CLL groups. To do this CLL cells will be cultured in conditions 
which mimic the circulating compartment (co-culture with NTL), or the tissue 
microenvironment (co-culture with NTL/CD154+IL-4). Following stimulation CLL 
cells will be assessed for: 
 Changes in the surface protein expression levels of CD20, CD52, CD55 and 
CD59 upon co-culture in our different systems; 
o In particular analysis will be conducted to determine whether there 
are any differences between the CLL cytogenetic sub-groups. 
 Differences in the induction of CDC by RTX and OFA when CLL subtypes 
are stimulated on the different co-culture systems; 
 Modulations of CDC induction between the CLL cytogenetic subsets on the 
different co-culture systems. 
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5.3 Results 
5.3.1 Microenvironmental stimulation differentially regulates the 
expression of selected surface markers within CLL 
prognostic subgroups 
Chapter 4 demonstrated that different surface proteins were deregulated in CLL 
cells and for CD20 expression levels this significantly impacted on amount of OFA 
or RTX induced CDC. Using conditions which recapitulates the LN 
microenvironment CLL cells were stimulated to establish the impact upon the 
expression of the surface proteins CD20, CD52, CD55 and CD59. CLL cells were 
either cultured on plastic (no stimulation), or co-cultured on NTL or NTL cells 
expressing CD154 with IL-4 added (NTL/CD154+IL-4) for 24-72 hr. After this time 
CLL cells were removed and the surface expression was analysed. The MFI 
produced from plastic at each time point was subtracted from the MFI ratio 
produced from either NTL or NTL/CD154+IL-4.  
5.3.1.1 CD20 expression  
Cytogenetically normal cells were those with no 17p del, 11q del or NOTCH1MUT 
detected. Analysis of CD20 expression levels showed that for cytogenetically 
normal CLL cells there is little change in CD20 expression levels for all samples 
when cultured on NTL. However two CLL samples displayed an increase in CD20 
expression when co-cultured on NTL/CD154+IL-4 (CLL57 and CLL70). For CLL57 
there is minimal increase in CD20 expression but for CLL70 there is a rapid 
increase in CD20 expression levels with an 8 fold increase in CD20 MFI ratio from 
24 to 72 hr (Figure 5.1A). For 11q del CLL patients there was little change in 
CD20 expression levels on NTL, whereas on NTL/CD154+IL-4 for one CLL patient, 
CLL86, CD20 expression levels decreased in comparison to plastic. For two of the 
11q del CLL samples expression levels of CD20 increased (Figure 5.1B). For 17p 
del CLL patients CD20 expression levels did not change on either of the two co-
culture systems (Figure 5.1C). Interestingly in NOTCH1MUT CLL cells, there was an 
increase in CD20 expression at 24 hr on NTL for CLL101 and 50% of the 
NOTCH1MUT CLL samples analysed displayed reduced CD20 surface expression 
when co-cultured on NTL/CD154+IL-4.  
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5.3.1.2 CD52 expression  
Following 24, 48, and 72 hr culture on plastic and co-culture on NTL or 
NTL/CD154+IL-4 CD52 expression levels were measured. There was a small 
increase in expression of CD52 for cytogenetically normal CLL samples following 
NTL stimulation. However upon NTL/CD154+IL-4 stimulation there was a slight 
down-regulation of CD52 in 75% of the normal CLL cells, from 24 to 72 hr the 
mean fold reduction in CD52 expression was 0.8 (Figure 5.2A). 11q del CLL cells 
displayed differential regulation on NTL and similar to normal CLL cells 75% of 
the CLL samples displayed down-regulation of CD52 when co-cultured on 
NTL/CD154+IL-4, although the down-regulation in 11q del CLL cells was more 
prominent (Figure 5.2B). 17p del CLL samples all display down-regulation on 
NTL/CD154+IL-4, contrasting the up-regulation they display on NTL stromal cells 
(Figure 5.2C). NOTCH1MUT CLL cells displayed a similar pattern to 17p del 
patients with a prominent down-regulation of CD52 on NTL/CD154+IL-4, and up-
regulation on NTL (Figure 5.2D). Intriguingly the down-regulation of CD52 was 
more notable and consistent in the poorer prognostic subgroups especially in 17p 
del and NOTCH1MUT CLL cells. 
5.3.1.3 CD55 and CD59 expression  
CD55 and CD59 are known to confer resistance to complement fixation and CDC 
induction, therefore it was important to establish how LN microenvironmental 
stimulation altered the expression patterns of CD55 and CD59. For 
cytogenetically normal CLL cells CD55 displayed little change in expression levels 
on either NTL or NTL/CD154+IL-4 (Figure 5.3A). For 11q del CLL patients there 
was little difference in CD55 expression when cells are cultured on NTL or 
NTL/CD154+IL-4, with 75% of the samples showing an up-regulation of CD55 
when we mimic the tissue microenvironment (Figure 5.3B). 17p del CLL samples 
displayed the highest up-regulation of the complement inhibitory protein CD55 
on NTL, and 40% of the samples examined displayed a down-regulation of CD55 
upon stimulation with NTL/CD154+IL-4 (Figure 5.3C). All of the NOTCH1MUT CLL 
samples displayed an up-regulation of CD55 on both NTL and NTL/CD154+IL-4 
and for CLL101 there was a large increase in CD55 expression level (Figure 5.3D). 
These results indicate that up-regulation of CD55 following LN 
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microenvironmental stimulation may play a key role in conferring resistance and 
warrants further investigation.  
CD59 expression levels appear to differentially regulate between CLL samples 
from all the cytogenetic subsets. In comparison to CD59, CD55 expression is 
more readily up-regulated with an MFI ratio approximately 100 fold or above, 
whereas CD59 MFI ratio displayed approximately 20-30 fold up-regulation. For 
cytogenetically normal CLL samples following co-culture with NTL there 
appeared to be a gradual increase in expression of CD59 over time, and on 
NTL/CD154+IL-4 50% of the CLL samples displayed a rapid increase in CD59 
expression whilst the other 50% of samples remained the same (Figure 5.4A). 11q 
del CLL cells displayed no specific pattern for CD59 regulation on NTL whilst on 
NTL/CD154+IL-4 there was a trend for a small peak in CD59 expression at 48 hr 
(Figure 5.4B). There was little change in expression on NTL in 17p del CLL 
samples and on NTL/CD154+IL-4 40% of the CLL samples displayed increased 
expression of CD59. In one patient sample, CLL109, there was a substantial 
increase in CD59 expression (Figure 5.4C). For NOTCH1MUT CLL cells when co-
cultured on NTL/CD154+IL-4 only one CLL patient displayed an increase in CD59 
expression over time (Figure 5.4D).  
5.3.1.4 Simulating the tissue microenvironment impacts the surface 
expression of different markers depending on the CLL cytogenetics 
To evaluate the observed changes in MFI ratios for CD20, CD52, CD55 and CD59 
in more detail the mean values ± SEM were compared for all cytogenetic subsets 
following NTL/CD154+IL-4 stimulation. CD20 expression levels gradually 
increased over time for 11q del CLL cells following NTL/CD154+IL-4 co-culture. 
Cytogenetically normal CLL cells displayed a similar trend however the mean is 
skewed by the high up-regulation of CD20 in sample CLL70. In 17p del patients 
CD20 expression remained the same and for NOTCH1MUT CLL cells expression was 
reduced. Previous results from Chapter 4 demonstrated that 17p del had the 
lowest expression levels of CD20 shortly followed by NOTCH1MUT CLL cells (Figure 
4.3). In combination with this data it would appear that in both these two poor 
prognostic subsets there is de-regulation of CD20 expression so that lower 
expression is exhibited (Figure 5.5A). Interestingly for all the CLL cytogenetic 
subsets there was a down-regulation of CD52 when co-cultured with 
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NTL/CD154+IL-4, although this was only marginal with cytogenetically normal 
CLL samples. At 48 and 72 hr NOTCH1MUT displayed significantly lower CD52 
expression, approximately 40 fold and 5 fold less expression respectively, than 
cytogenetically normal CLL cells. Anti-CD52 MAb alemtuzumab is known to be 
less effective at targeting CLL cells that have migrated to the LN260,370, our data 
would suggest that this is due to rapid down-regulation of CD52 within the LN, 
which is more prominent in CLL cells with poor prognostic cytogenetics (Figure 
5.5B). Chapter 4 results demonstrated that within primary CLL samples 
NOTCH1MUT CLL cells displayed the highest levels of CD55 expression (Figure 4.3) 
and with NTL/CD154+IL-4 co-culture NOTCH1MUT CLL displayed the largest up-
regulation of CD55. This indicates that NOTCH1MUT CLL cells favour an up-
regulation of CD55 compared to other CLL cytogenetic subsets and may explain 
some of the reduced activity against anti-CD20 MAbs (Figure 5.5C). CD59 
expression did not display as large a range in MFI ratio in comparison to CD55, 
cytogenetically normal CLL cells and 17p del CLL cells displayed a similar gradual 
increase in CD59 expression whereas 11q del and NOTCH1MUT CLL cells increased 
CD59 expression which peaked at 48 hr (Figure 5.5D). The ability to down-
regulate CD20 and CD52 whilst up-regulating CD55 and CD59 following 
microenvironmental stimulation may play a key role in resistance to 
immunotherapy in CLL. 
5.3.2 Anti-CD20 MAb CDC activity is enhanced with 
microenvironmental stimulation in CLL cells 
The differential regulation of surface markers on CLL cells following LN 
microenvironment simulation was assessed for the impact upon the ability of 
RTX and OFA to induce a CDC response on CLL cells. CLL cells were cultured with 
or without MAb on plastic, NTL or NTL/CD154+IL-4 for 24 to 72 hr. CLL cells 
cultured without MAb were removed from culture and treated with MAb prior to 
carrying out CDC analysis, as previously described in section 2.4.1. In chapter 3 
data from one CLL patient (CLL127) indicate the high dose at which OFA is 
administered during immunotherapy results in OFA remaining within the 
circulating peripheral blood for up to 7 days after infusion and that it is stable 
enough to result in high levels of CDC on untreated HG3 cells (Figure 3.19). For 
this reason CLL cells were also co-cultured with MAbs to determine what effect 
leaving anti-CD20 MAbs in culture had on CDC activation. 
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5.3.2.1 Microenvironmental CDC activity of RTX 
Cytogenetically normal CLL cells displayed a slight increase in RTX CDC activity 
when co-cultured on NTL/CD154+IL-4. As previously shown little CDC activity 
was observed on plastic and similar results were obtained with NTL co-culture. 
As predicted from CD20 expression data there was an increase in CDC activity 
when CLL cells were cultured with NTL/CD154+IL-4, this was also observed when 
RTX was incubated with CLL cells over 72 hr (Figure 5.6).  
11q del CLL cells displayed a small percentage of cell death following RTX 
induced CDC activity on plastic and NTL over the 72 hr time period, however 
following co-cultured with NTL/CD154+IL-4 there was a notable increase in CDC 
at 24 hr, and by 48 hr CDC activity improved by 30.17% for cells cultured in the 
absence of RTX and 42.5% for CLL cells cultured in the presence of RTX (p value; 
0.0747 and 0.0992 respectively). This increase in CDC activity was maintained at 
the 72 hr time point although there was a slight drop in CDC activity, 8.25% less 
dead cells, for cells cultured with RTX (Figure 5.7). 
17p del CLL cells only displayed a small amount of cell death following CDC 
activity with RTX when co-cultured on NTL/CD154+IL-4 (Figure 5.8). These 
results in conjunction with those from Chapter 4 which indicated that 17p del 
patients displayed the lowest levels of CD20, and the second lowest levels of 
CDC with OFA (Figure 4.3 and 4.5), suggest 17p del patients like NOTCH1MUT CLL 
cells have reduced susceptibility to anti-CD20 MAbs . Unlike cytogenetically 
normal and 11q del CLL cells the 17p del CLL cells showed no increase in CD20 
over the 72 hr time period, and both complement inhibitory proteins CD55 and 
CD59 were up-regulated, which may explain why CDC activity was limited. 
NOTCH1MUT CLL cells display no clinical efficacy to RTX treatment108, we and 
others have demonstrated that NOTCH1MUT CLL cells have low CD20 expression 
levels233 (Figure 4.3) and demonstrate the lowest levels of CDC induction with 
OFA (Figure 4.5). NOTCH1MUT CLL samples displayed a reduction in CD20 
expression over time when co-cultured on NTL/CD154+IL-4, and a large up-
regulation of CD55. Despite this by 72 hr there was an increase in CDC by 18.67% 
cell death when co-cultured with RTX on NTL/CD154+IL-4 (p value 0.0621) 
(Figure 5.9). 
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Combining these data, the mean RTX induced CDC when co-cultured with 
NTL/CD154+IL-4 over the 72 hr time period was compared between the different 
cytogenetic groups. 11q del CLL patients had significantly higher RTX induced 
CDC, for CLL cells cultured without RTX, than other poor prognostic CLL cells 
from 48 hr of co-culture onwards (Figure 5.10A). Despite the increase in CDC in 
cytogenetically normal CLL cells by 72 hr the effect was lost, even though CD20 
expression levels continuing to increase over the 72 hr time period. This drop in 
CDC activity could be explained by the increase in CD59 expression in 
cytogenetically normal CLL cells. RTX CDC activity was also compared between 
CLL cells cultured in the presence of RTX on NTL/CD154+IL-4. Initially 
significantly lower levels of CDC was observed when comparing NOTCH1MUT CLL 
cells with cytogenetically normal CLL cells, but then gradually an increase in 
RTX activity occurred, despite a reduction in CD20 expression levels and high 
CD55 expression. Cytogenetically normal, 11q del and 17p del all displayed a 
CDC peak at 48 hr (Figure 5.10B). Again 11q del CLL patients displayed the 
highest levels of CDC and had significantly higher levels than 17p del patients at 
48 to 72 hr. As previously stated 11q del CLL patients have been clinically shown 
to respond well to RTX treatment346, and our research supports these findings.  
5.3.2.2 Microenvironmental CDC activity of OFA 
Cytogenetically normal CLL cells display enhanced CDC activity with OFA in all 
the co-culture systems, compared to RTX. Although one CLL patient CLL81 
displayed no enhancement in CDC activity, which corresponded to low CD20 
expression levels with an MFI ratio of 1.6 on plastic culture. The enhanced CDC 
induction with OFA makes the drop in CDC activity when OFA is present in 
culture with CLL cells more prominent, this was observed even at 24 hr on 
plastic where there was 15.34% less cell death (p=0.0272) when OFA was left in 
culture. This suggests that OFA bound to CD20 is being removed over time in 
culture, either through internalisation or loss from the surface of the CLL cell. 
Once again the enhanced CDC effect on NTL/CD154+IL-4 peaked at 48 hr and 
then diminished (Figure 5.11). 
As observed with RTX cultures, 11q del CLL cells displayed high susceptibility to 
OFA induced CDC, which was observed in all three of the CLL samples (Figure 
5.12). Interestingly for 11q del CLL samples there was a more pronounced drop 
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in CDC activity when OFA was present in co-culture on plastic and NTL, the 
percentage of dead cells did not rise above 9%, whereas there was no drop in 
CDC when OFA was present in co-cultured with NTL/CD154+IL-4. This suggests 
that for 11q del CLL cells there are protective interactions with NTL/CD154+IL-4 
stimulation that stop OFA bound to CD20 from being removed or internalised by 
the CLL cell. 
CLL cells with 17p del, as with the other cytogenetic sub-sets analysed, 
displayed either internalisation or loss of OFA-CD20 complex in culture. For 17p 
del CLL cells there was significant benefit to OFA induced CDC at 24 hr on 
NTL/CD154+IL-4 when OFA was not present in culture. There does not seem to 
be a dramatic peak in CDC activity at 48 hr as seen with cytogenetically normal 
and 11q del CLL cells. There was a gradual increase in CDC observed when OFA 
was co-cultured with NTL/CD154+IL-4 which continued to rise at each time point 
(Figure 5.13). 
Finally, NOTCH1MUT CLL cells displayed significantly more CDC on co-culture with 
NTL/CD154+IL-4 when OFA was not present in the culture at 24 hr only, over 
time as with 17p del CLL cells there was a gradual increase in CDC when OFA 
was present in culture. NOTCH1MUT CLL cells displayed significantly more OFA 
induced CDC when co-cultured on NTL/CD154+IL-4 than when cultured on plastic 
for 24 hr only. The benefits received from the co-culture started to be lost with 
longer culture (48 and 72 hr), which could be due to the reduced levels of CD20 
that occurred in NOTCH1MUT CLL cells following co-culture. 
Combining these data, the mean OFA induced CDC when co-cultured with 
NTL/CD154+IL-4 over the 72 hr time period was compared between the different 
cytogenetic groups (Figure 5.15A). For CLL cells not cultured with OFA, 11q del 
CLL cells were the most susceptible to anti-CD20 MAb CDC as they displayed the 
highest levels of OFA CDC, with NOTCH1MUT CLL cells demonstrating significantly 
lower levels of CDC when compared to 11q CLL cells. 11q and cytogenetically 
normal CLL cells displayed the same CDC peak at 48 hr before losing the benefit 
of the co-culture at later time points. Interestingly 17p del CLL cells displayed 
no peak in OFA CDC activity, with activity remaining constant. Whereas 
NOTCH1MUT CLL cells displayed a gradual loss in CDC activity following 24 hr, 
which may reflect the reduction in CD20 expression levels observed following 
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NTL/CD154+IL-4 co-culture. When OFA was present in co-culture cytogenetic 
subgroups other than 11q del displayed at least a 20% drop in CDC activity at 24 
hr (Figure 5.15B). Normal and 11q del CLL cells again displayed the same 48 hr 
peak trend, but interestingly both 17p del and NOTCH1MUT CLL cells 
demonstrated an increase in CDC over the 72 hr time period. This suggests that 
there may be a common phenotype between these two distinct subgroups that 
results in this gradual increase in CDC when OFA is present in the co-culture 
only. 
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5.4 Discussion 
CLL currently remains an incurable disease and one likely cause for this is the 
cross-talk between accessory stromal cells and T cells that interact with the 
malignant B cells and help promote tumour growth, survival and drug resistance. 
Chemoterapeutic agents such as fludarabine and chlormabucil function by 
causing DNA damage which should result in apoptosis to destroy the CLL 
cell246,248. However signals generated from the microenvironement result in up-
regulation of the Bcl-2 family of anti-apoptotic within CLL cells, rendering these 
drugs less effective in vitro141,190. However type I anti-CD20 MAbs cause CLL cell 
death through CDC and ADCC primarily, therefore they may be beneficial for 
targeting CLL cells within the LN/BM. Proliferation centres within the LN and BM 
provide nurturing pro-survival and pro-proliferative signals, enabling new cells to 
enter into the circulating, accumulating compartment. The cytoprotective 
signals generated in the proliferation centres must be overcome in order to 
provide a promising therapy for CLL366. The interaction of CLL cells with other 
cells within proliferation centres is likely to cause either an up or down-
regulation of different surface markers. Interestingly for all the CLL cells 
analysed there was a prominent loss of CDC activity for both RTX and OFA when 
these MAbs were present in culture on plastic and importantly in co-culture with 
NTL cells. NTL cells mimic the interactions observed for the circulating 
compartment of CLL cells, suggesting there would be internalisation of the 
MAb/CD20 complex or loss from the surface of the CLL cell in vivo. When CLL 
cells were being stimulated with NTL/CD154+IL-4 there was still a reduction in 
CDC if OFA or RTX was present in the co-culture but the reduction was far less 
prominent. This indicates that NTL/CD154+IL-4 stabilises the MAb/CD20 
complex, allowing the MAb to remain active overtime. This supports the use of 
OFA as a first line therapy for all CLL patients due to OFA being a potent inducer 
of CDC and displaying enhanced efficacy against CLL cells stimulated with 
NTL/CD154+IL-4. Improved efficacy of chemotherapeutic agents when CLL cells 
are stimulated with LN microenvironmental signals is not observed with first line 
therapies such as fludarabine and chlorambucil140,141,176,190,333,369. For all the CLL 
cell cytogenetic subsets analysed there was an increase in OFA induced CDC on 
NTL/CD154+IL-4, despite the differences in expression of the different surface 
markers. Others have also shown that CLL cells stimulated with CD40 are 
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sensitised to RTX and OFA-induced cell death, which occurred independently of 
any rise in CD20 expression176. However programmed cell death only took place 
when these MAbs were in the presence of a cross-linking antibody176,333. Type 1 
MAbs such as OFA and RTX are not known potent inducers of apoptosis, and 
therefore require a cross-linking antibody for this to occur254,255. Therefore not 
only is there an increase in the activity of these MAbs to induce CDC but there is 
also an increase in apoptosis. This suggest that there is activation of one or 
several molecular pathways when CLL cells are co-cultured with NTL/CD154+IL-4 
that results in greater susceptibility to the activity of OFA or RTX independently 
of CD20 expression levels.  
These results in conjunction with our previous data has implications for OFA 
immunotherapy, which after the first initial low dose is administered at high 
doses of 2000 mg. Data from CLL127 (Figure 3.21) has shown that OFA is still 
stable within the peripheral blood 7 days after infusion with serum resulting in 
high levels of CDC on untreated HG3 cells. Chapter 3 demonstrated that 
complement levels are rapidly exhausted in vivo following anti-CD20 MAb 
infusion, this may therefore potentially lead to OFA remaining in circulation. Our 
results show that when OFA was present within co-culture with CLL and NTL 
cells, there was a dramatic loss in CDC induction possibly through loss of OFA 
bound to CD20 or internalisation. NTL stimulation of CLL cells mimics the 
circulating compartment; therefore it is possible that in vivo after OFA infusion 
there is complement depletion resulting in incomplete clearance of CLL cells. 
Circulating CLL cells then lose OFA bound to CD20 through shaving, 
internalisation and trogocytosis. Trogocytosis occurs when effector cells such as 
phagocytic cells remove OFA bound to CD20 from the surface of the CLL 
cell317,371. When complement levels within the peripheral blood have restored 
CDC induction will be impaired due to loss of OFA bound to CD20 on the 
remaining circulating CLL cells. Therefore despite the more efficient clearance 
of CLL cells co-cultured with NTL/CD154+IL-4 by OFA, once these cells have 
been removed the CLL cells in circulation that have escaped OFA CDC will be 
able to take their place, possibly leading to clonal evolution of CLL cells more 
resistant to OFA treatment. This suggests that lower doses of OFA may be more 
beneficial to CLL patients undergoing immunotherapy.  
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5.4.1 CD52 expression levels on NTL/CD154+IL-4 indicate why 
alemtuzumab is not effective against CLL cells within the LN 
Interestingly when CLL cells are co-cultured with NTL/CD154+IL-4 a down-
regulation of CD52 was observed, which was most prominent in our CLL cells 
with poor prognostic genetics. Alemtuzumab is known to be less clinically active 
against CLL cells that are located within the LN as opposed to the peripheral 
blood or BM, and our results indicate that this is at least in part due to the 
down-regulation of CD52260,370. Research by Jak M. et al., also analysed the 
ability of CD52 to cause apoptosis on CLL cells stimulated with CD40. RTX 
displayed enhanced programmed cell death induction with CD40 stimulation, 
whereas there was no significant induction in programmed cell death with 
alemtuzumab and CD40 stimulation176. Therefore it would be interesting to also 
analyse whether there was a drop in the CDC activity of anti-CD52 MAbs on these 
CLL cells. Cytogenetically normal CLL cells did not display a prominent down-
regulation of CD52 expression, suggesting that these cells would still be 
susceptible to alemtuzumab. This highlights that different pathways are de-
regulated within CLL cells and this corresponds to the cytogenetic abnormality, 
which also affects the response of CLL cells to the microenvironment and their 
susceptibility to different treatments.  
5.4.2 Anti-CD20 MAbs are an effective treatment for 11q del CLL 
patients 
Chapters 3 and 4 have shown that 11q del CLL patients have reduced 
complement exhaustion, high CD20 expression and good CDC induction with OFA. 
This suggests that despite 11q del being a more aggressive form of CLL, they are 
still susceptible to anti-CD20 MAbs, which is also observed clinically346. Further 
to this, 11q del CLL cells also demonstrate susceptibility to anti-CD20 MAbs even 
when they undergo tissue microenvironment stimulation. In addition 11q del CLL 
cells displayed an up-regulation of CD20 upon co-culture with NTL/CD154+IL-4 
and a down-regulation of the complement inhibitory protein CD55, which may 
explain why 11q del cells displayed superior CDC with both RTX and more 
prominently with OFA than even cytogenetically normal CLL cells. As expected 
from our previous CDC data, OFA is more potent at inducing CDC than RTX in 
cells co-cultured with NTL/CD154+IL-4. Our data supports OFA as an effective 
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treatment regime for 11q del CLL patients, resulting in effective clearance of 
CLL cells that are both in circulating and tissue compartments. 
5.4.3 NOTCH1MUT CLL cells 
Chapter 4 identified that NOTCH1MUT CLL cells displayed low levels of CDC and 
ADCC with OFA and RTX compared to cytogenetically normal CLL cells, and they 
also had low CD20 expression levels and high expression of CD55 (Figure 4.3 & 
4.5). Our complement analysis did not reveal any deficiencies to explain this 
resistance against anti-CD20 MAbs. Here we demonstrate that when NOTCH1MUT 
CLL cells were stimulated with NTL/CD154+IL-4, the mean CD20 expression falls 
which, in conjunction with the already low CD20 expression levels help build 
resistance to anti-CD20 MAbs. It is also important to establish at the molecular 
level whether ICN expression is up-regulated within CLL cells upon 
NTL/CD154+IL-4 stimulation. Research by Pozza et.al., suggests that chronic 
activation of ICN within NOTCH1MUT CLL cells causes competition between ICN 
and the epigenetic gene silencer HDAC for binding to the CSL transcriptional 
complex233. ICN preferentially binds to the CSL complex, unbound HDAC is then 
free to bind to the promoter of CD20 causing epigenetic silencing of the gene 
resulting in the down-regulation of CD20 surface expression on NOTCH1MUT CLL 
cells233. If ICN is over expressed with NTL/CD154+IL-4 stimulation then there 
would be an expected down-regulation of CD20 within the NOTCH1MUT CLL cells, 
which was observed within 50% of our NOTCH1MUT CLL cohort. Recent research 
into CLL co-culture with BM derived stromal cells demonstrated that a significant 
down-regulation of CD20 was observed within CLL cells only after a 2 week time 
period144. Therefore future experiments with NOTCH1MUT CLL cell co-culture with 
NTL/CD154+IL-4 might demonstrate more pronounced results with longer co-
culture times. Interestingly results from the CLL co-culture study also showed 
that after 2 weeks of co-culture with BM derived stromal cells there was also an 
increase in CD59 expression on CLL cells, however they did not assess CD55 
expression144. Our results suggest that CD55 is more prominently up-regulated 
with NTL/CD154+IL-4 stimulation which is most notable within NOTCH1MUT CLL 
cells. NOTCH1MUT CLL cells in co-culture with NTL/CD154+IL-4 stimulation 
displayed approximately 65% higher expression of CD55. Previous results 
demonstrate that there is no statistical correlation between CD55 and CD59 
expression and CDC induced cell death (Figure 4.7). Therefore any changes of 
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CD55 and CD59 expression with NTL/CD154+IL-4 co-culture may cause no 
changes to anti-CD20 MAb induced CDC for CLL cells. Performing CD55 and CD59 
inhibition assays in combination with OFA induced CDC on CLL cells co-cultured 
with NT/CD154+IL-4 stimulation may provide more insight into the effect the 
expression levels of these two complement inhibitory proteins have upon OFA 
induced CDC induction.  
Experiments with NOTCH1MUT CLL cells demonstrated that at 24 hr there was a 
rise in OFA CDC activity, indicating there is an interaction between CLL cells and 
NTL/CD154+IL-4 that results in an increase in CDC induction independently of 
changes in CD20, CD55 and CD59 expression. Therefore it would be of interest to 
analyse the CLL cells at the molecular level to establish if there is an activation 
of the NOTCH1 pathway on NTL/CD154+IL-4 that could result in the resistance of 
NOTCH1MUT CLL cells after 48 hr. Interestingly when OFA and RTX were co-
cultured with NOTCH1MUT CLL cells and NTL/CD154+IL-4 there was a steady 
increase in CDC overtime, therefore it appears that OFA bound to CD20, 
interacts or activates one or several molecular pathways that then alters the 
way in which these cells respond. The same response was not observed on NTL 
cells; therefore it seems unlikely that NTL cells express a ligand for the Notch1 
receptor. Our lab has previously demonstrated an up-regulation of the NF-κB 
pathway in CLL cells when stimulated with NTL/CD154+IL-4, and others have 
identified that NF-κB can induce the expression of the Notch1 receptor ligand, 
Jagged1, in B-cells217,230,369. This suggests that NOTCH1MUT CLL cells upon 
stimulation with NTL/CD154+IL-4 are undergoing autocrine activation of the 
Notch1 pathway, de-regulating the response to anti-CD20 MAbs. Jak M. et al. 
identified that the increase in RTX induced apoptosis when CLL cells were 
stimulated with CD40 was possibly due to the role of CD20 as a store-operated 
Ca2+ channel. They found that CD40 stimulation caused CLL cells to be sensitised 
to RTX-induced cell death through a rise in cytoplasmic Ca2+ levels, it would be 
interesting to establish if this was through CD20 alone or if CD20 couples with 
another Ca2+ channel when bound with RTX176. Increased cytoplasmic Ca2+ levels 
caused a Ca2+- dependent increase in ROS production leading to programmed cell 
death176. This further highlights the need to analyse NOTCH1MUT CLL cells 
response to NTL/CD154+IL-4 stimulation at a molecular level, which could hold 
the key to understanding their resistance to RTX and OFA.  
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NOTCH1MUT CLL cells also displayed an increase in RTX mediated CDC when RTX 
was present in co-culture with NTL/CD154+IL-4, yet there is no clinical benefit 
observed for RTX when added to FC108,372. This suggests that the brief clinical 
efficacy observed with OFA is not due to OFA being bound to CLL cells within the 
LN for long periods of time before undergoing CDC109. 
It would appear that the reduced activity of anti-CD20 MAbs against NOTCH1MUT 
CLL cells is due to a combination of several different factors, and not just one 
clear difference between these CLL cells and others. A trial investigating the 
effect of chlorambucil with or without OFA, observed an improvement in PFS 
with chlorambucil plus OFA in NOTCH1MUTCLL patients109. However this response 
only occurred during the first 18 months, after which the affect was lost and PFS 
mirrored patients treated with chlorambucil alone in the NOTCH1MUT cohort109. 
NOTCH1MUT CLL cells returning into circulation after receiving Notch1 activating 
signals within the LNs, may have conferred resistance to anti-CD20 MAbs due to 
low CD20 expression. A potential explanation for the short period of 
effectiveness of OFA in combination with chlorambucil may be due to its high 
efficacy at inducing CDC on the circulating CLL cells, which will likely be a 
combination of CLL cells with and without NOTCH1MUT. But after the clearance of 
these cells there is no longer effective killing of the CLL cells leaving the LNs 
allowing the malignant NOTCH1MUT clone to emerge. Others have also reported 
that CLL cells with the highest expression levels of Notch1 are those located 
within the LNs101.  
In conclusion we have further characterised how the different CLL cytogenetic 
subsets affect the efficacy of anti-CD20 MAbs. For the majority of poor prognosis 
CLL cells, except those with NOTCH1MUT, stimulation via the tissue 
microenvironment proves beneficial to anti-CD20 MAb activity, making OFA and 
RTX better immunotherapy options for targeting CLL cells within the LN than 
alemtuzumab. 
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Figure 5.1 CD20 expression levels change differentially depending on the cytogenetic sub-
set and microenvironmental stimulation 
 
CLL cells were cultured in the three different culture systems for 24 to 72 hr. Changes in 
expression of CD20 was determined by flow cytometry and MFI ratio was calculated from the MFI 
signal from stained divided by unstained CLL cells. The MFI ratio produced on plastic was 
subtracted from the MFI ratios produced on NTL and NTL/CD154+IL-4. A. Cytogenetically normal 
(n=4). B. 11q del (n=4). C. 17p del (n=5). D. NOTCH1
MUT
 (n=4).  
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Figure 5.2 CD52 expression is down-regulated on CLL cells when cultured with 
NLT/CD154+IL-4 
 
CLL cells were cultured in the three different culture systems for 24 to 72 hr. Changes in 
expression of CD52 was determined by flow cytometry and MFI ratio was calculated from the MFI 
signal from stained divided by unstained CLL cells. The MFI ratio produced on plastic was 
subtracted from the MFI ratios produced on NTL and CD154/IL-4. A. Cytogenetically normal (n=4). 
B. 11q del (n=4). C. 17p del (n=5). D. NOTCH1
MUT
 (n=4). 
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Figure 5.3 CD55 expression levels are de-regulated in poor prognostic CLL cells with 
microenvironmental stimulation 
 
CLL cells were cultured in the three different culture systems for 24 to 72 hr. Changes in 
expression of CD55 was determined by flow cytometry and MFI ratio was calculated from the MFI 
signal from stained divided by unstained CLL cells. The MFI ratio produced on plastic was 
subtracted from the MFI ratios produced on NTL and CD154/IL-4. A. Cytogenetically normal (n=4). 
B. 11q del (n=4). C. 17p del (n=5). D. NOTCH1
MUT
 (n=4).  
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Figure 5.4 CD59 expression levels are de-regulated in CLL cells upon microenvironmental 
stimulation 
 
CLL cells were cultured in the three different culture systems for 24 to 72 hr. Changes in 
expression of CD59 was determined by flow cytometry and MFI ratio was calculated from the MFI 
signal from stained divided by unstained CLL cells. The MFI ratio produced on plastic was 
subtracted from the MFI ratios produced on NTL and CD154/IL-4. A. Cytogenetically normal (n=4). 
B. 11q del (n=4). C. 17p del (n=5). D. NOTCH1
MUT
 (n=4).   
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Figure 5.5 NTL/CD154+IL-4 microenvironmental stimulation alters the expression of surface 
markers  
 
CLL cells were cultured on NTL/CD154+IL-4 for between 24 to 72 hr. Changes in expression of 
CD20, CD52, CD55 and CD59 were determined by flow cytometry and MFI ratio was calculated 
from the MFI signal from stained divided by unstained CLL cells. The MFI ratio produced on plastic 
was subtracted from the MFI ratios produced on NTL/CD154+IL-4. The mean + SEM MFI ratio are 
shown from cytogenetically normal CLL samples (n=4), 11q del (n=4), 17p del (n=5) and 
NOTCH1
MUT
 (n=4). A. CD20 expression levels. B. CD52 expression levels. C. CD55 expression 
levels. D. CD59 expression levels. p values were determined by an un-paired t-test (*, p<0.05).  
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Figure 5.6 RTX CDC activity is marginally improved in cytogenetically normal CLL samples 
upon microenvironmental stimulation 
 
Cytogenetically normal CLL cells were cultured on the three different culture systems; plastic , NTL 
or CD154 (NTL/CD154+IL-4) and were either incubated with or without RTX for between 24-72 hr. 
At each 24 hr interval CLL cells were removed and cells not cultured with MAb were either left 
without MAb or incubated for 30 min with 20 μg/ml of RTX (control + RTX), all cells then underwent 
CDC. The percentage of dead cells is relative to untreated control.  A. CLL42. B. CLL57. C. CLL70. 
D. Cytogenetically normal CLL cells, mean + SEM (n=3).  
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Figure 5.7 RTX CDC activity is significantly improved in 11q del CLL samples upon 
microenvironmental stimulation 
 
11q del CLL cells were cultured on the three different culture systems; plastic , NTL or CD154 
(NTL/CD154+IL-4) and were either incubated with or without RTX for between 24-72 hr. At each 24 
hr interval CLL cells were removed and cells not cultured with MAb were either left without MAb or 
incubated for 30 min with 20 μg/ml of RTX (control + RTX), all cells then underwent CDC. The 
percentage of dead cells is relative to untreated control.  A. CLL91. B. CLL92. C. CLL94. D. 11q del 
CLL cells, mean + SEM (n=3). p value was determined by a paired t-test (*, p<0.05). 
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Figure 5.8 RTX CDC activity is minimal in 17p del CLL samples upon microenvironmental 
stimulation 
 
17p del CLL cells were cultured on the three different culture systems; plastic , NTL or CD154 
(NTL/CD154+IL-4) and were either incubated with or without RTX for between 24-72 hr. At each 24 
hr interval CLL cells were removed and cells not cultured with MAb were either left without MAb or 
incubated for 30 min with 20 μg/ml of RTX (control + RTX), all cells then underwent CDC. The 
percentage of dead cells is relative to untreated control.  A. CLL28. B. CLL80. C. CLL109. D. 
CLL119. E. 17p del CLL cells, mean + SEM (n=4).  
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Figure 5.9 RTX CDC activity is minimal in NOTCH1
MUT
 CLL samples upon 
microenvironmental stimulation 
 
NOTCH1
MUT
 CLL cells were cultured on the three different culture systems; plastic , NTL or CD154 
(NTL/CD154+IL-4) and were either incubated with or without RTX for between 24-72 hr. At each 24 
hr interval CLL cells were removed and cells not cultured with MAb were either left without MAb or 
incubated for 30 min with 20 μg/ml of RTX (control + RTX), all cells then underwent CDC. The 
percentage of dead cells is relative to untreated control.  A. CLL67. B. CLL101. C. CLL108. D. 
CLL133. E. NOTCH1
MUT
 CLL cells, mean + SEM (n=4).   
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Figure 5.10 11q del CLL cells display the highest level of RTX induced CDC upon 
microenvironmental stimulation, and co-culture with RTX produces the highest efficacy for 
most CLL samples 
 
Primary CLL cells were cultured on CD154 (NTL/CD154+IL-4) and were either incubated with or 
without RTX for between 24-72 hr. At each 24 hr interval CLL cells were removed and cells not 
cultured with MAb were either left without MAb or incubated for 30 min with 20 μg/ml of RTX 
(control + RTX), all cells then underwent CDC. The mean + SEM percentage of dead cells are 
shown from cytogenetically normal CLL samples (n=3), 11q del (n=3), 17p del (n=4). D. 
NOTCH1
MUT
 (n=4). The percentage of dead cells is relative to untreated control.  A. CLL cells 
cultured on CD154 without MAb (control + RTX). B. CLL cells cultured with MAb. p values between 
different cytogenetic subsets were determined by an un-paired t-test, and p values within a 
cytogenetic subset were determined by a paired t test (*, p<0.05; **, P<0.01).  
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Figure 5.11 OFA CDC efficacy is significantly improved in cytogenetically normal CLL 
samples upon microenvironmental stimulation 
 
Cytogenetically normal CLL cells were cultured on the three different culture systems; plastic , NTL 
or CD154 (NTL/CD154+IL-4) and were either incubated with or without OFA for between 24-72 hr. 
At each 24 hr interval CLL cells were removed and cells not cultured with MAb were either left 
without MAb or incubated for 30 min with 20 μg/ml of OFA (control + OFA), all cells then underwent 
CDC. The percentage of dead cells is relative to untreated control.  A. CLL42. B. CLL57. C. CLL70. 
D.CLL81. E. Cytogenetically Normal CLL cells, mean + SEM (n=4). p values were determined by a 
paired t-test (*, p<0.05). 
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Figure 5.12 OFA CDC activity is significantly improved in 11q del CLL samples upon 
microenvironmental stimulation 
 
11q del CLL cells were cultured on the three different culture systems; plastic , NTL or CD154 
(NTL/CD154+IL-4) and were either incubated with or without OFA for between 24-72 hr. At each 24 
hr interval CLL cells were removed and cells not cultured with MAb were either left without MAb or 
incubated for 30 min with 20 μg/ml of OFA (control + OFA), all cells then underwent CDC. The 
percentage of dead cells is relative to untreated control.  A. CLL91. B. CLL92. C. CLL94. D. 11q del 
CLL cells, mean + SEM (n=3). p values were determined by a paired t-test (*, p<0.05). 
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Figure 5.13 The significant improvement in OFA induced CDC in 17p del CLL samples upon 
microenvironmental stimulation is relatively short lived 
 
17p del CLL cells were cultured on the three different culture systems; plastic , NTL or CD154 
(NTL/CD15+/IL-4) and were either incubated with or without OFA for between 24-72 hr. At each 24 
hr interval CLL cells were removed and cells not cultured with MAb were either left without MAb or 
incubated for 30 min with 20 μg/ml of OFA (control + OFA), all cells then underwent CDC. The 
percentage of dead cells is relative to untreated control.  A. CLL28. B. CLL80. C. CLL109. D. 
CLL119. E. 17p del CLL cells, mean + SEM (n=4). p values were determined by a paired t-test (*, 
p<0.05). 
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Figure 5.14 OFA CDC activity is significantly improved in NOTCH1
MUT
 CLL samples upon 
microenvironmental stimulation 
 
NOTCH1
MUT
 CLL cells were cultured on the three different culture systems; plastic , NTL or CD154 
(NTL/CD154/IL-4) and were either incubated with or without OFA for between 24-72 hr. At each 24 
hr interval CLL cells were removed and cells not cultured with MAb were either left without MAb or 
incubated for 30 min with 20 μg/ml of OFA (control + OFA), all cells then underwent CDC. The 
percentage of dead cells is relative to untreated control.  A. CLL67. B. CLL101. C. CLL108. D. 
CLL133. E. NOTCH1
MUT
 CLL cells, mean + SEM (n=4). p values were determined by a paired t-test 
(*, p<0.05).  
  176 
 
 
Figure 5.15 11q del CLL cells display the highest level of OFA induced CDC upon 
microenvironmental stimulation 
 
Primary CLL cells were cultured on CD154 (NTL/CD154/IL-4) and were either incubated with or 
without OFA for between 24-72 hours. At each 24 hour interval CLL cells were removed and cells 
not cultured with MAb were either left without MAb or incubated for 30 mins with 20 μg/ml of OFA 
(control + OFA), all cells then underwent CDC. The mean + SEM percentage of dead cells are 
shown from cytogenetically normal CLL samples (n=4), 11q del (n=3), 17p del (n=4). D. 
NOTCH1
MUT
 (n=4). The percentage of dead cells is relative to untreated control.  A. CLL cells 
cultured on CD154 without MAb (control + OFA). B. CLL cells cultured with MAb. p values between 
different cytogenetic subsets were determined by an un-paired t-test, and p values within a 
cytogenetic subset were determined by a paired t test (*, p<0.05).  
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6 Molecular profile of NOTCH1MUT CLL cells  
6.1 Introduction 
Type I anti-CD20 MAbs function predominantly through harnessing the body’s 
innate immune system for the induction of ADCC, CDC and phagocytosis262. Their 
ability to cause direct cell death through the induction of apoptosis is ambiguous 
and currently not considered clinically relevant. Previous research into the 
mechanisms relating to RTX and OFA resistance have focused upon the 
expression levels of complement inhibitory proteins and CD20308,310,312. CDC 
induction is critically dependent on expression levels of the target antigen and 
loss of CD20 expression on the surface of the CLL is an important contributing 
factor in MAb resistance254,311,317,319. Recent genome sequencing studies have 
identified recurrent mutations in NOTCH1, observed in 12% of CLL cases88. 
Clinical trials have indicated that addition of OFA and RTX to chemotherapy 
provides no clinical benefit to NOTCH1MUT CLL patients108,109. The genetic 
mechanisms that could result in resistance to anti-CD20 MAbs are not well 
elucidated.  
Recent research suggests that the mechanism behind the reduced activity of 
anti-CD20 MAbs observed in NOTCH1MUT CLL cells is due to their reduced 
expression of CD20233. They attributed the lower expression of CD20 to increased 
expression at the mRNA and protein level of HDAC1 and HDAC2233. HDAC genes 
encode for histone deacetylase proteins which act as epigenetic regulators of 
gene expression by catalysing the removal of acetyl groups from core histones. 
This in turn results in chromatin compaction leading to the repression of gene 
transcription359,360. Our research confirmed these findings with lower levels of 
CD20 observed in NOTCH1MUT CLL patients cells when compared to normal 
cytogenetic CLL cells, however 17p del CLL cells also expressed lower levels of 
CD20 and yet had marginally higher levels of OFA induced CDC (Figure 4.3 & 
4.5). These data suggest that although CD20 levels are an important contributing 
factor, there is likely to be a complicated interplay with other factors resulting 
in the reduced activity of anti-CD20 MAbs against NOTCH1MUT CLL cells.  
CLL cells within the LN and BM receive pro-survival signals from cross-talk with 
accessory cells within the microenvironmental niche, which leads to an up-
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regulation of the Bcl-2 family anti-apoptotic genes such as Bcl-XL, Bfl-1 A1 and 
MCL-1139,168. Fludarabine and chlorambucil which cause cell death through the 
induction of apoptosis are consequently less active against CLL cells upon 
microenvironmental stimulation in vitro141,190. The Notch1 pathway has also been 
shown to be activated in CLL cells within the LN/BM, therefore these CLL cells 
may also be gaining further chemotherapeutic resistance against anti-CD20 MAbs 
in a Notch1 dependent manner226-228,232. Our results thus far from the four 
distinct cytogenetic subsets of CLL patients, indicate that the activity of anti-
CD20 MAbs are associated with more than just expression of CD20 and 
complement inhibitory proteins. Therefore more detailed molecular analysis is 
required to determine the pathways involved in MAb therapy resistance. 
Several important mechanisms are known to be involved in chemoresistance in 
cancer including alterations in the cell cycle, pathways involved in apoptosis and 
cell signalling. Indeed the poor prognostic cytogenetic aberrations 11q (ATM) 
and 17p (TP53) del both demonstrate different susceptibility to anti-CD20 MAbs. 
TP53 encodes for p53, a key player in the regulation of uncontrolled cell cycle 
progression. p53 activity is crucial for preventing the replication of cells with 
DNA damage, by regulating the transition of dividing cells from G1 to S phase 
367,373,374. ATM is also involved in stopping DNA damage from entering into the 
genetic make-up of the cell, becoming activated in the presence of undesired 
double strand breaks caused by either an endogenous or DNA damaging agent, 
and halts the cell at either G1/S or G2/M phase by preventing Cdk activity77,79,80. 
Both these genetic aberrations contain genes involved in DNA damage repair, yet 
our research suggests that like NOTCH1MUT, CLL patients with 17p del have 
reduced susceptibility to anti-CD20 MAbs through a down-regulation of CD20. 
Whereas 11q del CLL samples demonstrate enhanced susceptibility to RTX and 
OFA through low levels of complement exhaustion, high CD20 expression levels 
and high CDC levels which were further improved with NTL/CD154+IL-4 co-
culture.  
This demonstrates that although the role and function of CD20 is not fully 
elucidated in CLL there is clearly a complex interplay with other genetic 
pathways that may result in evasion of MAb therapy. This further highlights the 
importance for understanding the genetics of CLL cells that have evaded anti-
CD20 MAbs tumour lysis, and for understanding the different responses of the 
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individual cytogenetic sub-sets to anti-CD20 MAbs. Identifying genes 
differentially regulated in CLL cells that have evaded OFA induced CDC may lead 
to the identification of a drugable target which could aid the activity of anti-
CD20 MAbs. 
 
6.2 Aim 
The main focus was to determine the molecular profile of NOTCH1MUT CLL cells 
compared to other cytogenetic subsets of CLL, to elucidate the potential 
mechanisms by which NOTCH1MUT CLL cells evade anti-CD20 MAbs. To accomplish 
this we aimed to: 
 Identify genes involved in cell cycle, apoptosis and cell signalling that are 
de-regulated in CLL cells that have evaded OFA induced CDC; 
 Characterise differences in gene expression levels of key genes involved in 
the NOTCH1 pathway in the different CLL cytogenetic subsets;  
 Identify a gene signature de-regulated in our NOTCH1MUT CLL cohort 
compared to other CLL cohorts, and investigate this further using 
microenvironmental stimulation (NTL/CD154+IL-4 co-culture) with and 
without the presence of OFA treatment. 
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6.3 Results 
Results from the previous chapters have highlighted that NOTCH1MUT CLL cells 
are resistant to anti-CD20 MAbs, however the mechanisms surrounding this 
resistance are still unclear. Therefore we aim to elucidate the molecular profile 
of NOTCH1MUT CLL cells to determine a potential cause for resistance. 
6.3.1 Genomic mutations within CLL and NOTCH1MUT CLL 
patients 
CLL samples identified as being positive for NOTCH1 mutation by ARMS PCR, 
together with CLL samples that were cytogenetically normal, were sequenced 
and analysed by Oxford BRC Molecular Diagnostic Laboratory in collaboration 
with Professor Anna Schuh (Figure 6.1). Mutations were observed in 18 different 
genes, the most frequently of which were within ATM, followed by TP53. ATM 
and TP53 are associated with 11q and 17p del cytogenetic abnormalities 
respectively and result in a more aggressive poor prognostic disease. Of the 
samples assessed only 14% displayed no genomic mutation (Figure 6.1C). The 
NOTCH1MUT status for two CLL samples was confirmed and two samples that were 
identified as being partially positive by ARMS PCR were determined to carry low 
frequency of mutation and were therefore excluded from the NOTCH1MUT cohort. 
Two CLL patients (CLL90 and CLL125) had mutations in FBXW7. FBXW7 targets 
ICN for ubiquitination, and mutations within this gene in CLL are thought to 
abrogate its function therefore this could result in a NOTCH1MUT phenotype95. 
Consequently these samples were removed from the cytogenetically normal 
cohort of CLL samples. 
6.3.2 Gene regulation changes following OFA induced CDC 
Results from Chapter 5 demonstrated that there was an increase in OFA induced 
CDC for CLL cells co-cultured with NTL/CD154+IL-4. However despite this a 
substantial proportion of CLL cells escape OFA induced CDC. The evasion of CDC 
induction is most notable within our NOTCH1MUT CLL cohort (Figure 5.15). 
Therefore it was important for us to establish whether the cells escaping OFA 
induced CDC were altering particular gene pathways to escape lysis. The 
experimental design is discussed in more detail in section 2.5.2 and shown in 
Figure 2.1. Briefly, CLL cells were cultured on NTL/CD154+IL-4 for 24 hr prior to 
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OFA treatment. OFA was present in culture for a further 24 hr, thereafter CLL 
cells underwent CDC (Figure 6.2), and surviving cells were placed back into co-
culture with NTL/CD154+IL-4 for an additional 24 hr prior to RNA extraction. RNA 
was screened for 181 genes involved in different key pathways associated with 
CLL and tumourgenesis, using Fluidigm array analysis. In support of our previous 
analysis (Figure 5.15), NOTCH1MUT CLL cells displayed significantly less CDC than 
both normal and 11q del CLL cells (Figure 6.2). CDC induction levels were used 
to provide a cut-off for RNA extraction, 30% or more CDC was deemed sufficient 
to establish a gene expression signature for CLL cells escaping OFA induced CDC. 
Therefore two NOTCH1MUT and one 17p del CLL sample were excluded from gene 
analysis.  
Following analysis of our CLL samples no distinct pattern was observable, genes 
that showed significant change in expression levels did not belong to any one 
particular pathway, or cellular process such as evading apoptosis. Of the genes 
analysed, three were consistently up-regulated in CLL cells evading OFA CDC 
(Figure 6.3). Interestingly one of the genes, CD247 encodes for T cell receptor 
CD3ζ chain, which forms part of the TCR-CD3 complex. In particular the ζ chain 
is important for intracellular signal transduction in T cells375. MMPs are a large 
family of matrix metallopeptidase enzymes which have been linked with tumour 
growth and metastasis and are involved in different biological processes from 
cell migration to tissue repair. MMP9 in particular is the principle MMP produced 
by lymphocytes associated with the digestion of the main component of 
basement membranes, type IV collagen, and plays an important role in CLL cell 
migration376-378. The third gene, GATA3 is a transcription factor more commonly 
associated with T cell development379. When gene expression levels were 
compared against the percentage of CLL cells killed by CDC, CD247 displayed a 
nearly significant positive linear correlation (p=0.0571, r2= 0.3456) (Figure 6.4A). 
GATA3 did not display a positive linear correlation with CDC (Figure 6.4Bi). 
However when expression levels were separated depending on the cytogenetic 
subset, 11q del subset showed a skew towards greater up-regulation of GATA3 
(Figure 6.4Bii), than cytogenetically normal CLL samples that had comparable 
induction of CDC (61.6 and 65.3% of dead cells respectively). MMP9 expression 
displayed a strong positive linear correlation with CDC levels (p=0.0057, r2= 
0.6876) (Figure 6.4C). These data suggest that following OFA CDC induction 
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there was an up-regulation of genes involved in cross-talk to T cells, and tissue 
invasion, suggesting that the cells remaining following OFA CDC are those with 
the potential to migrate into either the LN or BM.  
6.3.3 Gene Expression Profiling (GEP) 
To assess the molecular profile of CLL patients, RNA was extracted from 
peripheral blood samples and Fluidigm analysis was performed for selected 
genes. Gene expression levels were determined relative to normal healthy B 
cells unless otherwise stated. The panel of genes selected were linked to CLL 
progression and poor prognosis phenotypes. Hierarchical clustering was 
performed based on the gene expression levels (Figure 6.5). Of the 44 genes 
analysed 10 were unchanged, 11 were up-regulated, 14 were down-regulated 
and 9 were differentially expressed between the different CLL patient samples 
examined. Several genes had similar expression between CLL cells and B cells, 
such as NFATC3 and MAX. Whereas AXIN2 displayed elevated expression in CLL 
cells compared to B cells as did PRKCA although expression varied from sample 
to sample. A cluster of 6 genes were identified as being consistently up-
regulated in the CLL patients cells, some of which were associated with cell 
cycle progression such as E2F3, CDK2 and CCND1 (Figure 6.5).  
Several genes were not included in the heat map due to extremes in gene 
expression levels or loss of expression in the CLL cells, these are shown in Figure 
6.6. FOS was down-regulated in CLL cells compared to B cells, with 17p del 
subset displaying a slightly elevated expression compared to the other CLL 
subsets (Figure 6.6A). Interestingly 11q del CLL cells had markedly reduced 
expression of GATA3 compared to normal B cells, approximately 30 fold less. 
NOTCH1MUT CLL cells displayed lower expression levels of GATA3, however this 
was only around a 2.5 fold reduction in expression (Figure 6.6B). Therefore it 
would appear that 11q del CLL cells display a bias towards up-regulating this 
gene within cells that have evaded OFA CDC in comparison to unstimulated CLL 
cells within the peripheral blood. Several CLL samples lacked MMP9 expression, 
on average only 40% of normal CLL and NOTCH1MUT CLL samples exhibited 
detectable MMP9 expression (Figure 6.6C). However none of the 11q del CLL 
samples assessed had any detectable MMP9 expression, whereas all 17p del CLL 
samples had some expression albeit very low in two samples. This suggests that 
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11q del CLL cells switch on and up-regulate MMP9 expression following 
NTL/CD154+IL-4 stimulation and exposure to OFA induced CDC.  
6.3.3.1 Cell cycle genes 
Cell cycle genes are very important determinants for the aggressiveness of many 
different cancers, through their effect on cell cycle arrest and proliferation 
rates. Although heatmaps provide a valuable tool for observing global changes in 
gene expression levels, subtle differences in expression levels between the 
different cytogenetic subsets were not easily observed. A significant up-
regulation of CCND1 was detected in all of our CLL samples compared to B cells 
(Figure 6.7A), with normal cytogenetic CLL cells displaying significantly higher 
expression than NOTCH1MUT CLL cells. Although not significant, CCNE2 expression 
was also higher in cytogenetically normal CLL cells when compared against 11q 
del CLL cells, which displayed 2.5 fold lower mean expression levels (Figure 
6.7B; p=0.0727). CDK2 expression was elevated in all CLL subsets compared with 
normal B cells (Figure 6.7C). CDKN1A, which encodes the Cdk inhibitor 
p21WAF1/CIP1, was expressed approximately 10 fold lower in CLL cells compared to 
normal B cells (Figure 6.7D). 17p del subset displayed significantly lower 
expression of CDKN1A than 11q del CLL samples. Our data demonstrates that 
genes involved in cell cycle progression are de-regulated in CLL, which may aid 
in the progression of the disease through altered proliferation rates and defects 
in cell cycle arrest. However, our findings indicate that the different cytogenetic 
sub-groups differentially regulate cell cycle genes in distinct ways, highlighting 
the heterogeneity of the disease. Some of these findings may relate to the loss 
of p53 and ATM observed in the 17p and 11q del patients. 
In addition several genes were assessed which are associated with Ca2+ 
signalling, given the role of CD20 as a store-operated Ca2+ channel (Figure 6.8A-
C). Expression of NOXA1 in NOTCH1MUT CLL cells was lower than that observed 
for cytogenetically normal CLL cells (p=0.109), whereas expression of RRAD and 
JUN displayed little difference between the cytogenetic subsets. CD247, which 
was identified as being up-regulated in CLL cells evading OFA CDC, 
demonstrated that 11q del CLL samples displayed significantly lower levels of 
CD247 (p=0.0181), than normal B cells (Figure 6.8D). Of interest was the 
expression levels of CD247, GATA3 and MMP9 in 11q del CLL samples, as these 
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genes were all highly expressed in cells evading OFA CDC, despite having the 
lowest basal gene expression levels. Our results demonstrate that 11q del CLL 
patients respond well to anti-CD20 MAbs treatment, therefore part of this may 
be attributed to the lower levels of expression of CD247, GATA3 and MMP9 
within circulating cells. 
6.3.3.2 NOTCH1 pathway 
A panel of genes associated with the NOTCH1 pathway were assessed in our CLL 
cells to determine if there were indications of de-regulation in our NOTCH1MUT 
CLL cells (Figure 6.9). Interestingly several genes known to be modulated by the 
NOTCH1 pathway, the HES family of genes and HEY1 were down-regulated in our 
CLL patient cohort compared to normal B cells, even though NOTCH1 was up-
regulated in the majority of samples. FBXW7 involved in ICN degradation was 
down-regulated, whereas ADAM10 was up-regulated indicating that NOTCH1 
could potentially be more readily cleaved into ICN and expression may be 
prolonged due to loss of degradation. These findings suggest that there is a skew 
towards constitutively active NOTCH1 signalling in CLL. 
Comparing the expression levels of NOTCH1 between our CLL subsets, the 
highest expression levels were observable in both our normal cytogenetic and 
NOTCH1MUT CLL cells. Interestingly NOTCH1MUT CLL cells only had approximately 
0.2 fold higher gene expression levels than cytogenetically normal CLL cells 
(Figure 6.10A). 17p del CLL samples displayed the lowest levels of NOTCH1 
expression, with levels similar to that observed in the healthy B cells. In contrast 
NOTCH2 was slightly down-regulated in our CLL samples, 17p del patients 
displayed the highest expression but this was similar to that observed in the 
normal B cells (Figure 6.10B). NOTCH3 was not expressed in the normal B cell 
samples assessed, and therefore gene expression was shown relative to the CLL 
normal sample CLL57 (Figure 6.10C; ΔCt values are shown in Supplementary 
Figure 6.1). Only one 11q del CLL patient displayed NOTCH3 expression, 
cytogenetically normal and 17p del CLL cells had varied gene expression levels. 
NOTCH4 expression was the highest within normal cytogenetic CLL cells, but 
again there was wide variation in expression from sample to sample (Figure 
6.10D). These data suggest that 11q del CLL patients consistently had the lowest 
expression levels of all the NOTCH genes, however a larger cohort of patients 
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are required to confirm these observations. Given the link between 
constitutively active Notch1 signalling and resistance to anti-CD20 MAbs108,109,233, 
it is noteworthy that the good responders 11q del CLL samples 346 displayed the 
lowest expression levels. 
NOTCH1 downstream target genes HES1 and HEY1 expression levels, were down-
regulated in our CLL patient cohort, even in NOTCH1MUT CLL cells when 
compared against normal B cell samples (Figure 6.11A&B). HES1 was significantly 
down-regulated compared to normal B cells, >100 fold lower, and as expected 
from our previous data 11q del CLL patients had the lowest expression levels. 
DELTEX a positive regulator of NOTCH1 was significantly up-regulated in our 
NOTCH1MUT samples compared to cytogenetically normal CLL cells (3 fold higher 
expression, p=0.0181; Figure 6.11C). 11q del CLL cells had significantly lower 
expression of the NOTCH1 ligand gene DLL1 (p=0.0181; Figure 6.11D). As 
expected our 17p del CLL patients displayed significantly lower expression of 
TP53 than the other cytogenetic subsets. Interestingly the oncogene MYC 
expression levels were lower in CLL samples from peripheral blood compared 
with control B cells, but presumably MYC would be up-regulated compared to 
normal B cells in the LN and BM where there are stronger signals for cell division 
(Figure 6.12)380. 
Overall our data clearly demonstrate that normal B cells express components of 
the NOTCH pathway, and within CLL there is cytogenetic subset specific de-
regulation of this pathway.  
6.3.4 Gene expression and OFA NTL/CD154+IL-4 stimulation 
To elucidate the mechanisms responsible for NOTCH1MUT CLL cells resistance to 
anti-CD20 MAbs, gene expression analysis was performed on cytogenetically 
normal and NOTCH1MUT CLL cells co-cultured on NTL/CD154+IL-4 with and 
without the presence of OFA. By comparing gene expression levels from freshly 
isolated CLL samples, several pathways appeared to be de-regulated in our 
NOTCH1MUT CLL sample cohort. As expected this included the NOTCH1 pathway 
but in addition genes associated with cell cycling and Ca2+ signalling were 
altered, prompting further investigation. Therefore, CLL cells were treated for 
48 hr either on plastic (with and without OFA) or NTL/CD154+IL-4 (with and 
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without OFA) and then changes in gene expression levels were determined by 
Fluidigm array analysis. Unless otherwise stated all fold change in gene 
expression is relative to CLL70 cultured on plastic without the presence of OFA. 
CLL70 was used for calibration as it is a normal cytogenetic CLL sample which 
Oxford sequencing data identified as having no additional genomic mutations. 
6.3.4.1 NOTCH1 signalling pathway 
NOTCH1 pathway genes as well as several genes linked with WNT signalling were 
assessed, as the two pathways have been shown to interact in the presence of 
Ca2+ 224,368,381. The NOTCH1 pathway was up-regulated with NTL/CD154+IL-4 
stimulation, with a clear up-regulation of HEY1 in both our normal cytogenetic 
CLL and NOTCH1MUT CLL samples (Figure 6.13). DELTEX expression, which was 
up-regulated in the freshly isolated NOTCH1MUT samples when compared to 
normal CLL samples, was down-regulated following culture on plastic and further 
down-regulated with NTL/CD154+IL-4 stimulation in our NOTCH1MUT CLL cells 
(Figure 6.14A; ΔCt values are shown in Supplementary Figure 6.2A). The 
cytogenetically normal CLL samples displayed little change in NOTCH1 gene 
expression levels until co-cultured with OFA and NTL/CD154+IL-4, whereby 
NOTCH1 expression was increased. This is in contrast to NOTCH1MUT CLL samples 
which upon NTL/CD154+IL-4 stimulation displayed down-regulation of NOTCH1 
which was further abrogated by the presence of OFA in culture, resulting in 
significantly lower NOTCH1 expression between normal cytogenetic CLL cells and 
NOTCH1MUT (p=0.0405; Figure 6.14B; ΔCt values are shown in Supplementary 
Figure 6.2B). Interestingly the expression of ROR2, a tyrosine kinase receptor 
protein associated with the non-canonical WNT signalling pathway, was only 
present in two samples on plastic, CLL121 (CLL normal) and CLL133 
(NOTCH1MUT). Gene expression levels were made relative to CLL121 cultured on 
plastic without OFA (Un-calibrated ΔCt values are shown in Supplementary Figure 
6.2C). Upon stimulation with NTL/CD154+IL-4 there was an up-regulation of 
ROR2 (over 1,500 fold increase; Figure 6.14Ci).Surprisingly NTL/CD154+IL-4 
stimulation induced ROR2 expression in all the samples examined, which was 
more notable in our NOTCH1MUT CLL cells (n=3; 40 fold higher; p=0.2761; Figure 
6.14Cii).  
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6.3.4.2 Cell cycle 
Previous reports have shown that upon stimulation with NTL/CD154+IL-4 or 
alternatively IL-21, B cells and CLL cells have the ability to start to 
proliferate382,383. Therefore it was not surprising that after 24 hr on 
NTL/CD154+IL-4 co-culture several genes involved in cell cycle progression such 
as CCNE2 and CDK1 were up-regulated in the CLL cells (Figure 6.15). NOTCH1MUT 
CLL cells displayed a more pronounced de-regulation of genes involved in cell 
cycle progression in comparison to cytogenetically normal CLL cells. CCND1 was 
more significantly up-regulated in NOTCH1MUT CLL cells than cytogenetically 
normal CLL cells (Figure 6.16A; ΔCt values are shown in Supplementary Figure 
6.3A ). NOTCH1MUT CDK1 expression was at least double that observed in normal 
cytogenetic CLL samples, when cultured on both plastic (0.91 vs 2.66 ΔΔCt values 
respectively) and NTL/CD154+IL-4 (20.35 vs 46.90 ΔΔCt values respectively; 
Figure 6.16B; ΔCt values are shown in Supplementary Figure 6.3B). NOTCH1
MUT 
CDK2 expression was two fold higher than that of cytogenetically normal CLL 
cells when cultured on NTL/CD154+IL-4 (7.39 vs 18.03 ΔΔCt values respectively; 
Figure 6.16C; ΔCt values are shown in Supplementary Figure 6.3C). Interestingly 
for CCNE2 expression both NOTCH1MUT and normal cytogenic CLL cells 
demonstrate marginal down-regulation when OFA was added to plastic culture, 
whereas when OFA was present in NTL/CD154+IL-4 co-culture NOTCH1MUT CLL 
cells displayed a significant up-regulation of CCNE2 (1.3 fold higher expression; 
p=0.0259). Normal cytogenetic CLL cells also displayed an up-regulation (1.6 fold 
increase; p=0.0731; Figure 6.16D; ΔCt values are shown in Supplementary Figure 
6.3D). This suggests that CLL normal cytogenetic and NOTCH1MUT CLL cells both 
prepare for cell division when co-cultured with NTL/CD154+IL-4, however this 
appears more enhanced in NOTCH1MUT CLL samples. The changes demonstrated 
in CCNE2 expression in CLL cells, cultured with OFA on both plastic and 
NTL/CD154+IL-4 suggests that the binding of OFA to CD20 sends signals to the 
CLL cell to increase cell division in the presence of NTL/CD154+IL-4. 
6.3.4.3 BCR and Ca2+ signalling 
Analysis of genes linked with Ca2+ and BCR signalling provided a less clear 
differential in gene expression levels, following culture on either plastic or 
NTL/CD154+IL-4 (Figure 6.17). There was also much more patient variation 
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observed in gene expression levels within both normal cytogenetic and 
NOTCH1MUT CLL subsets. However JUN was consistently up-regulated following 
NTL/CD154+IL-4 stimulation with expression more prominently up-regulated in 
the cytogenetically normal CLL cells compared to NOTCH1MUT CLL (Figure 6.18A; 
ΔCt values are shown in Supplementary Figure 6.4A). Whereas the oncogene MYC 
was largely down-regulated in NOTCH1MUT CLL cells when cultured on plastic, 
upon co-culture with NTL/CD154+IL-4 expression increased 20 fold as opposed to 
4 fold in the normal cytogenetic CLL sample cohort (Figure 6.18B; ΔCt values are 
shown in Supplementary Figure 6.4B). This concurs with the data collected for 
the cell cycle genes and suggests that NOTCH1MUT CLL cells are more primed 
towards cell division. RRAD, which is associated with regulation of voltage-
dependent L-type calcium channel, was down-regulated on plastic, with 
expression in normal cytogenetic CLL cells further down-regulated when OFA 
was present in plastic (p=0.121; Figure 6.18C; ΔCt values are shown in 
Supplementary Figure 6.4C). Interestingly in NOTCH1MUT CLL cells, RRAD 
expression was up-regulated on plastic with OFA compared with untreated 
control (1.3 fold increase; p=0.0237). NTL/CD154+IL-4 stimulation caused further 
up-regulation of RRAD in NOTCH1MUT CLL cells which was further increased with 
OFA stimulation, although this was not statistically significant. NOTCH1MUT CLL 
cells displayed lower SYK expression levels than normal cytogenetic CLL, but for 
both cytogenetic sub-sets, expression was down-regulated approximately two 
fold on NTL/CD154+IL-4, significantly so for normal cytogenetic CLL cells with 
OFA (p=0.0456; Figure 6.18D; ΔCt values are shown in Supplementary Figure 
6.4D). This data suggests that constituently active NOTCH signalling may target 
several different genes linked with Ca2+ signalling in order to induce resistance 
to anti-CD20 MAbs. 
6.3.4.4 Notch1 activation on NTL/CD154+IL-4 
Protein expression levels were also determined for cytogenetically normal CLL 
samples (n=3) and NOTCH1MUT CLL samples (n=3) cultured on plastic and 
NTL/CD154+IL-4 with and without the presence of OFA for 48 hr by Western 
blotting (Figure 6.19). Protein levels for Notch1, 2 and 4 all represent the active 
intracellular form of the protein. Incomplete transfer of proteins from gel to 
membrane occurred for sample CLL70/CLL108 cultured on plastic with and 
without OFA, therefore some immune-blotting data is missing for these samples 
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(Figure 6.19C). Corroborating our gene expression analysis, the Notch1 signalling 
pathway is activated by NTL/CD154+IL-4 stimulation in both cytogenetic subsets. 
Notch2 also appeared activated by NTL/CD154+IL-4 stimulation, while Notch3 
expression was only detected in one out of six CLL samples analysed, NOTCH1MUT 
CLL101 on plastic (Figure 6.19D). Notch4 expression remains consistently 
unchanged by stimulation. This suggests that NTL/CD154+IL-4 stimulation causes 
preferential activation of Notch1/2. Interestingly one CLL normal sample, CLL42, 
displayed continuous activation of Notch1/2, which remained unchanged by 
NTL/CD154+IL-4 stimulation indicating a potential mutation of a regulator of the 
Notch1/2 pathway for this patient (Figure 6.19B). ADAM-10 further highlights 
Notch1 activation by NTL/CD154+IL-4 stimulation as shown by the presence of 
the lower band, which represents the active form (~60 kDa) of the protein 
(Figure 6.19 A&B).  
The up-regulation of phospho GSK3β (Ser9) and total GSK3β levels in the CLL 
samples assessed, suggests activation of the Akt and Wnt signalling pathways 
(Figure 6.19A&B). Expectedly the cell cycle protein CCNE1 was up-regulated 
with NTL/CD154+Il-4 stimulation in both NOTCH1MUT and normal cytogenetic CLL 
cells (Figure 6.19A&B). CCNE2 expression however was only observed when cells 
were cultured with NTL/CD154+IL-4 in the presence of OFA. Therefore longer 
stimulation than 48 hr may be required to observe a more notable up-regulation. 
CCNE2 expression was also up-regulated at the gene level following OFA 
stimulation which was most prominent in our NOTCH1MUT CLL cells (Figure 6.16), 
CCNE2 protein expression levels also appear more up-regulated in NOTCH1MUT 
CLL samples compared to cytogenetically normal CLL cells. Although a larger 
patient cohort would be required to determine if this is a statistically significant 
trend. CCNE2 results would suggest that CD20 bound with OFA could act to 
regulate CCNE2 expression presumably through the Ca2+ signalling cascade, or 
via the CD20/OFA complex stimulating another receptor/pathway to cause 
changes in CCNE2 expression.  
6.3.5 NOTCH1MUT CLL patients display calcium flux upon BCR 
stimulation 
Differences in expression of genes associated with Ca2+ signalling between 
normal cytogenetic and NOTCH1MUT CLL samples led us to analyse the Ca2+ flux 
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with BCR and OFA/RTX stimulation. Others have shown that Ca2+ flux only occurs 
when anti-CD20 MAb are combined with BCR stimulation. Soluble IgM fragments 
F(ab’)2 or IgM was used stimulate the BCR in combination with anti-CD20 MAb, 
and as a positive control Ca2+ ionophore Ionomycin (Iono) was used334. Ca2+ flux 
was measured using Fluo-4. A minimal Ca2+ response, determined by an increase 
in MFI, was observed in normal cytogenetic CLL cells following BCR crosslinking 
(F(ab’)2 + 89 MFI and IgM + 124 MFI; n=4; Figure 6.20). When the MFI signal 
produced over time was assessed there was very little change observed 
compared to NDC (Figure 6.21). However in NOTCH1MUT CLL samples upon BCR 
crosslinking there was an obvious flux in Ca2+ for three patients (F(ab’)2 + 507 
MFI and IgM + 220 MFI; n=4; Figure 6.22). A Ca2+ flux was observed in NOTCH1MUT 
samples when CLL cells were incubated with either OFA or RTX but not quite so 
prominently, suggesting that Ca2+ signalling is possibly a contributing mechanism 
for the resistance of NOTCH1MUT CLL cells to anti-CD20 MAbs.  
Investigating MFI changes over the 2 min period demonstrated that the response 
between F(ab’)2 and IgM BCR stimulation was different (Figure 6.23). F(ab’)2 
stimulation appeared to cause an immediate Ca2+ flux which, due to the several 
second delay in our ability to record the data, meant we were only able to 
measure the end part of the flux when levels were returning back to normal. 
However IgM stimulation leads to a slower gradual increase in Ca2+ flux. 
Comparing the mean MFI levels for cytogenetically normal and NOTCH1MUT CLL 
cells confirmed that NOTCH1MUT cells demonstrate a large Ca2+ flux with BCR 
stimulation (Figure 6.24A). When CLL cells were stimulated with MAb, 
cytogenetically normal CLL cells demonstrated a slight flux in Ca2+ when pre-
incubated with RTX or OFA, this flux increased further with BCR stimulation 
(Figure 6.24B&C). NOTCH1MUT CLL cells however did not demonstrate a notable 
flux with MAb co-culture; this may be attributed to the lower expression levels 
of CD20 on NOTCH1MUT CLL cells. Low CD20 expression levels could lead to 
insufficient MAb binding for the formation of CD20 into lipid rafts and 
subsequently reduced Ca2+ flux. Upon BCR stimulation there was an observable 
flux in Ca2+ within the NOTCH1MUT CLL samples, but this response was muted in 
comparison to BCR stimulation alone (Figure 6.24). Overall these findings 
indicate that alteration in Ca2+ flux may play a role in NOTCHMUT CLL resistance 
to anti-CD20 MAB therapies. 
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6.4 Discussion 
6.4.1 Genetic instability in CLL cells 
Whole genome sequencing revealed the extensive heterogeneity between 
different CLL patients. When the 13 CLL patients with mutations were compared 
no two CLL patients displayed the same set of mutated genes. ATM mutations 
were the most frequently reported with some patients having 2 or 3 mutations 
within ATM. This supports other studies which have also observed that ATM 
mutations are one of the most frequently occurring in CLL80,384. Although the 
NOTCH1MUT CLL patient cohort we have is too small to draw any conclusions. It 
would be interesting to determine how frequently mutations within ATM are 
observed within NOTCH1MUT CLL cells and how this impacts upon their response 
to anti-CD20 MAbs, as we and others found that 11q del patients respond well to 
anti-CD20 MAbs346. Of the two NOTCH1MUT CLL patients screened for mutations, 
CLL67 displayed one mutation in the ATM gene, which did not improve its 
susceptibility to OFA induced CDC, with the percentage of dead cells observed 
being 14.4% compared to the mean average for NOTCH1MUT CLL cells at 15.1%. 
Although this deletion may only affect one of the alleles, it would be interesting 
to determine if mutations of both ATM alleles in NOTCH1MUT CLL cells results in 
any measurable improvement in susceptibility to anti-CD20 MAbs as observed 
with 11q del CLL patients. NOTCH1MUT have been identified within CLL patients 
with 17p del however NOTCH1MUT have not yet been observed in CLL patients 
with 11q del, suggesting they are mutually exclusive aberrations88,108.  
6.4.2 CLL cells escaping OFA induced CDC 
Understanding the ability of malignant CLL cells to escape OFA CDC may lead to 
new targetable cancer therapies and help pinpoint the genes involved in 
NOTCH1MUT resistance to anti-CD20 MAbs. Therefore we initiated OFA induced 
CDC on CLL cells cultured with NTL/CD154+IL-4, any surviving cells were then re- 
cultured with NTL/CD154+IL-4 overnight and cells harvested for gene expression 
analysis using Fluidigm array.  
Analysis of the genes revealed that no specific common pathway was activated 
in the surviving CLL cells. The majority of genes that showed >2 fold change in 
  192 
 
expression levels were specific to individual samples. After screening our CLL 
samples, three genes were identified as being consistently up-regulated in CLL 
cells escaping OFA CDC; CD247, GATA-3 and MMP9. MMPs are a large family of 
enzymes linked with tumour growth and metastasis and are involved in different 
biological processes from cell migration to tissue repair. MMP9 in particular is 
the principle MMP produced by lymphocytes associated with the digestion of the 
main component of basement membranes, type IV collagen. Increased MMP9 
expression has been associated with poor patient survival and advanced clinical 
stage in CLL376,377. High MMP9 expression has also been linked to extensive BM 
infiltration377. Infiltration of both the LN and BM by malignant CLL cells is 
associated with increased risk of morbidity and death via the suppression of 
normal haematopoiesis and immunity. Therefore it is possible that CLL cells that 
have successfully evaded OFA induced CDC are over expressing MMP9 to enhance 
invasion of the LN or BM, thus enabling the aberrant CLL cells to be protected 
within these niches. Once in these niches the pro-survival signals provided will 
also help the surviving CLL cells to proliferate.  
Possibly in support of this, the two other genes up-regulated are associated with 
T cell development and signalling, GATA-3 and CD247 respectively. GATA-3 has 
been identified as a marker for the hormone response in breast cancer, but little 
is known about its role in CLL385. GATA-3 is commonly understood to be an 
important transcription factor in T cell development, and is crucial for the 
transformation of naïve CD4+ T cells in the presence of IL-4 and APC into TH2 
cells. GATA-3 expression is specific to TH2 lineage, and is not observed in TH1 
cells379. TH2 are associated with expression of IL-4, which we have previously 
described as aiding the expansion of CLL cell clones and assisting 
survival138,139,366,386. CD247 encodes for a TCR associated protein, the CD3ζ chain, 
CD3 is assembled with the TCR heterodimer in T cells. TCR signal activation can 
lead to several different cellular processes such as; proliferation, differentiation 
and also cytokine production375. TCR engagement with antigens results in the 
tyrosine phosphorylation of ITAMs located within the ζ subunit of CD3 (CD247), 
resulting in the sequential activation of Lck and Fyn and consequently 
orchestrates the activation of several different cellular pathways such as ERK, 
NFAT and NF-κB pathway387. Typically T cell associated proteins, ZAP-70 and Lck 
expression have been identified in CLL patients, with a propensity towards 
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unmutated IGHV patients. Within CLL, ZAP-70 and Lck expression leads to 
enhanced BCR signalling. BCR signalling results in an up-regulation in pro-survival 
pathways, which aids CLL cell survival45,46,388. Therefore our data suggests that 
CLL cells evading OFA induced CDC are those actively trying to migrate into the 
LN or BM with enhanced ability to cross-talk and tailoring their 
microenvironment to aid survival and expansion of the malignant clone.  
Interestingly when gene expression levels for these three genes were compared 
within fresh CLL samples 11q del CLL patients demonstrated significantly lower 
expression levels of GATA-3 and CD247 than cytogenetically normal CLL cells, 
whilst expression of MMP9 was undetectable. Throughout this body of research 
we have demonstrated the susceptibility of 11q del CLL samples to anti-CD20 
MAbs. In particular we have highlighted their enhanced levels of OFA induced 
CDC with and without stromal co-culture, supporting our findings which suggest 
that higher expression of these genes results in reduced MAb activity. NOTCH1MUT 
CLL sample expression levels for these genes revealed no significant differences 
other than lower levels of GATA-3, which if our findings are correct should aid 
CDC. Therefore this would indicate that NOTCH1MUT CLL cells have a novel 
mechanism for evading MAb CDC, which requires further investigation. 
6.4.3 GEP of unstimulated NOTCH1MUT CLL cells displays a 
similar pattern of expression to cytogenetically normal CLL 
cells 
No particular gene or pathway was highlighted as being deregulated between 
each of the four cytogenetic sub-groups, despite having different mutations. 
However. closer examination revealed subtle differences in the expression of 
several genes. Previous findings have identified that Notch1 expression results in 
both cell cycle progression and arrest depending on the tissue type. Within 
pancreatic cancer and T-ALL NOTCH expression results in increased passage to 
the G1/S phase. However within the RNA of NOTCH1
MUT fresh CLL samples, we 
identified significantly lower expression levels of the cell cycle regulatory genes 
CCND1 and nearly significant levels of reduced CCNE2 expression 
(p=0.0727)389,390. This may be due to a lack of NOTCH stimulation for CLL cells 
within the peripheral blood. Investigating NOTCH1 expression levels identified 
marginally elevated levels in our NOTCH1MUT subset compared to cytogenetically 
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normal CLL cells. HES1 expression was also slightly higher but there was little 
difference within the other NOTCH1 downstream genes HES5 and HEY1. This 
suggests similar expression of NOTCH1 pathway genes between cytogenetically 
normal and NOTCH1MUT CLL cells located within the circulating compartment. 
Interestingly in the NOTCH1MUT CLL subset, there was significantly higher 
expression of DELTEX1 a positive regulator of NOTCH1, suggesting that 
NOTCH1MUT are more readily primed towards constitutively active NOTCH1 
signalling391. Pozzo et al., established that in NOTCH1MUT CLL cells, those with 
lowest levels of CD20 expression were enriched for NOTCH1 expression, 
concurrent with an up-regulation of both HDAC1/2 at the transcriptional and 
protein level233. By performing co-immunoprecipitation assay they determined 
that the reduced CD20 expression levels was due to competition between 
HDAC1/2 and Notch1 binding to CBF1233. CBF1 in combination with suppressor of 
hairless and Lag-1 make up the transcription factor complex CSL. CSL is the 
principle transcription factor responsible for activating gene transcription 
downstream of Notch1, and also binds HDAC1 and HDAC2. However Notch1 is 
able to outcompete HDAC1/2 to bind to CSL392,393. Presumably this then leaves 
the elevated levels of HDAC1/2 to bind to and repress the activity of the 
transcription factor Sp1, a CD20 specific transcription factor394. Pozzo et al., 
further identified an increase in the expression of CD20 in NOTCH1MUT CLL cells 
upon the treatment with the HDAC inhibitor VPA, although they do not report 
whether this resulted in increased lysis by CDC and ADCC following Mab 
treatment. Our investigation was carried out prior to this research therefore 
HDAC1 or HDAC2 genes were not investigated in our panel of genes, however 
HDAC4 was included. HDAC4 was down-regulated in our NOTCH1MUT CLL cells 
compared to cytogenetically normal CLL cells, however HDAC4 is a type IIa 
HDAC, whereas HDAC1/ 2 are type I, which subsequently have different binding 
sites and repress different pathways359-361,395. 
6.4.4 Microenvironmental stimulation and NOTCH1MUT CLL cells 
6.4.4.1 NOTCH1 pathway 
To further understand the molecular mechanisms behind NOTCH1MUT CLL cell 
resistance to OFA we incubated CLL cells with and without OFA in co-culture for 
48 hr on plastic and NTL/CD154+IL-4. Downstream activation of the NOTCH1 
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pathway was observed at the transcriptional level via elevated HEY1 expression 
following culture with NTL/CD154+IL-4. Interestingly in our freshly isolated 
NOTCH1MUT CLL cells which displayed high DELTEX expression, upon culture on 
plastic expression is lowered compared to cytogenetically normal CLL cells. 
Following activation of NOTCH1 on NTL/CD154+IL-4 DELTEX is further down-
regulated in the NOTCH1MUT CLL cells. Although NOTCH1 levels are down-
regulated upon stimulation with NTL/CD154+IL-4, this may be due to the 
transcript being rapidly made into protein to activate the Notch1 pathway. This 
is corroborated by our immunoblotting results where overexpression of Notch1 
was observed at the protein level on NTL/CD154+IL-4 in both our normal and 
NOTCH1MUT CLL cells. Intracellular Notch1 and Notch2 also appear to be up-
regulated at the protein level following stimulation with NTL/CD154+IL-4, 
indicating Notch activation. However Notch3 and Notch4 were not well 
expressed at the transcriptional level and remained relatively unchanged at the 
protein level suggesting differential activation of the Notch receptors. It has 
previously been reported that the activation of Notch is due to the up-regulation 
of NF-κB on NTL/CD154+IL-4, which was able to induce expression of the Notch 
receptor ligand Jagged1230. This would support our findings, as Jagged1 
preferential activates Notch1 and Notch2. Activation of the Notch1 pathway at 
the protein level is further supported by the presence of the active form of 
ADAM10 on NTL/CD154+IL-4396. One of the normal CLL samples, CLL42, displayed 
Notch1 and Notch2 activation on plastic and NTL/CD154+IL-4, suggesting a 
potential downstream mutation causing constitutive signalling; therefore it 
would be interesting to analyse this sample for a NOTCH pathway related 
mutation. CLL42 however, unlike the other CLL samples assessed, appeared to 
be insensitive to further Notch1 or Notch2 activation by NTL/CD154+IL-4, which 
may be due to this sample already having constitutively active signalling.  
An up-regulation of phospho GSK3β and total GSK3β was observed at the protein 
level on NTL/CD154+IL-4, in both NOTCH1MUT and cytogenetically normal CLL 
cells, suggesting activation of the Akt and Wnt signalling pathways, although 
some genes in the Wnt pathway did not show an up-regulation such as AXIN1/2 
and DV1. Further cross-talk between these two pathways could explain this, 
reports have shown that GSK3β is able to bind and phosphorylate the 
intracytoplasmic region of Notch following cleavage. GSK3β phosphorylation of 
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Notch then effects its transcriptional activity by modulating HES1 expression397. 
APC, a negative regulator of the Wnt signalling pathway had higher expression in 
our cytogenetically normal CLL cells224,398. Lef1 which forms the transcriptional 
complex with β-catenin, the transcriptional regulator of canonical Wnt 
signalling, was more strongly up-regulated at the transcriptional level upon 
NTL/CD154+IL-4 stimulation in our NOTCH1MUT CLL cells suggesting that 
NOTCH1MUT CLL samples also have increased Wnt signalling. ROR2 encodes for a 
membrane bound receptor tyrosine kinase which when bound by WNT5A 
activates the non-canonical β-catenin independent Wnt signalling pathway399,400. 
Non-canonical WNT5A signalling has been described as both a tumour suppressor 
and tumour enhancing pathway. When acting as a tumour suppressor, the 
protein displays an association with degrading β-catenin and therefore 
suppressing the tumour activity of canonical Wnt signalling causing a down-
regulation of c-MYC401. However our results demonstrated an increase in MYC 
expression at the transcriptional level following NTL/CD154+IL-4 stimulation, 
therefore it would appear more likely that WNT5A expression in our 
cytogenetically normal and NOTCH1MUT CLL cells is oncogenic. Increased levels of 
Ca2+are involved in this process, activating Ca2+ sensitive receptors initiates 
WNT5A expression 399,400. Jak et al., have reported increased Ca2+ within CLL 
cells when stimulated with CD40176. When WNT5A is active it functions in 
concert with the canonical Wnt pathway to cause an up-regulation of genes 
involved in the invasive nature of malignant cancer cells, such as MMP expression 
which as previously described displays a correlation with CLL cells evading OFA 
induced CDC.  
Interestingly previous gene expression profiling experiments had identified ROR1 
as a signature gene of CLL cells and consequently as a target for MAb 
therapy118,402,403. Within these two independent studies ROR1 was identified as 
being highly expressed in CLL cells, whilst ROR2 was not. ROR1 and ROR2 share 
97% sequence homology to each other402. The two CLL samples that had ROR2 
expression when unstimulated on plastic (CLL121 &CLL133) both up-regulated 
ROR2 expression to a similar extent when stimulated with NTL/CD154+IL-4. In 
the remaining CLL samples NTL/CD154+IL-4 stimulation resulted in an activation 
of ROR2 expression in all the samples. This suggests another mechanism by 
which CLL cells maintain non-canonical Wnt signalling to aid their survival in the 
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LN microenvironment. NOTCH1MUT CLL samples demonstrated more enhanced 
ROR2 activation in comparison to cytogenetically normal CLL cells suggesting 
they are primed towards non-canonical Wnt signalling to aid 
survival/proliferation resulting in their more aggressive phenotype.  
6.4.4.2 Cell cycle 
It has previously been characterised by carboxyfluorescein diacetate 
succinimidyl ester (CFSE) assay that resting B cells upon stimulation with 
CD154/IL-4 will proliferate, and the same has been observed for CLL 
cells382,383,404. Therefore it was not surprising that many of the genes involved in 
cell cycle were largely up-regulated upon NTL/CD154+IL-4 stimulation in our CLL 
samples, CCNE1 and CCNE2 at the protein level also displayed up-regulation in 
expression upon NTL/CD154+IL-4 stimulation. Freshly isolate NOTCH1MUT CLL 
cells were characterised by GEP as having lower expression levels of cell cycle 
genes indicating slow cycling. However upon stimulation with NTL/CD154+IL-4 
they demonstrated a much higher up-regulation of cell cycle genes; such as 
CDK1, CDK2 and CCNE2, which indicates rapid cycling. This further highlights the 
more aggressive nature of NOTCH1MUT CLL than normal CLL cells. Unexpectedly 
CCNE2 expression in CLL cells was further up-regulated by the presence of OFA, 
when stimulated with NTL/CD154+IL-4. For two of the three samples, this was 
more prominent in our NOTCH1MUT CLL samples. G1 to S phase transition is 
dependent on a reduction in intracellular Ca2+ levels. It has previously been 
established that CD20 activity is associated with B cell activation and 
proliferation and that different CD20 MAb’s are able to either inhibit or enhance 
cell cycle progression through binding to CD20 and changing intracellular Ca2+ 
homeostasis 291. Therefore our data would suggest that OFA binding to CD20 
potentially reduces Ca2+ influx lowering intracellular levels so that CLL cells are 
activated towards proliferation291.  
6.4.4.3 Calcium signalling 
In order to clarify how different CLL cytogenetic cohorts alter Ca2+ signalling 
following MAb binding we investigated this pathway further. When NOTCH1MUT 
and cytogenetically normal CLL cells were stimulated with NTL/CD154+IL-4 
several genes related to Ca2+ signalling were identified as being deregulated in 
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our NOTCH1MUT CLL cells. These genes included ROR2, RRAD a suppressor of 
voltage-gated L-type Ca2+ currents and SYK upstream of BCR induced Ca2+ 
signalling. Notch has been implicated in different tissue types as utilising Ca2+ 
signalling, within pulmonary arterial smooth muscle cells Notch stimulation with 
soluble Jagged 1 caused a release in store-operated Ca2+ entry which 
subsequently caused a release of Ca2+ from intracellular stores405. Within 
glioblastoma Notch expression has been identified as causing hypoxia induced 
up-regulation of the TCRPC6 cation channel from the transient receptor 
potential subfamily406. TCRP6 expression results in elevated intracellular Ca2+ 
levels which causes NFAT pathway activation. Within glioblastoma Notch 
expression through Ca2+ signalling results in a malignant phenotype with 
enhanced proliferation and migration capabilities406. In conjunction with our 
findings of aberrant Ca2+ signalling in NOTCH1MUT CLL cells, others also identified 
that NOTCH1MUT down-regulate CD20 a Ca2+ channel, due to increased HDAC1 and 
HDAC2 expression as previously described. Although only preliminary, our data 
investigating Ca2+ signalling would suggest that NOTCH1MUT CLL cells have 
enhanced BCR signalling as they respond to BCR stimulation with a prominent 
flux in Ca2+. Within BCR signalling an increase in cytosolic Ca2+ levels causes a 
further cascade of Ca2+ release from store-operated calcium channels, which 
activate both NFAT and classical PKCs 17,20,22. PKCβ in turn then causes the 
activation of the pro-survival NF-κB pathway14,15. In support of enhanced BCR 
signalling through NOTCH1MUT, CLL42 a cytogenetically normal patient which 
displayed by immunoblotting constitutively active Notch1/2 demonstrated the 
strongest Ca2+ flux with BCR stimulation, F(ab’)2 stimulation compared with other 
cytogenetically normal CLL samples.  
In conclusion this study has implications for the use of anti-CD20 MAbs in the 
treatment of NOTCH1MUT CLL cases. We provide evidence to suggest NOTCH1MUT 
CLL cells have tailored de-regulated Ca2+ signalling to aid their resistance to 
anti-CD20 MAbs and produce a more aggressive phenotype. Development of an 
effective Notch1 blocking or γ secretase inhibitor for the treatment of CLL may 
prove beneficial not only for increased susceptibility to anti-CD20 MAbs but to 
also reduce BCR signalling within CLL cells. In order to treat NOTCH1MUT CLL 
patients effectively, a dual targeting approach may be required, which includes 
using a Notch1 inhibitor capable of abrogating the complex de-regulation of Ca2+ 
  199 
 
signalling in NOTCH1MUT CLL alongside an anti-CD20 MAb. Without this, the 
ineffective clearance of NOTCH1MUT cells with the current treatment regimens 
could result in the accumulation of resistant cells within the BM and LN resulting 
in clonal take over by the malignant NOTCH1MUT clone. Overall these data 
suggest that NOTCH1MUT CLL patients require more tailored treatment strategies. 
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Figure 6.1 CLL patients are susceptible to the acquisition of multiple different genomic 
mutations 
 
The genomes of fifteen CLL patients were sequenced on Miseq (Illumina, Inc) by Oxford MRC 
Molecular Diagnostic Laboratory, and the analysis provided was also performed by Oxford 
University. A. Total number of mutations observed per gene. B. Total number of mutations per CLL 
patient. C. Pie chart showing the number of mutations observed per CLL patient. D. Association 
between CLL patients and the specific gene mutation observed. 
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Figure 6.2 NOTCH1
MUT
 CLL cells display significantly less OFA-CDC than normal and 11q 
del CLL cells 
 
Primary CLL cells (n=16) were cultured on NTL/CD154+IL-4 for 24 hr before 20 μg/ml OFA was 
added. CLL cells were then cultured with OFA for an additional 24 hr before undergoing CDC. The 
mean + SEM percentage of dead cells are shown from cytogenetically normal CLL samples (n=5), 
11q del (n=4), 17p del (n=4). NOTCH1
MUT
 (n=3). The percentage of dead cells is relative to 
untreated control. p values were determined by an un-paired t-test (**, p<0.01).  
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Figure 6.3 Genes linked with migration, T-cell development and signalling are up-regulated 
in CLL cells escaping OFA CDC 
 
Primary CLL cells (n=13) were cultured on NTL/CD154+IL-4 for 24 hr before 20 μg/ml OFA was 
added. CLL cells were cultured with OFA for a further 24 hr before undergoing CDC. After CDC 
surviving CLL cells were then cultured with NTL/CD154+IL-4 for an additional 24 hr, after which 
RNA was extracted and gene expression levels were then determined by Fluidigm array analysis
a
. 
Gene expression levels are shown relative to NDC cells that underwent CDC without MAb (Figure 
2.1 samples II.). GEP were calculated using ΔΔCt method with the average of four housekeeping 
genes as reference. A. CD247 (n=11). B. GATA-3 (n=13). C. MMP9 (n=10). The mean + SEM are 
shown. p values were determined by an unpaired t-test (*, p<0.05).  
a
 Experimental design is described in section 2.5.2 and shown in Figure 2.1. 
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Figure 6.4 Genes associated with surviving OFA induced CDC show a positive correlation in 
expression and the level of CDC observed 
 
Primary CLL cells were cultured on NTL/CD154+IL-4 for 24 hr before 20 μg/ml  OFA was added. 
CLL cells were cultured with OFA for a further 24 hr before undergoing CDC (Figure 2.1 samples 
IV.). After CDC surviving CLL cells were cultured with NTL/CD154+IL-4 for an additional 24 hr, 
after which RNA was extracted and gene expression levels were determined by Fluidigm array 
analysis. Gene expression levels are shown relative to NDC cells that underwent CDC without MAb 
(Figure 2.1 samples II.). GEP were calculated using ΔΔCt method with the average of four 
housekeeping genes as reference. Gene expression levels were plotted against the percentage of 
CDC observed. A. CD247 (n=11), r
2
, 0.3456, p value, <0.0571. B.i. GATA-3 expression vs. CDC 
(n=13), r
2
, 0.1263, p value, 0.2334. ii. Gene expression vs. CDC based on cytogenetic subset; CLL 
normal (n=4), 11q del (n=4) and 17p del (n=3). mean + SEM is shown. C. MMP9 expression vs. 
CDC (n=10), r
2
, 0.6876 and p value, 0.0057 (statistically significant). 
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Figure 6.5 GEP between CLL samples are similar between the different cytogenetic sub-
groups 
 
GEP of genes previously identified as being deregulated in CLL cells surviving OFA induced CDC 
were performed. GEPs were determined from normal healthy B cells (n=6), and CLL cells after 
purification from peripheral blood. GEP levels were determined by Fluidigm array analysis. Relative 
gene expression levels were determined using the average normal B cell value as calibrator 
calculated using the ΔΔCt method using an average of four housekeeping genes as reference. 
GEPs were determined for CLL samples that had no 11q or 17p del (CLL normal) (n=16), 11q del 
(n=5), 17p del (n=5), and NOTCH1
MUT
 CLL patients (n=7). Heat maps were produced using 
PermutMatrix software.  
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Figure 6.6 Focused gene analysis identifies differences between gene regulation and the 
different cytogenetic CLL subsets 
 
Gene expression was determined from normal healthy B cells and CLL cells after purification from 
peripheral blood. Gene expression levels were determined by Fluidigm array analysis. Relative 
gene expression levels were determined against the average normal B cell values calculated using 
the ΔΔCt method with an average of four housekeeping genes as reference. A. FOS expression 
from healthy B cells (n=6), CLL normal (n=16), 11q del (n=5), 17p del (n=5), and NOTCH1
MUT
 
(n=7). B. GATA-3 expression from healthy B cells (n=6), CLL normal (n=16), 11q del (n=5), 17p del 
(n=5), and NOTCH1
MUT
 (n=7). C. MMP9 expression from healthy B cells (n=6), CLL normal (n=6), 
11q del (n=0)
a
, 17p del (n=5), and NOTCH1
MUT
 (n=3). p values were determined by an unpaired t-
test (*, p<0.05, ** p<0.01, *** p<0.001). 
a
 MMP9 gene expression levels were undetectable for all 11q del CLL samples (n=5) assessed. 
 
  
  206 
 
 
Figure 6.7 Cell cycle genes are de-regulated in CLL cells 
 
Gene expression was determined from normal healthy B cells (n=6), and CLL cells after purification 
from peripheral blood. Gene expression levels was determined by Fluidigm array analysis using the 
ΔΔCt method with an average of four housekeeping genes as reference, fold change is relative to 
the average normal healthy B cell value. Gene expression levels were determined for CLL Normal 
(n=16), 11q del (n=5), 17p del (n=5), and NOTCH1
MUT
 (n=7) unless otherwise stated. A. CCND1 
expression. B. CCNE2 expression C. CDK2 expression. D. CDKN1A expression levels for CLL 
Normal (n=15), 11q del (n=5), 17p del (n=5), and NOTCH1
MUT
 (n=7), p values were determined by 
an unpaired t-test (*, p<0.05, ** p<0.01, *** p<0.001). 
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Figure 6.8 CD247, a gene of interest in CLL cells escaping OFA induced CDC, is significantly 
down-regulated in 11q del CLL samples 
 
Gene expression was determined from normal healthy B cells (n=6), and CLL cells after purification 
from peripheral blood. Gene expression levels was determined by Fluidigm array analysis using the 
ΔΔCt method with an average of four housekeeping genes as reference, fold change is relative to 
normal healthy B cells. Gene expression levels were determined for CLL Normal (n=16), 11q del 
(n=5), 17p del (n=5), and NOTCH1
MUT
 (n=7) unless otherwise stated. A. NOXA1 expression levels 
for CLL Normal (n=15), 11q del (n=5), 17p del (n=5), and NOTCH1
MUT
 (n=7). B. RRAD expression 
C. JUN expression. D. CD247 expression levels for CLL Normal (n=14), 11q del (n=3), 17p del 
(n=5), and NOTCH1
MUT
 (n=6). p values were determined by an unpaired t-test (*, p<0.05, ** 
p<0.01, *** p<0.001). 
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Figure 6.9 NOTCH signalling pathway is de-regulated in all CLL subsets compared to normal 
healthy B cells 
 
GEPs were determined from normal healthy B cells (n=6), and CLL cells after purification from 
peripheral blood. GEP levels were determined by Fluidigm array analysis. Relative gene 
expression levels were determined by ΔΔCt method using an average of four housekeeping genes 
as reference and the average normal B cell value as the calibrator. GEP’s were determined for CLL 
patients that are CLL Normal with no 11q or 17p del (n=16), 11q del (n=5), 17p del (n=5), and 
NOTCH1
MUT
 CLL patients (n=7). Heat maps were produced using PermutMatrix software. GEP of 
genes associated with the NOTCH1 signalling pathway. 
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Figure 6.10 All NOTCH receptors apart from NOTCH2 are up-regulated in our CLL samples 
 
Gene expression was determined from normal healthy B cells, and CLL cells after purification from 
peripheral blood. Gene expression levels was determined by Fluidigm array analysis. Relative 
gene expression levels were determined by ΔΔCt method using an average of four housekeeping 
genes as reference, fold change is relative to normal healthy B cells unless stated otherwise. A. 
NOTCH1 expression for normal healthy B cells (n=6), CLL Normal (n=16), 11q del (n=5), 17p del 
(n=5), and NOTCH1
MUT
 (n=7). B. NOTCH2 expression for normal healthy B cells (n=6), CLL 
Normal (n=15), 11q del (n=5), 17p del (n=5), and NOTCH1
MUT
 (n=7). C. NOTCH3 expression, fold 
change relative to CLL normal sample CLL57. Expression was determined for CLL Normal (n=11), 
11q del (n=1), 17p del (n=4), and NOTCH1
MUT
 (n=4). D. NOTCH4 expression levels for normal 
healthy B cells (n=4), CLL Normal (n=13), 11q del (n=4), 17p del (n=5), and NOTCH1
MUT
 (n=7). p 
values were determined by an unpaired t-test (*, p<0.05, ** p<0.01). 
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Figure 6.11 Target genes downstream of NOTCH1 are down-regulated in CLL compared to 
normal healthy B cells 
 
Gene expression was determined from normal healthy B cells (n=6), and CLL cells after purification 
from peripheral blood. Gene expression levels was determined by Fluidigm array analysis. Relative 
gene expression levels were determined by ΔΔCt method using an average of four housekeeping 
genes as reference, fold change is relative to normal healthy B cells. Gene expression levels were 
determined for CLL Normal (n=16), 11q del (n=5), 17p del (n=5), and NOTCH1
MUT
 (n=7) unless 
otherwise stated A. HES1 expression levels for CLL Normal (n=15), 11q del (n=2), 17p del (n=4), 
and NOTCH1
MUT
 (n=7). B. HEY1 expression for CLL Normal (n=14), 11q del (n=1), 17p del (n=4), 
and NOTCH1
MUT
 (n=7). C. DELTEX expression. D. DLL1 expression levels. p values were 
determined by an unpaired t-test (*, p<0.05, ** p<0.01, *** p<0.001). 
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Figure 6.12 CLL samples display significantly different TP53 and MYC gene expression 
patterns compared to normal B cells  
 
Gene expression was determined from normal healthy B cells (n=6), and CLL cells after purification 
from peripheral blood. Gene expression levels was determined by Fluidigm array analysis. Relative 
gene expression levels were determined by ΔΔCt method using an average of four housekeeping 
genes as reference, fold change is relative to normal healthy B cells. Gene expression levels were 
determined for CLL Normal (n=16), 11q del (n=5), 17p del (n=5), and NOTCH1
MUT
 (n=7). A. TP53 
expression. B. MYC expression. p values were determined by an unpaired t-test. (*, p<0.05, ** 
p<0.01, *** p<0.001). 
 
  
  212 
 
 
 
Figure 6.13 NOTCH1 signalling pathway is stimulated by NTL/CD154+IL-4 for both 
cytogenetically normal and NOTCH1
MUT
 CLL cells 
 
CLL normal (n=4) and NOTCH1
MUT
 (n=4) were cultured on plastic and NTL/CD154+IL-4 with and 
without 20 μg/ml OFA for 48 hr. CLL cells were then isolated and RNA extracted and GEP levels 
determined by Fluidigm array analysis. Relative gene expression levels were determined by ΔΔCt 
method using an average of four housekeeping genes as reference, fold change is relative to a 
CLL normal sample (CLL70) cultured on plastic without the presence of OFA. Heat maps were 
produced using PermutMatrix software. GEP of genes associated with the NOTCH1 and WNT 
signalling pathways. 
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Figure 6.14 Genes associated with NOTCH1 and WNT signalling are de-regulated between 
CLL normal and NOTCH1
MUT
 CLL cells following stimulation with NTL/CD154+IL-4 
 
CLL normal (n=4) and NOTCH1
MUT
 (n=4) were cultured on plastic and NTL/CD154+IL-4 with and 
without 20 μg/ml OFA for 48 hr. CLL cells were then isolated and RNA extracted and GEP levels 
determined by Fluidigm array analysis. Relative gene expression levels were determined by ΔΔCt 
method using an average of four housekeeping genes as reference, fold change is relative to a 
CLL normal sample (CLL70) cultured on plastic without the presence of OFA, unless stated 
otherwise. A. DELTEX1 expression. B. NOTCH1 expression. C. ROR2 fold change expression 
levels are relative to CLL normal sample (CLL121) cultured on plastic without OFA. i. Expression 
levels for the CLL normal sample CLL121 and NOTCH1
MUT
 CLL 133. i. The mean ROR2 
expression levels for CLL normal (n=3) and NOTCH1
MUT
 (n=3) CLL samples cultured on  
CD154/IL-4 with and without OFA. The mean + SEM is shown. p values were determined by an 
unpaired t-test. (*, p<0.05). 
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Figure 6.15 Cell cycle genes are up-regulated in CLL cells co-cultured with NTL/CD154+IL-4 
 
CLL normal (n=4) and NOTCH1
MUT
 (n=4) were cultured on plastic and NTL/CD154+IL-4 with and 
without 20 μg/ml OFA for 48 hr. CLL cells were then isolated and RNA extracted and GEP levels 
determined by Fluidigm array analysis. Relative gene expression levels were determined by ΔΔCt 
method using an average of four housekeeping genes as reference, fold change is relative to a 
CLL normal sample (CLL70) cultured on plastic without the presence of OFA. Heat maps were 
produced using PermutMatrix software. GEP of genes associated with the cell cycle regulation. 
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Figure 6.16 NOTCH1
MUT
 CLL cells activate cell cycle genes to a greater extent than normal 
CLL cells when co-cultured with NTL/CD154+IL-4 
 
CLL normal (n=4) and NOTCH1
MUT
 (n=4) were cultured on plastic and NTL/CD154+IL-4 with and 
without 20 μg/ml OFA for 48 hr. CLL cells were then isolated and RNA extracted and GEP levels 
determined by Fluidigm array analysis. Relative gene expression levels were determined by ΔΔCt 
method using an average of four housekeeping genes as reference, fold change is relative to a 
CLL normal sample (CLL70) cultured on plastic without the presence of OFA. A. CCND1 
expression. B. CDK1 expression. C. CDK2 expression. D. CCNE2 expression. The mean + SEM is 
shown. p values were determined by a paired t-test (*, p<0.05, ** p<0.01, *** p<0.001). 
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Figure 6.17 CLL cells differentially regulate genes associated with Ca
2+
 and BCR signalling 
upon stimulation with NTL/CD154+IL-4 
 
CLL normal (n=4) and NOTCH1
MUT
 (n=4) were cultured on plastic and NTL/CD154+IL-4 with and 
without 20 μg/ml OFA for 48 hr. CLL cells were then isolated and RNA extracted and GEP levels 
determined by Fluidigm array analysis. Relative gene expression levels were determined by ΔΔCt 
method using an average of four housekeeping genes as reference, fold change is relative to a 
CLL normal sample (CLL70) cultured on plastic without the presence of OFA. Heat maps were 
produced using PermutMatrix software. GEP of genes associated with Ca
2+
 and BCR signalling. 
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Figure 6.18 NOTCH1
MUT
 CLL cells display an elevated response in genes associated with 
Ca
2+
 and BCR signalling upon NTL/CD154+IL-4 stimulation  
 
CLL normal (n=4) and NOTCH1
MUT
 (n=4) were cultured on plastic and NTL/CD154+IL-4 with and 
without 20 μg/ml OFA for 48 hr. CLL cells were then isolated and RNA extracted and GEP levels 
determined by Fluidigm array analysis. Relative gene expression levels were determined by ΔΔCt 
method using an average of four housekeeping genes as reference, fold change is relative to a 
CLL normal sample (CLL70) cultured on plastic without the presence of OFA. A. JUN expression. 
B. MYC expression. C. RRAD expression. D. SYK expression. The mean + SEM is shown. p 
values were determined by a paired t-test (*, p<0.05). 
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Figure 6.19 Notch1 and Notch2 appear activated at the protein level upon stimulation with 
NTL/CD154+IL-4 for both CLL normal and NOTCH1
MUT
 CLL cells 
 
CLL normal (n=3) and NOTCH1
MUT
 (n=3) were cultured on plastic and NTL/CD154+IL-4 with and 
without 20 μg/ml OFA for 48 hr. CLL cells were then isolated and protein extracted and expression 
levels determined by western blot analysis. Expression levels for Notch1-4 all represent the active 
intracellular forms of the protein. A. CLL normal, CLL121, and NOTCH1
MUT
, CLL101. B. CLL 
normal, CLL42, and NOTCH1
MUT
, CLL67. C. CLL normal, CLL70, and NOTCH1
MUT
, CLL108. D. 
CLL normal, CLL121, and NOTCH1
MUT
, CLL101 intracellular Notch3 expression. 
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Figure 6.20 Cytogenetically normal CLL samples display no Ca
2+
 flux upon BCR stimulation 
 
Fluo-4 (2 μM) calcium indicator was used to determine calcium flux in CLL patients by flow 
cytometry. CLL patients were incubated with fluo-4 for 45 min, CLL cells were then washed and left 
to incubate for a further 30 min. CLL cells were either not treated (NDC) or incubated with 20 μg/ml 
OFA or RTX for 15 min prior to reading fluo-4 signal in the FITC channel on the FACS Canto II. 
NDC or OFA/RTX incubated CLL cells, calcium signal was measured immediately following either 
10 μg/ml F(ab’)2, 10 μg/ml IgM, 20 μg/ml OFA, 20 μg/ml RTX or 500 nM Ionomycin (Iono) addition 
(+). Fluo-4 signal was recorded for 2 min and the MFI is shown. Normal CLL samples (n=4). 
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Figure 6.21 Cytogenetically normal CLL samples display no Ca
2+
 flux over time upon BCR 
stimulation 
 
Fluo-4 (2 μM) calcium indicator was used to determine calcium flux in CLL patients by flow 
cytometry. CLL patients were incubated with fluo-4 for 45 min, CLL cells were then washed and left 
to incubate for a further 30 min. CLL cells were either not treated (NDC) or incubated with 20 μg/ml 
OFA or RTX for 15 min prior to reading fluo-4 signal in the FITC channel on the FACS Canto II. 
NDC or OFA/RTX incubated CLL cells, calcium signal was measured immediately following either 
10 μg/ml F(ab’)2, 10 μg/ml IgM, 20 μg/ml OFA, 20 μg/ml RTX or 500 nM Ionomycin (Iono)  addition 
(+). Fluo-4 signal was recorded for 2 min and FITC signal vs. time is shown. Cytogenetically normal 
CLL samples (n=4). 
 
  
  221 
 
 
Figure 6.22. CLL samples with NOTCH1
MUT
 display differential Ca
2+
signalling with BCR 
stimulation compared to cytogenetically normal CLL samples 
 
Fluo-4 (2 μM) calcium indicator was used to determine calcium flux in CLL patients by flow 
cytometry. CLL patients were incubated with fluo-4 for 45 min, CLL cells were then washed and left 
to incubate for a further 30 min. CLL cells were either not treated (NDC) or incubated with 20 μg/ml 
OFA or RTX for 15 min prior to reading fluo-4 signal in the FITC channel on the FACS Canto II. 
NDC or OFA/RTX incubated CLL cells, calcium signal was measured immediately following either 
10 μg/ml F(ab’)2, 10 μg/ml IgM, 20 μg/ml OFA, 20 μg/ml RTX or 500 nM Ionomycin (Iono)  addition 
(+).Fluo-4 signal was recorded for 2 min and the MFI is shown. NOTCH1
MUT
 CLL samples (n=4). 
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Figure 6.23 CLL samples with NOTCH1
MUT
 display differential Ca
2+
 signalling with different 
BCR stimulation over time 
 
Fluo-4 (2 μM) calcium indicator was used to determine calcium flux in CLL patients by flow 
cytometry. CLL patients were incubated with fluo-4 for 45 min, CLL cells were then washed and left 
to incubate for a further 30 min. CLL cells were either not treated (NDC) or incubated with 20 μg/ml 
OFA or RTX for 15 min prior to reading fluo-4 signal in the FITC channel on the FACS Canto II. 
NDC or OFA/RTX incubated CLL cells, calcium signal was measured immediately following either 
10 μg/ml F(ab’)2, 10 μg/ml IgM, 20 μg/ml OFA, 20 μg/ml RTX or 500 nM Ionomycin (Iono)  addition 
(+).Fluo-4 signal was recorded for 2 min and the FITC signal vs. time is shown. NOTCH1
MUT
 CLL 
samples (n=4). 
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Figure 6.24 CLL samples with NOTCH1
MUT
 display muted Ca
2+
 signalling with OFA/RTX 
treatment 
 
Fluo-4 (2 μM) calcium indicator was used to determine calcium flux in CLL patients by flow 
cytometry. CLL patients were incubated with fluo-4 for 45 min, CLL cells were then washed and left 
to incubate for a further 30 min. CLL cells were either not treated (NDC) or incubated with 20 μg/ml 
OFA or RTX for 15 min prior to reading fluo-4 signal in the FITC channel on the FACS Canto II. 
NDC or OFA/RTX incubated CLL cells, calcium signal was measured immediately following either 
10 μg/ml F(ab’)2, 10 μg/ml IgM, 20 μg/ml OFA, 20 μg/ml RTX or 500 nM Ionomycin (Iono) addition 
(+).Fluo-4 signal was recorded for 2 min and the MFI is shown for cytogenetically normal (n=4) and 
NOTCH1
MUT
 (n=4) CLL cells. A. Stimulation response without RTX or OFA treatment. B. RTX 
stimulation. C. OFA stimulation. The mean + SEM is shown. p values were determined by a paired 
t-test (*, p<0.05). 
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Supplementary Figure 6.1 ΔCt levels for NOTCH3 expression  
 
NOTCH3 gene expression was determined from CLL cells after purification from peripheral blood. 
Gene expression levels were determined by Fluidigm array analysis. ΔCt gene expression levels 
were determined using an average of four housekeeping genes as reference NOTCH3 expression, 
fold change relative to CLL normal sample CLL57. Expression was determined for CLL Normal 
(n=11), 11q del (n=1), 17p del (n=4), and NOTCH1
MUT
 (n=4).  
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Supplementary Figure 6.2 ΔCt levels for genes associated with NOTCH1 and WNT signalling  
 
CLL normal (n=4) and NOTCH1
MUT
 (n=4) CLL cells were cultured on plastic and NTL/CD154+IL-4 
with and without 20 μg/ml OFA for 48 hr. CLL cells were then isolated and RNA extracted and GEP 
levels determined by Fluidigm array analysis. ΔCt gene expression levels were determined using 
an average of four housekeeping genes as reference. A. DELTEX1 expression. B. NOTCH1 
expression. C. ROR2 fold change expression levels are relative to CLL normal sample (CLL121) 
cultured on plastic without OFA. i. Expression levels for the CLL normal sample CLL121 and 
NOTCH1
MUT
 CLL 133. i. The mean ROR2 expression levels for CLL normal (n=3) and NOTCH1
MUT
 
(n=3) CLL samples cultured on CD154/IL-4 with and without OFA. p values between different 
cytogenetic subsets were determined by an unpaired t-test, and p values within a cytogenetic 
subset were determined by a paired t test (*, p<0.05, ** p<0.01). 
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Supplementary Figure 6.3 ΔCt levels for genes associated with cell cycle progression  
 
CLL normal (n=4) and NOTCH1
MUT
 (n=4) CLL cells were cultured on plastic and NTL/CD154+IL-4 
with and without 20 μg/ml OFA for 48 hr. CLL cells were then isolated and RNA extracted and GEP 
levels determined by Fluidigm array analysis. ΔCt gene expression levels were determined using 
an average of four housekeeping genes as reference. A. CCND1 expression. B. CDK1 expression. 
C. CDK2 expression. D. CCNE2 expression. p values were determined by a paired t-test (*, 
p<0.05, ** p<0.01). 
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Supplementary Figure 6.4 ΔCt levels for genes associated with Ca
2+
 and BCR signalling 
 
CLL normal (n=4) and NOTCH1
MUT
 (n=4) CLL cells were cultured on plastic and NTL/CD154+IL-4 
with and without 20 μg/ml OFA for 48 hr. CLL cells were then isolated and RNA extracted and GEP 
levels determined by Fluidigm array analysis. ΔCt gene expression levels were determined using 
an average of four housekeeping genes as reference. A. JUN expression. B. MYC expression. C. 
RRAD expression. D. SYK expression. p values between different cytogenetic subsets were 
determined by an unpaired t-test, and p values within a cytogenetic subset were determined by a 
paired t test (*, p<0.05, ** p<0.01). 
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7 General discussion 
Anti-CD20 MAbs are an integral part of the first line treatment of CLL. OFA, a 
next generation type I anti-CD20 MAb, has recently been given FDA approval for 
the treatment of CLL patients in combination with chlorambucil for previously 
untreated CLL patients, and as a single agent for CLL patients that are double 
refractory. We, and others, have shown OFA to be a far superior inducer of CDC 
than RTX315,344. The ability of OFA to elicit a CDC response is an important part 
of its efficacy. We have demonstrated that OFA activity is limited in the 
treatment of CLL by several different factors including; complement levels, 
CD20 expression, microenvironmental stimulation and CLL genetic mutations. 
7.1 Clinical efficacy of OFA 
Within clinical trials, OFA demonstrated great promise for the treatment of CLL. 
For 59 CLL patients that were double refractory to both fludarabine and 
alemtuzumab, OFA infusion resulted in ORR of 58%, CR in 57% of patients, PFS of 
5.7 months and OS 13.7 months257. Despite superior results as a single agent in 
comparison to RTX, OFA is not licenced as a first line therapy for CLL patients. 
While improved treatment options are now available, CLL is currently incurable 
and most CLL patients with aggressive disease will relapse. Ineffective clearance 
can result in the appearance of MRD, which has been associated with reduced 
OS281. The presence of MRD can be assessed by either allele specific 
oligonucleotide PCR or four/six colour flow cytometry, which is able to detect 1 
CLL cell in 104 leukocytes. MRD negativity is considered to be less than 1 CLL cell 
present in 104 cells/μl280,282,407. OFA demonstrates improved efficacy in 
combination with chlorambucil and bendamustine chemotherapy. GIMEMA 
multicentre Phase II trial of bendamustine with OFA in relapsed or refractory CLL 
patients (n=47) observed at a median follow up of 24.2 months 83.6% OS, PFS 
49.6% and median PFS of 23.6 months408. COMPLEMENT I phase III trial 
investigated the efficacy of chlorambucil alone (n=227) or chlorambucil plus OFA 
(n=217). Trial results demonstrated superior efficacy of chlorambucil plus OFA 
compared to chlorambucil alone, PFS was 22.4 and 13.1 months respectively, 
and objective response occurred in 82.4% and 68.6% respectively279. 
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When comparing the responses of OFA in a phase III clinical trial with the BCR 
antagonist ibrutinib within 391 relapsed refractory CLL and small cell lymphoma 
(SLL) patients, ibrutinb had superior responses. After 12 months, median survival 
for patients receiving ibrutininb vs. OFA was 90% vs. 81% and ORR was 42.6% with 
ibrutinib and 4.1% for those receiving OFA (p<0.001)409. It would appear that OFA 
and other type I anti-CD20 MAbs function most efficiently when used in 
combination therapy. A phase I trial of idelalisib in 54 relapsed or refractory CLL 
patients ORR was 72% and 15.8 months PFS268. A phase I trial of 21 relapsed or 
refractory CLL patients found a combination of idelalisib and OFA produced 76% 
ORR and 17.8 months PFS410. However recent publications suggest that there 
may be some antagonistic activity between BCR inhibitors and anti-CD20 MAbs 
and more research is required411. Type I anti-CD20 MAbs are thought to trigger 
direct cell death through coupling with the BCR to hijack the Ca2+ flux resulting 
in activation ROS and cell death176. However, cross-linking of antibodies is 
required for this to occur in vitro and therefore may not be clinically relevant. 
BCR inhibitors may cause down modulation of CD20, one recent publication 
found that co-culture with ibruitinib or idelalisib caused down-regulation of 
CD20 which then negatively impacted upon the ability of OFA or RTX to induce 
CDC. This reduced efficacy was more prominent with ibrutinib411. Another recent 
study also found that ibrutinib and to a lesser extent idelalisib caused NK cell 
degranulation abrogating ADCC function as well as phagocyte activation412. ADCC 
is an important pathway for anti-CD20 MAb efficacy413. However BCR signalling 
inhibitors have been shown to cause egress of CLL cells into the peripheral 
blood, this may provide an opportunity for a potent inducer of CDC, such as OFA 
to eradicate the cells414,415. Therefore any dosing schedules in BCR/anti-CD20 
MAb combination therapies will have to be carefully considered to avoid 
antagonistic activity. 
7.2 Limitations of complement 
The identification that a large proportion of CLL patients harbour complement 
deficiencies, 37.5% in our CLL patient cohort, has important implications not 
only for anti-CD20 MAbs but also other MAbs, such as alemtuzumab, which utilise 
the CDC pathway. We identified that an even larger proportion (42.3%) of CLL 
patient sera became exhausted of complement when used for a second time in 
vitro. Complement exhaustion was also observed in vivo following OFA and RTX 
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immunotherapy, with preliminary results suggesting that complement levels took 
longer than 7 days to be regenerated. Our in vitro studies with primary CLL cells 
and different tumour burdens also provided important implications for 
complement consumption in vivo. The concentrations of CLL cells that we used 
were modest and do not represent the high lymphocyte counts typical of CLL 
patients that are eligible for OFA treatment. Impaired innate immunity through 
complement dysregulation further highlights the wide spread pathogenesis of 
CLL. CLL patient’s immunity is further compromised through T cells involved in 
both adaptive and immune function displaying dysregulation, as well as NK cells 
which are important for the induction of ADCC 137,162-164,416. Therefore, adding to 
complement deficiencies, there appears to be widespread CLL related immune 
suppression. 
Our results suggest that the dosing schedule for OFA is inappropriate for maximal 
efficacy. The recommended treatment schedule for OFA infusion involves an 
initial low dose of 300 mg followed by weekly doses of 2000 mg for 7 weeks, 
after this time 2000 mg is administered monthly. RTX treatment on the other 
hand is administered every 4 weeks for at least 5 cycles of 375 mg/m2. For 
comparison the average male is 1.9 m2 whilst females are 1.7 m2 therefore this 
would make the monthly doses 712.5 mg and 637.5 mg respectively417. Our 
results indicate that at the high doses of OFA, complement levels require longer 
than 7 days to recover. Whereas the monthly doses of RTX were long enough 
apart for complement levels to be restored in all CLL patients excluding the 
patient with complement deficiencies. It would appear therefore that the high 
doses of OFA may do more harm than good. A way of restoring the efficacy of 
OFA and RTX treatment is the inclusion of FFP with chemoimmunotherapy. 
Although our results would suggest that the most benefit would be from 
receiving C2 complement. However individual complement components are not 
currently clinically achievable, whereas FFP is readily available within the clinic. 
The side effects associated with adding FFP to treatment could include 
transfusion related lung injury, transfusion related circulatory overload and 
allergic reaction to transfusion418, with the most common resulting from a lack 
of regulation when administering FFP. Apart from transfusion related risks there 
is also an elevated risk of infection as FFP is a human product, which is a 
particularly important consideration when administering FFP as many CLL 
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patients are immunosuppressed. Therefore with strict regulations for 
administering FFP the potential increase in OFA efficacy could be high. Two 
small clinical studies have already shown that the effect of adding FFP to RTX 
produced superior results than without FFP347,348. Adding FFP may also prove 
valuable in preventing the risk of serious infection within CLL patients.  
One of the major causes of morbidity and mortality within CLL patients is not 
disease related but rather due to infections338,345. Disorders with complement 
deficiencies are associated with reduced efficiency of immune clearance and 
susceptibility to re-occurring infections322-324. It has also been identified that 
within CLL trogocytosis occurs, which causes rapid depletion of CD20 levels. 
Trogocytosis occurs when effector cells cleave the CD20/anti-CD20 MAb 
complex. Effector cells which include monocytes, macrophages, neutrophils and 
NK cells recognise the Fcγ portion of the MAb and instead of destroying the 
target cell cleave off the MAb with its target instead. This has been observed 
both in vivo and in vitro for both OFA and RTX, and severely compromises their 
activity317,319,329,419. CDC is incredibly fast acting; we observed maximal CDC 
activity after only 1 hour incubation of serum with HG3 cells. Sera from CLL 
patients undergoing RTX immunotherapy also demonstrate fast complement 
exhaustion, which occurs 24 hours post infusion. If, as predicted by our findings, 
it takes longer than 7 days to restore complement levels this provides a window 
of opportunity for the effector cells to perform trogocytosis. Ineffective 
clearance and subsequent loss of CD20 from the surface of the CLL cell can lead 
to anti-CD20 MAb resistance. Further to this, our CLL and NTL co-culture 
experiment, which mimics the circulating compartment of CLL cells, suggest 
that when OFA was present in culture there was a dramatic reduction in CDC 
activity even after only 24 hr of co-culture. This highlights that even in the 
absence of effector cells to perform trogocytosis CLL cells are effective at 
removing the anti-CD20 MAb/CD20 complex from the surface of the cell either 
from loss or internalisation. Trials using low dose RTX are promising and limit the 
loss of CD20 from the surface of CLL cells, so perhaps the same strategy can be 
applied to OFA dosing420,421. In support of low dosing for OFA and RTX our in vitro 
ADCC assay indicated that optimal efficacy was achieved at 100 ng/ml and 1 
μg/ml respectively, concentrations above this then resulted in reduced ADCC 
induction. A 2000 mg dose of OFA equates to 400 μg/ml within the circulating 
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blood supply, therefore it may be possible that there is reduced ADCC efficacy 
at this concentration.  
7.3 Microenvironmental stimulation and anti-CD20 MAb 
efficacy 
A significant part of CLL pathogenesis is due to resistance to apoptosis and 
subsequent chemoresistance. These factors are enhanced through signals 
derived from their microenvironmental niche136. The microenvironment provides 
important protective signals to CLL cells that assist in cell survival and 
chemoresistance. In vitro experiments have demonstrated that co-culture with 
BM cells gives rise to resistance to fludarabine and chlorambucil141,190. Therefore 
we aimed to establish the impact microenvironmental stimulation had on the 
efficacy of anti-CD20 MAbs. Others have shown that CD40 stimulation sensitised 
CLL cells to RTX induced direct cell death due to increased cytosolic Ca2+ levels 
and ROS induced cell death. Our results demonstrate that there is also an 
increase in the induction of CDC with both RTX and more notably with OFA when 
CLL cells were stimulated with CD154 and IL-4. This increase in CDC was 
independent of any notable changes in CD20 expression levels or complement 
inhibitory proteins CD55 or CD59. A recent study demonstrated that CD20 
expression levels were reduced after 2 weeks of co-culture with BM stromal 
cells, which conferred reduced susceptibility to RTX induced CDC144. CDC levels 
are critically dependent on the expression levels of the target antigen311. CLL 
cells have reduced CD20 expression compared to normal healthy B cells and 
other B cell malignancies and any further drop in CD20 expression limits MAb 
efficacy. Our experiments were only carried out over a 72 hour time period; 
however it does appear that after the peak in CDC at 48 hours CDC levels started 
to drop after this point. This suggests that microenvironmental stimulation could 
potentially provide resistance to anti-CD20 MAbs in the long term.  
BM stromal cells also display expression of Notch1 ligands, enhancing the 
induction of Notch1 within the LN226-228. Notch1 expression can also be induced 
by the presence of NF-κB signalling which leads to Jagged 1 expression. An 
enrichment of NOTCH1MUT CLL cells230 has been observed in vivo within the LN as 
well as higher expression levels of ICN in vitro following co-culture with stromal 
cells observed by us and others101,232. Notch1 signalling also leads to an increase 
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in expression of the anti-apoptotic protein MCL-1200. MCL-1 is a key protein 
down-stream of BCR signalling associated with the resistance of CLL cells to 
apoptosis175. Further to this, Notch1 downstream target is c-MYC, a well-known 
oncogene, and the expression of both has been identified as producing glycolytic 
switch within CLL cells co-cultured with BM stromal cells422. Glucose metabolism 
has been identified as a key pathway cancer cells utilise when developing drug 
resistance. A study of CLL patients (n=692) identified that NOTCH1MUT CLL 
patients had lower expression levels of CD20. This was due to HDAC being 
displaced from the CSL transcriptional complex by ICN, subsequently HDAC then 
bound to the promoter of CD20 resulting in epigenetic silencing of the gene233. 
Presumably within the LN where there is enhanced activation of Notch1 this 
mechanism will be exacerbated. Notch1 and Notch2 inhibitors, after 3 days in 
co-culture with CLL cells and BM stromal cells, resulted in increased 
susceptibility to chemotherapeutic agents. This suggests that Notch1 inhibitors 
are a possible therapeutic avenue for CLL treatment. Notch1 inhibitors include 
Abs which target the Notch1 receptor so that it no longer can be activated by 
ligand binding 232and γ-secretase inhibitors which block the activation of ICN 423. 
Overexpression of Notch1 is observed within our NOTCH1 wild-type CLL samples 
as well as NOTCH1MUT when co-cultured with NTL/CD154+IL-4. Therefore an 
inhibitor of Notch1 may prove to be an important therapeutic target for 
disrupting the pro-survival signals gained from CLL cells interacting with the 
microenvironment.  
Although very preliminary our genetic and Ca2+ signalling data provide an 
interesting and novel way in which NOTCH1 display resistance to anti-CD20 MAbs 
and potentially other chemotherapeutic agents. Upon BCR stimulation our 
NOTCH1MUT CLL samples displayed an immediate flux in Ca2+, although this will 
have to be corroborated with more thorough experimentation. This suggests that 
NOTCH1MUT CLL samples have enhanced BCR signalling, which may lead to the 
up-regulation of Bcl-2 related anti-apoptotic proteins aiding survival. Therefore 
an appropriate treatment regime for NOTCH1MUT CLL patients may be the use of 
BCR inhibitors, idelalisib or ibrutinib. Although NOTCH1MUT CLL patients 
displayed improvements in PFS with the addition of OFA plus chlorambucil this 
only lasted 18 months109. Our data would suggest that the initial benefit is likely 
through CDC eradication of CLL cells not expressing NOTCH1MUT. The remaining 
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CLL cells are then only those with higher ICN expression. It appears that 
NOTCH1MUT CLL cells favour localising within the LN, as observed in vivo228. 
Within the LN NOTCH1MUT CLL cells have chronic Notch1 activation which 
presumably leads to further reduced efficacy of anti-CD20 MAb therapies101. This 
is corroborated by our in vitro co-culture of NOTCH1MUT CLL cells with 
NTL/CD154+IL-4 which displayed lower OFA-CDC levels than our cytogenetically 
normal patient cohort. The ineffective clearance of NOTCH1MUT CLL cells by anti-
CD20 MAbs could lead to an enhanced level of MRD after treatment, and allow 
clonal evolution of the malignant cells. This suggests that anti-CD20 MAbs should 
not be used for the treatment of CLL patients with a high proportion of 
NOTCH1MUT CLL cells. CLL patients with low clonal levels of NOTCH1MUT CLL cells 
may benefit from a dual strategy of anti-CD20 MAb in combination with a Notch 
inhibitor and BCR inhibitor. Although some antagonistic activity between BCR 
inhibitors and anti-CD20 MAbs have been identified, through the down 
modulation of CD20412 and NK cell granulation causing reduced ADCC411, these 
factors will have to be considered against the potential benefit. Benefits could 
be observed through BCR inhibitors causing egress of CLL cells from the BM414,415, 
long term co-culture of CLL cells with BM stromal cells have been shown to 
cause significant down modulation of CD20144 and without BM stimulation there 
will be less stimulation of the Notch1 pathway232, highlighting the potential 
synergistic activity of these two chemotherapies. A proposed mechanism by 
which NOTCH1MUT CLL cells evade OFA CDC is shown in Figure 7.1. We 
hypothesise that high OFA dosing and complement deficiencies result in high 
rates of complement exhaustion within CLL patients. Complement exhaustion in 
conjunction with ADCC effector cell exhaustion would result in ineffective 
clearance of the CLL cell. NOTCH1MUT CLL cells with low CD20 expression will 
likely escape OFA induced CDC.  
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Figure 7.1 Hypothetical response of NOTCH1
MUT
 CLL cells to OFA 
 
OFA demonstrates stronger binding and slower dissociation rates than RTX and 
our experiments suggest it is still stable and active 7 days after infusion. ADCC 
effector cells have also demonstrated exhaustion following anti-CD20 MAb 
infusion in CLL patients with high tumour burdens371,424. Exhausted complement 
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and ADCC cells allows time for trogocytosis effector cells to remove any bound 
OFA and CD20 leading to a further reduction in the expression of CD20 on the 
surface of the cell. The NOTCH1MUT CLL cell can then travel to the LN/BM to gain 
further pro-survival signals. BM cells express Notch1 ligands and therefore lead 
to activation of ICN232. BM cells also provide stimulation for BCR signalling137. 
Downstream targets of Notch1 include oncogene c-Myc. Our results corroborate 
this as MYC expression was more actively up-regulated in NOTCH1MUT CLL cells 
than NOTCH1 wild-type cells. Our results also suggest that NOTCH1MUT CLL cells 
are more primed towards proliferation upon NTL/CD154+IL-4 stimulation than 
our normal cytogenetic CLL subset, possibly enhancing clonal expansion. 
NOTCH1MUT CLL cells also demonstrated sensitivity to BCR stimulation and 
displayed de-regulation of genes identified to be involved in Ca2+ signalling, 
including ROR2 and RRAD. Pro-apoptotic gene NOXA was also down-regulated in 
our NOTCH1MUT CLL patients. Together the microenvironmental signals provide 
enhanced survival and chemoresistance signals for NOTCH1MUT CLL cells, allowing 
the clonal evolution of NOTCH1MUT CLL cells. 
In conclusion anti-CD20 MAbs are an important treatment strategy for CLL 
patients. However our data would suggest that the clinical efficacy of OFA is 
reduced by complement deficiencies within a large proportion of CLL patients. 
The dosing schedule of OFA does not allow suitable time for complement levels 
to be restored and therefore any subsequent dosing will have reduced efficacy. 
Although OFA is superior to RTX in the induction of CDC, like RTX OFA is most 
effective when used in combination therapy. This body of research provides 
additional evidence for the inclusion of FFP with MAb infusion to further improve 
clinical response. As the role of NOTCH1MUT in the pathogenesis of CLL continues 
to be further elucidated it would appear that due to the complex network of 
Notch1 signalling, type I anti-CD20 MAbs are rendered ineffective treatments in 
this patient cohort. Therefore to avoid poor CLL cell clearance, type I anti-CD20 
MAbs should not be considered a suitable therapy for NOTCH1MUT CLL patients, a 
more appropriate treatment regime would be the use of novel BCR-targeting 
therapies which may then provide a successful clinical outcome for this poor 
prognostic subset of CLL patients. 
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